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It has been predicted that by 2050, 10 million deaths will occur as a result of resistant 
microbials.  This is a growing concern which is creating an urgent need for the development of 
new antimicrobials as well as additional selective media for the identification of these bacteria. 
When designing new antimicrobial compounds, their selectivity to different bacterial strains, 
and their solubilities, must be optimised, for example through prodrug strategies. Since some 
bacterial strains are documented to have different levels of glycosidase enzymes, glycoside 
based prodrugs have proven of interest in antibacterial strategies. The overarching aim of this 
work was therefore to design, synthesise and analyse a range of glycoside prodrugs both as 
antibacterial agents and agents for the selective recovery of bacteria. Through this work, 
structure-activity relationships for the parent compounds and the prodrugs against a range of 
gram-negative and gram-positive bacteria could also be determined based on minimum 
inhibitory concentration values which were determined using a bioscreen or agar method.  
Therefore, β-glucosides and β-galactosides of 2-benzylphenol and 
bis(2-hydroxyphenyl)methane were synthesised using an aq. Michael addition method. All the 
β-glycosides had MIC values of >128 μg/mL. 2-Benzylphenol was found to have MIC values 
of 64 μg/mL for Streptococcus agalactiae, Streptococcus pneumoniae and Streptococcus 
pyogenes which is similar to the MIC value for cefaclor and cefaoxil, which are used in the 
clinic. Using a different synthetic route based on phase transfer catalysis, β-glucosides and 
β-galactosides of 7-hydroxyflavone, chrysin and 7,8-dihydroxyflavone were synthesised. All 
the β-glycosides had MIC values of >128 μg/mL whilst 7,8-dihydroxyflavone and 7-
hydroxyflavone had values of 25 and 6.25 μg/mL for Staphylococcus epidermidis and 50 and 
12.5 μg/mL for Staphylococcus aureus, respectively. These compounds were also tested using 
an MTT assay, against the breast cancer MCF-7 and MDA-MB231 cell lines to obtain toxicity 
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data to evaluate their anticancer properties. The preliminary cell assays concluded that all 
compounds had an IC50 >2 mM.  
1,2,3-Triazole derivatives of azidothymidine were also prepared using  ‘click’ chemistry, with 
copper catalysed reactions affording the 4’ isomers, and ruthenium catalysed reactions 
affording the 5’ isomers. 3’-Deoxy-3’-(5-hydroxymethyl-1,2,3-triazol-1-yl)-β-D-thymidine 
had comparable MIC values to azidothymidine, against Escherichia coli and Klebsiella 
pneumoniae, specifically 8 and 0.5 μg/mL, respectively. To probe the antiviral activity of these 
compounds, the compounds were fitted using Pymol into the active site of the HIV reverse 
transcriptase enzyme, which is central for antiviral activity. All compounds were found to fit 
into the active site; however, further studies are needed to definitively determine their antiviral 
activity. 
The work presented in this report display further advances the knowledge of structure-activity 
relationships within the three different classes of compounds. This can be used to further design 
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Antibiotics are compounds that have ‘the ability to form a complex with a molecule essential 
for the growth of a bacterial cell, thus inhibiting its function’.1 These compounds can either 
block cell growth or induce apoptosis. Antibiotics may either be for a specific pathogen, or 
broad spectrum, meaning they kill a variety of pathogens.2 A substance can be classified as an 
antibiotic if it has the required biological effect and if any one of the following conditions are 
met: 
(a) It is a product of a metabolism pathway. 
(b) It is a synthetic product formed as a structural analogue of a naturally occurring 
antibiotic 
(c) It antagonises the growth or survival of one or more species of microorganisms 
(d) It is effective in producing a biological effect at low concentrations.3 
The use of antibiotics could have prevented many epidemics. An example of this is the plague, 
also known as Black Death. This disease was caused by a gram-positive bacterium called 
Yersinia pestis and caused both strains of the plague: bubonic and pneumonic. There were two 
major outbreaks which were estimated to have killed nearly 40-60% of the European population 
at the time, dependant on location.4 With the introduction of the use of antibiotics, the number 
of bacterial-based infections considered as fatal has drastically reduced. It has also stopped the 
spread of these infections, which in turn has reduced the number of bacterial epidemics. 
Diphtheria is a good example of how the introduction of a certain antibiotic, penicillin and later 
followed by erythomycin, has reduced the mortality rate. This disease is caused by a gram-
positive bacterium, Corynebacterium diphtheriae, and was the third leading cause of deaths in 
England and Wales in the 1930’s. With the introduction of an antibiotic vaccine, diphtheria 
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antitoxin followed by intravenous penicillins or erythromycin, the death toll has reduced and 
now, since 1994, there have been only three cases of diphtheria in England.5 
1.1.1 The Discovery of Antibiotics 
 
 
It was Louis Pasteur who observed: ‘if we could intervene in the antagonism observed between 
some bacteria, it would offer perhaps the greatest hopes for therapeutics’.6 This statement then 
initiated an area of medicine which is collectively named antibiotics. Paul Erlich, a pioneer in 
antimicrobial chemotherapy, also imagined a ‘magic bullet’. This term represents a small 
molecule used to target the disease-causing pathogen, with the outcome of treating the said 
pathogen more effectively and in a more targeted fashion.7  In 1909, he discovered the 
compound arsphenamine and investigated its use in the treatment of syphilis. This is considered 
the first modern antibiotic, though Erlich himself did not call it an antibiotic; he used the term 
chemotherapy. In 1928, Sir Alexander Fleming discovered the antibiotic penicillin and 
published his findings of mould juice, but could not isolate the active ingredient.8 His discovery 
led the way for scientists to research this new field. It was not until 1945 that Sir Fleming 
received recognition for his discovery in the form of a Nobel Prize in medicine. He shared this 
prize with both Howard Florey and Ernest Chain. Florey and Chain isolated penicillin and 
started trials into the efficacy of penicillin as a antimicrobial. However, they had very little 
penicillin so their attention turned to large scale production. This antibiotic proved 
indispensable in World War II.  
The term ‘antibiotic’ was coined by Selman Waksman. Considered the ‘father of antibiotics’, 
Waksman’s approach was a stark contrast to that of Alexander Fleming. Sir Fleming’s approach 
relied mostly on fortunate choices, whereas Wakman’s approach was to apply a systematic 
screen that removes the luck element.5 Wakman’s research was based on screening soil-derived 
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Actinomycetes. This systematic screening process allowed for the discovery of streptomycin, 
the first effective compound to be used against tuberculosis.  
1.1.2 Classes of Antibiotics 
 
 
Since Waksman’s platform was discovered and utilised, many families of antibiotics have been 
found, however, recently there has been a decrease in antibiotic discoveries. Over the past 
twenty years there have been only two new classes of synthetic antibiotics identified: 
fluoroquinolones and oxazolidinones. The oldest of the classes are the β-lactams, this family 
includes all penicillins, which all contain a β-lactam ring. These target the cell wall, attaching 
to the penicillin binding proteins found on the bacterial cell walls. Table 1 shows this family 
along with other examples of different antibiotics classes. 
Table 1: A table showing examples of different classes of antibiotics. Table adapted from       
ref. 9 and 5. 
Class of antibiotic Examples in that class 
Year of 
discovery 
Mechanism of action 
β-lactam 
Penicillins 
Penicillin G, penicillin V, methicillin, 








acid, sulfadiazine, sulfisoxazole, 
sulfamethoxazole, sulfathalidine 
1932 
Inhibition of folic acid 
synthesis.12 
Aminoglycoside 
Streptomycin, neomycin, kanamycin, 
paromomycin, gentamicin, 
tobramycin, amikacin, netilmicin, 




synthesis, its target is 










synthesis, its target is 
aminoacyl-tRNA to the 
ribosomal acceptor site. 
15 
Cephalosporin 
First generation: Cephalothin, 
cephapirin, cephradine, 




cell wall synthesis 17 
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Third generation: Cefotaxime. 
Fourth generation: Cefpirome 






synthesis by binding to 
the 50S ribosomal 
subunit18,19 
Monobactam Aztreonam 1951 20 
Interference with cell 
wall synthesis 11 
Glycopeptide Vancomycin, teicoplanin, telavancin 1953 
Inhibits the late stage 
cell wall synthesis21 




Nalidixic acid, oxolinic acid, 
norfloxacin, pefloxacin, enoxacin, 
ofloxacin/levofloxacin, ciprofloxacin, 
temafloxacin, lomefloxacin, 






into toxic enzymes23 
Streptogramin Quinupristin, dalfopristin, pristinamycin 1963 
Inhibits protein 
synthesis by binding to 
the 50S ribosomal 
subunit18,24 
Lincosamide Lincomycin, clindamycin 1964 25 
Inhibits protein 
synthesis by binding to 
the 50S ribosomal 
subunit18 
Carbapenem Imipenem, meropenem, doripenem 1976 26 
Interference with 
cell wall synthesis27,28 
β-Lactamase 
inhibitor 
Clavulanate, sulbactam, tazobactam 1976 26 Inhibits ß-lactamase 
Lipopeptide Daptomycin 1986 







Ketolide Telithromycin 2000 19 
Inhibits protein 
synthesis by binding to 
the 50S ribosomal 
subunit31,32 
Others 






1.1.3 Mechanism of action of antibiotics 
 
There are differences between prokaryotic and eukaryotic cell structures, and this can allow 
antibiotics to selectively target one type of cell over the other. An example of a prokaryotic cell 
is a bacterium. Bacterial cells can be sub-divided into two separate classifications: 
gram-negative and gram-positive cells. Gram-negative bacteria have a thin peptidoglycan layer 
with an outer membrane. This extra outer layer is not present in gram-positive bacteria and this 
is the reason that once stained with crystal violet, only gram-positive bacteria are stained purple. 
This extra barrier also explains why gram-negative bacteria present an extra challenge when 
treating clinically.  
Different antibiotics use different pathways to effectively affect bacteria. These pathways refer 
to the mechanism of action for the antibiotic, and this is shown in Figure 1.33  Antibiotics can 
also be described as bacteriostatic or bactericidal agents. Bacteriostatic refers to the inhibition 
of growth of the bacterial cells, whereas bactericidal denotes the agents killing the bacteria. 
Clinically, however, this is not relevant without other information, such as pharmacokinetics.34 




In designing antibiotics it has to be considered whether the antibiotic will affect the cells and 
kill the bacteria. There are five targets that are used when developing antibacterial compounds: 
cell wall synthesis, fatty acid synthesis, folate synthesis, deoxyribonucleic acid (DNA) 
synthesis and protein/ ribonucleic acid (RNA) synthesis. Each involves unique biological 
pathways which are exploited and targeted by the antibacterial molecule.  
 
1.1.3.1 Cell Wall Synthesis  
 
Cell wall synthesis is the most commonly exploited target for antibacterial agents.  There is an 
inherent intrinsic target selectivity, as there is no counterpart found in human biology.35 The 
cell wall is structured from peptidoglycan; this is a crossed linked polymer containing long 
glycan chains that are bridged to form elastic and flexible structures. The polysaccharide 
chains are β-1, 4-linked N-acetylglucosamine (GlcNAc) and N-acetylmuramic acid (MurNAc) 
subunits. The differences between the gram-positive and gram-negative cell walls are shown in 
Figure 2.36 The initial stages of cell wall synthesis occur in the cytoplasm. The sugar nucleotide, 
UDP-N-acetylglucosamine (UDP-GluNAc) is used to synthesise UDP-N-acetylmuramic acid 
(UDP-MurNAc). This synthesis involves the enolpruvyl functionality that is found in 
phosphoenolpyruvate (PEP) being attached to UDP-GluNAc by an enzyme called 
UDP-GlcNAc enolpyruvyl transferase, immediately followed by a reduction of the enol group 
to a lactyl group. Then, a peptide linker is added to increase flexibility and D-Ala-D-Ala is added 
via coupling reactions using adenosine triphosphate (ATP) as a source of energy. This, thus, 
creates the UDP-MurNAc-pentapeptide molecule. This molecule is then transported across the 
cytoplasmic membrane by a lipid carrier. The second stage sees the UDP-moiety of 
UDP-MurNAc being replaced with undecaprenyl phosphate. GlcNAc is then coupled to 
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MurNAc-pentapeptide, which is catalysed by a protein which has been encoded by the murG 
gene. The new compound, GlcNAc-MurNAc-pentapeptide, undergoes transglycosylation and 
cross-linking to assemble the peptidoglycan layer once it has been translocated to the extra-
cellular side of the cytoplasmic membrane.37–39  
Examples of antibiotics that interrupt and inhibit the cell wall synthesis include β-lactam and 
glycopeptide antibiotics. As previously mentioned, penicillins are part of the β-lactam family 
and work by inhibiting the synthesis of the peptidoglycan layer in the cell wall. Facilitating the 
final step in the synthesis of peptidoglycan are penicillin-binding proteins (PBP). The 
4-membered β-lactam ring is involved in binding to the enzyme DD-transpeptidase.40 This 
therefore means that the enzymes cannot catalyse the formation of the cross-links, and an 
imbalance between cell wall production and degradation develops, causing the cell to rapidly 
die. The bacteria have, however, built resistance to this over time by synthesising an enzyme, 
Figure 2: The structure of the cell walls for both gram-positive and gram-negative bacteria. 
     Adapted from ref. 36. 
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β-lactamase, in gram-negative bacteria and penicillinases in gram-positive bacteria,41 to attack 
the 4-membered ring before it binds to DD-transpeptidase. Minimum inhibitory concentration 
(MIC) data for penicillin in Streptococcus pneumoniae infection is ≤0.06 µg/mL in susceptible 
strains and ≥2 µg/mL in resistant strains (before 2008 for any syndrome).42 Other examples of 
β-lactam antibiotics that work in a similar fashion are monobactams and cephalosporins. The 
second class of antibiotics, glycopeptides, also interfere with peptidoglycan synthesis; 
vancomycin and teicoplanin are examples of these types of antibiotics. They bind to the amino 
acids within the cell wall, preventing the addition of new units to the peptidoglycan. A specific 
configuration is needed to fit into a space left in the peptidoglycan wall. It is this specificity 
which allows glycoproteins to be selectively toxic to bacterial cell walls.21 
 
1.1.3.2 Fatty acid synthesis  
 
The second most commonly exploited target for antibacterial agents is fatty acid biosynthesis. 
It is an attractive biosynthetic pathway for antibiotics to target as the fatty acid pathway in 
mammalian cells is different to that of bacterial cells , however, for the bacteria Streptomyces 
and Actinomyces it is not possible. This is because these bacteria are not able to produce fatty 
acid synthesis inhibitors due to the fatty acid synthetic pathway being so similar to polyketide 
biosynthesis. There are two molecular forms of fatty acid synthetic pathways: type I and type 
II. Type II refers to the enzymes used by bacteria, whereas type I refers to the enzymes used in 
mammalian cells.43 This pathway can allow development of broad spectrum antibiotics to target 
the many enzymes.44 There are three stages involved: initiation, elongation and termination. 
The initiation step involves creating molecules that can be used in the elongation stage. The 
first reaction involved in this step is the transfer of an acetyl group to the pantothenate group of 
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the acyl carrier protein (ACP). The subsequent reaction is an additional transfer, from the 
pantothenate of the ACP to the cysteine sulfhydral group on fatty acid synthase (FAS). This 
allows the pantothenate group to accept a malonyl group to permit the elongation to begin.  
The elongation stage allows the fatty acid to grow in length and can be seen in Figure 3.45This 
cycle is started by the condensation of malonyl-ACP 2 with acyl-ACP 1 carried out by the 
enzyme β-ketoacyl-ACP synthase. A reduction is the next reaction to produce the aldol product 
3. A dehydration then occurs to create the alkene 4 and this is reduced to create an acyl-ACP 










Once the fatty acid has reached the correct length the termination sequence may begin. This 
stage terminates the signals to stop the growth of the fatty acid. FabI/K and enoyl ACP reductase 
are used to catalyse the end of the elongation.45 There are many examples of drugs that target 
the fatty acid synthesis, these include triclosan and diazaborine. Triclosan targets the FabI step, 
Figure 3: The elongation stage of fatty acid synthesis. The antibiotics are shown in red,   
      displaying where they are effective. Modified from ref. 45. 
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which involves enoyl-acyl carrier protein reductase. It forms a stable complex with 
nicotinamide adenine dinucleotide+ (NAD+) and the protein, thus stopping the fatty acid 
synthesis pathway. Resistance to triclosan arises when the bacteria change the Fab1 gene 
through mutation of said gene.46  Diazaoborine works in a similar fashion by targeting the 
enoyl-acyl carrier protein reductase.47  
1.1.3.3 Protein/ RNA synthesis 
 
Another mechanism used as a target for antibiotics is the exploitation of protein/ RNA synthetic 
pathways that occur at the ribosomes of bacteria. This synthetic target is split into four different 
stages: initiation, elongation, termination and recycling of the ribosome. Both bacterial and 
mammalian cells have ribosomes; however bacteria contain 30S, 50S and 70S ribosomes, 
whereas mammalian cells contain 80S ribosomes. This means that the ribosomes are of different 
molecular weights and shapes.  
Aminoglycosides, tetracyclines, macrolides and streptogramins are all examples of protein 
synthesis inhibitors and are shown in Figure 4. The data shown below is the MIC values against 
S. pneumoniae.48,49 Macrolides 9 and streptogramins 10 use the 50S ribosome to inhibit protein 
synthesis, whereas aminoglycosides and tetracyclines target 30S. The examples mentioned 
above that are 50S inhibitors work by stopping entry to the peptidyltransfer ribonucleic acid 
(tRNA)’s to the ribosome, which in turn blocks the elongation reaction by steric hindrance and 
eventually causes the dissociation of tRNA.50 The mechanism of action of tetracycline 8 
involves blocking the aminoacetyl tRNAs,51 whereas aminoglycosides (such as streptomycin 






















1.1.3.4 Folate metabolism 
 
This is another pathway for antibiotics to target. This synthetic pathway is important since it 
allows DNA to be synthesised as it creates precursors for the base thymidine, 
Figure 4: Examples of antimicrobials that affect the protein/ RNA synthesis. Streptomycin 7 is 
    an example of an aminoglycoside. Tetracycline 848, erythromyocin 948 is a macrolide   
    and dafopristin 10 is an example of a streptogramin49. The MIC data displayed shows 
    their activities again S. pneumoniae. 
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N4-N10-methylene-tetrahydrofolate 16 being the precursor. Bacteria can also be selectively 
eradicated by targeting their metabolic pathways. All cells require folic acid and it can diffuse 
easily into human cells. In bacteria, however, folic acid cannot enter, thus, the bacteria has to 
synthesise their own.  
There are two examples of antibiotics that target folate synthesis: sulphonamides and 
trimethoprim. Where they stop the synthesis is shown below in Scheme 1.52 Sulphonamides 
mimic the structure of p-amino benzoic acid (PABA) 11.  
Scheme 1: The pathway used for folate synthesis is displayed. Where the antibiotics are   
        effective is summarised. Modified from ref. 52. 
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1.1.3.5 DNA synthesis 
 
There are four stages to DNA synthesis: initiation, elongation, termination and recycling. The 
initiation process is targeted by initiator proteins. The initiator proteins gather other proteins at 
the origin site and form a pre-replication complex, which unzips the double strand. Elongation 
starts at the replication fork using an enzyme called DNA polymerase. Nucleotides begin to 
align alongside the old strand, and are added together using DNA polymerase to start forming 
the new strand. To terminate the new DNA strand, a terminator protein interacts with the DNA 
to form a protein-DNA complex with the replication fork by antagonising the replicative 
helicase.53 
Quinolones are a key group of antibacterials which target DNA synthesis in bacteria. 
Topoisomerase IV and gyrase are both enzymes which are used in the cleavage of DNA. Both 
of these are type II bacterial Topoisomerases, therefore both cut both strands of DNA helix 
simultaneously to manage DNA tangles and supercoils.54 These are the two targets of 
quinolones. This class of antibiotics are also termed as topoisomerase poisons as they increase 
the concentrations of these enzymes. They non-covalently bind at the enzyme-DNA interface 









1.1.4 Antibiotic resistance 
 
There is a serious threat to the health of humans with the increase in drug-resistant bacteria. 
Antibiotic resistance occurs when the bacterium alters so that the drug is rendered ineffective 
in promoting apoptosis and inhibiting cell growth. Some restrictions on antibiotics have been 
put in place to try to control the rate of bacteria resistance. These restrictions have, however, 
caused a lack of interest to invest from pharmaceutical companies, thus slowing down the 
development of antibiotics.55 There has been a steady decrease in the number of approved 
antibiotics, as seen in Figure 5, and since 1987 there has been no new class of antibiotics. In the 
graph, the data from 2008shows that there is a resurgence in antibiotic research.56There have 
been several years (2002, 2003, 2006 and 2011) where no new antibiotic compounds were 
approved.57There was a dip in antibiotic research but with the recent pressures from 
governments there are new antibiotics coming through the system. Drug resistance is becoming 
a bigger problem as treatment options are becoming limited and resistant bacteria are 
problematic to treat. This leads to a rise in mortality rates for these diseases.58 
Figure 5: Systemic antibacterial new molecular entities approved by the US Food and Drug 

































The number of new antibiotics that were 
approved by the FDA from 1983-2017
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There are certain organisms which have been looked into closely because resistance to these 
has proved particularly challenging. These include Enterococcus faecium, 
Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas 
aeruginosa, and Enterobacter, collectively known at ESKAPE organisms. The media in recent 
times has concentrated on the methicillin-resistant staphylococcus aureus (MRSA), which is 
also referred to as the superbug, and Clostridium difficile. Both have a high mortality rate once 
infection occurs, with the superbug being associated with hospitals. In 2016/2017, there was a 
study performed by Public Health England which stated that 97.2% cases of MRSA could be 
linked to mortality, this is 97.4% in Clostridium difficile.59Although associated with hospitals, 
MRSA can also be contracted in a community setting. In 2017, the world health organisation 
(WHO) published a list of bacteria that are in urgent need of new antimicrobials, they are shown 
in Table 2.60 There are many reasons why resistance occurs but the main reason suggested is 
the incorrect use of antibiotics. Not finishing a course of antibiotics allows the bacteria that 
were not killed by the original antibiotics to mutate and change their genes to build a resistance 
to said antibiotics. This means that those bacteria would become harder to eradicate as the 









Table 2: A table showing the priority list provided by the WHO for which bacteria have become 
resistant and are in need of new antibiotics. Adapted from ref. 60. 
The WHO list of bacteria who urgently need new antimicrobials 
Priority 1: Critical 1. Acinetobacter baumannii, carbapenem-resistant 
2.  
1. Pseudomonas aeruginosa, carbapenem-resistant 
Enterobacteriaceae, carbapenem-resistant, ESBL-producing 
Priority 2: High 1. Enterococcus faecium, vancomycin-resistant 
2.  
1. Staphylococcus aureus, methicillin-resistant, vancomycin-
intermediate and resistant 
2.  
1. Helicobacter pylori, clarithromycin-resistant 
2.  




Neisseria gonorrhoeae, cephalosporin-resistant, fluoroquinolone-
resistant 
 
Priority 3: Medium Streptococcus pneumoniae, penicillin-non-susceptible 
 
Haemophilus influenzae, ampicillin-resistant 
 
Shigella spp., fluoroquinolone-resistant 
 
 
The rate at which antibiotic resistance occurs varies depending on the compound. The timeline 
in Figure 6 shows different drugs and when resistance started to develop.61 An example of this 
is resistance to tetracycline when compared to vancomycin and Ceftaroline. Tetracycline is a 
protein inhibitor and it took nine years to notice resistance occurring. Vancomycin is a cell wall 
synthesis inhibitor and it took sixteen years for resistance to develop in Enterococci and a 
further twelve years for resistance to develop in Staphylococci. Ceftaroline took less than a year 




1.1.4.1 Mechanism of resistance 
 
There are many mechanisms by which resistance can occur. The three fundamental mechanisms 
by which bacteria become resistant to antibiotics are enzymatic degradation of the drugs, 
alteration of bacterial proteins that are the targets for the antimicrobial agents, and changes in 
membrane permeability to antibiotics. Resistance to penicillin is one example of how enzymes 
are used to alter the drug to render it ineffective. Between the years of 1946-69 resistance to 
benzylpenicillin had risen from 14% to 80%.62 The enzyme β-lactamase is produced in resistant 
bacteria; this enzyme opens the β-lactam ring. This, thus, does not allow the drug to bind to the 
PBP and, therefore, it cannot interfere with cell wall synthesis. Rifampin is another antibiotic 
used in the treatment of tuberculosis (TB). It is produced by a gram-positive bacteria 
Amycolatopsis rifamycinica. Its mechanism of action is to target RNA polymerase; however, 
bacteria have started to mutate the rpoB gene, encoding the beta subunit of RNA polymerase. 
This causes a decreased affinity for rifampin and, hence, resistance. This is a key example of 
how bacteria can alter their structural proteins to overcome the drug. There are more examples 
of how bacteria have started to build resistance to certain antibiotic families in Table 3. 
Figure 6: A timeline of when antibiotics were introduced and when resistance was identified. 
      Adapted from ref. 61. 
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Table 3:Relating antibiotic class to its target and mechanism of action.63 




































phosphorylation, efflux, altered 
target 
Lincosamides Clindamycin Translation 
Nucleotidylation, efflux, 
altered target 
Streptogramins Synercid Translation 
C-O lyase ( type B 
Streptogramins), 
acetylation ( type A 
stretogramins), efflux, altered 
target 
Oxazolidinones Linezolid Translation Efflux, altered target 
Phenicols Chloroamphenicol Translation 





Acetylation, efflux, altered 
target 
Pyrimidines Trimethoprim C1 metabolism Efflux, altered target 
Sulfonamides Sulfamethoxazole C1 metabolism Efflux, altered target 







Cationic peptides Colistin 
Cell 
membrane 
Efflux, altered target 
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1.1.5 Uses of antibiotics 
 
As previously mentioned, antibiotics have been utilised for many years, through different 
methods such as injections (intervenous) and tablets. Many of these methods are discussed in 
the following section. These groups of compounds can be used clinically, aiding human and 
animal health through use of antibiotics. They can also be used to reduce the harmful bacteria 
outside of the body; biocides render harmful organisms as inoffensive. Antimicrobials can also 
be used to create a selective media. This could produce a media that selectively inhibits certain 
bacteria growth or encourage the growth another certain species of bacteria. This could allow 
doctors to ascertain which bacterial infection is harming a person’s health and prescribe clinical 
antibiotics as required.  
 
1.1.5.1 Clinical use 
 
Antibiotics have many uses; the most common is for clinical use. As previously described, 
antibiotics are compounds that have ‘the ability to form a complex with a molecule essential for 
the growth of a bacterial cell, thus inhibiting its function’.1 They fit into several classifications, 
depending on how the antibiotics work. They can be considered broad or narrow spectrum. 
Broad spectrum refers to a compound that can kill a variety of bacteria, for example penicillins 
which have a broad spectrum range as they can be used to kill both gram-positive and gram-
negative bacteria. Narrow spectrum refers to compounds which kill a specific bacteria or strain. 
Broad spectrum antibiotics are used when a) the infection cannot be treated by a certain drug 
or b) when they are unsure of what the infection is. The problem with these antibiotics, however, 
is that they give rise to antibiotic resistance, so physicians are trying to use alternatives.64  
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1.1.5.2 Biocides in clinical practice 
 
A biocide is defined as a chemical that is intended to destroy or render harmless any harmful 
organisms by chemical or biological means, similar to an antibiotic. These compounds are often 
found described as disinfectants, antiseptics or preservatives. Unlike antibiotics, biocides are 
not selective as to which bacteria they target. This creates a toxicity problem as they can be 
harmful to humans, dependant on which concentration is used.  
There are many key stages by which a biocide interacts with the bacteria. Firstly, the biocide is 
taken up by the cell from a solution. This is followed by accumulation of a certain biocide. This 













Table 4: A table showing examples of biocides, their targets and mechanism of action. 
Adapted from tables from ref. 66,67. 


























































1.1.5.2 The use of antimicrobials in the detection of microorganisms in media growth 
 
Growth medium is used in microbiology to support the growth of microorganisms. These 
semi-solid, solid, or liquid scaffolds are full of nutrients in which allow microorganisms to 
grow. Different media are used depending on many factors, including which bacterial strain is 
growing. There are two groups of media: complex (or undefined) and defined. Complex 
medium contain plenty of nutrients, including water soluble extracts from plants or animal 
tissue and a sugar to serve as a main energy store and carbon source. The exact composition is 
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unknown; hence the media being described as undefined. Tryptic soy broth is an example of 
this media with composition casein peptone (pancreatic), dipotassium hydrogen phosphate, 
glucose, sodium chloride and soya peptone.68 The casein peptone and soya peptone are the 
water soluble extracts and the glucose is the sugar source. Defined media are carefully 
composed with exact ingredients so the exact composition is known, hence its name. There are 
also sub-divisions within these two categories. Media can also be described as either selective 
or differential. Table 5 shows the difference between these four categories. 




Grow most heterotrophic organisms 
Defined Grow more specific heterotrophic organisms 
Selective Suppress unwanted microbes, or encourage desired 
microbes 
Differential Distinguished colonies of specific microbes from others 
 
Chromogenic media are described as a differential media. The addition of a chromogenic 
substrate to the media can be used to distinguish different bacteria, and thus their identification. 
Chromogenic compounds contain substrates that can be cleaved by various biological 
pathways, usually via enzyme pathways, to release a substrate that produces a colour. An 
example of this is ortho-nitrophenyl-β-galactoside (ONPG) 17. β-Galactosidase cleaves this 
compound and releases galactose and ortho-nitrophenol 18, as shown in Scheme 2. The latter 
compound is yellow in colour. It is used for the detection of the Enterbacteriae family.70 This 
compound, however, has an affinity to diffuse in agar. To overcome this problem, 
5-bromo-4-chloro-3-indolyl-β-D-galactopryanoside (X-GAL) 19 can be used. In the presence 
of β-galactosidase, X-GAL 19 produces 4-Chloro-3-Bromo-indol-3-ol 20. This then dimerises 
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in the presence of oxygen to form 4-Chloro-3-Bromo-indigo 21, which is an insoluble blue 






Scheme 3: The cleavage of the glycosidic bond in X-GAL 19 to produce 4-chloro-3-bromo-
indol-3-ol 20. This compound then dimerises to produce the insoluble indigo 21. 
 
Different bacteria contain varied glycoside profiles. As seen previously, 17 works due to 
cleavage to produce 18. However, not all bacteria contain the enzyme glucosidase, which 
allows for the specific detection of certain bacteria. In Table 6, three different bacteria are 
shown to have different glycosidase profiles.71 
Scheme 2: The cleavage of the glycosidic bond, by β-galactosidase, to produce ortho-   
        nitrophenol 18 and galactose. 
25 
 
Table 6: The different glycosidase profiles for three different bacteria: Es. coli, B. cereus and 
P. aeruginosa. Adapted from ref. 70. Key: glu=glucose, gal = galactose, man = mannose, Xyl 
= xylose, L-Fuc = L-fructose. 
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- - - - - - - - - 
- - - - - N/A - - N/A 
 
1.1.5.4 Selective recovery of bacteria from media 
 
As previously mentioned, selective media can be used to selectively grow certain bacteria, 
while suppressing others. This is very useful when identifying a certain bacteria for diagnostic 
reasons and for selective recovery. When growing bacteria on culture plates, using an undefined 
media, the growth of certain bacteria could be hindered by the other microorganisms present. 
These competitive flora could mask the bacteria that needs to be observed.72 The addition of 
selectivity to the media allows the desired bacteria to grow without the competition. There are 
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many examples of when a selective media has been used to selectively recover bacteria. These 
are shown in Table 7. 



















From the list above, there are bacteria that are on the WHO watch list, Table 2, and these are 
likely to develop resistance.  
To help provide this selectivity, antibiotics can be added to the media. The antibiotic can inhibit 
the growth of competition flora. An example of this is the FOXCA broth which was designed 
for the detection of MRSA. Several antibiotics were added, including cefoxitin, aztreonam and 
colistin. The cefoxitin was used to inhibit the growth of methicillin-susceptible Staphylococcus 
aureus (MSSA) due to the compound being able to induce methicillin resistances. Colistin is 
Desired bacteria Reason for selective media Ref. 
Pseudomonas aeruginosa 




 Detection in smoked fish for 
prevention of listeriosis. 
76,77 
Staphylococcus aureus 
 Detection in cystic fibrous 
patients 
 Food safety 
74,78,79 
Streptococcus anginosus 




 Detection in cystic fibrous 
patients 




 Detection in cystic fibrous 
patients 
 Oral health 
74, 83 
Gemella haemolysans. 





active against Pseudomonas species, and aztreonam inhibits the growth of Enterobacteraceae 
species.84 Other examples are shown in Table 8.  
Table 8: A table showing examples of media used to selectively recover or grow certain       
bacteria. The names in red denote an antibiotic. * Not technically an antibiotic but was added 
to provide selectivity.  
Media used Targeted bacteria Ref. 
VCAT (10% cooked horse blood, 
polyvitaminic supplement, colistin, 
trimethoprim, vancomycin and amphotericin 
B) 
Capnocytophaga species 85 
HPSPA formulation (vancomycin,  
amphotericin B, cefsulodin, polymyxin B, 
trimethoprim, and sulfamethoxazole) 
Helicobacter pylori 86 
10% tryptic soy agar (TSA), sucrose, glycerol, 
Casamino Acids , NaHCO3, MgSO4-7H20, 
K2HPO4, sodium lauroyl sarcosine (SLS), 
trimethoprim. For gram-negative crystal violet 




Humic Acid-Vitamin(HV) agar supplemented 
with cycloheximide* 
Actinomycetes 88 
FOXCA broth (Iso-Sensitest broth, NaCl, 
cefoxitin, colistin, and aztreonam) 
MRSA 84 
MS-SOB medium (Mitis Salivarius agar, 
aztreonam, fosfomycin, bacitracin and NaCl) 
Streptococcus sobrinus 89 
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1.2 Methods for drug design 
 
There are many routes by which a drug can be rationally designed. Two popular approaches 
that are explored when designing a drug are: Ligand-based drug design (LBDD) and structure-
based drug design (SBDD). The different methods are shown in Scheme 4.90 
 
 
Structure based drug designs use the knowledge of the 3D structure of the biological target. 
This 3D information can be obtained through various analytical methods, including X-ray 
crystallography.  If the structure is not available then computational methods can be employed 
to predict the intended target for the compound. Using this information, a prediction can be 
made as to whether a candidate drug will have a high affinity to the target.90 SBDD is further 
Scheme 4: The different methods for drug design. 
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split into two separate groups: de novo design and virtual screening. Virtual screening refers to 
a computational technique that searches libraries of small molecules. The likelihood of a drug 
to bind to the target site comes from these libraries.91 De novo design involves ligand molecules 
and building up compounds with the constraints of the binding pocket. This stepwise manner 
has an advantage of creating novel compounds not contained in any database.92 
LBDD differs from SBDD as it uses the knowledge of other molecules that bind to the target. 
From these compounds a pharmacophore model may be derived. This model can outline the 
minimum structural requirements for the compound to bind to the target. This method can be 
further split into four categories: quantitative structure-activity relationship (QSAR), Scaffold 




Prodrugs have been described as ‘a pharmacologically inactive compound that is converted to 
an active drug by metabolic biotransformation’. The term was first coined by Adrien Albert in 
1958. Ideally, prodrugs are converted to an active form of the drug once at the desired site, 
avoiding conversion too early or too late and it would be excreted before being converted to the 
target compound. This strategy has been used to increase the selectivity of the drug to the 
required site. The first prodrug to be used was methenamine, also known as hexamine, created 
by Schering in 1899. This compound decomposes at high acidity into formaldehyde and 
ammonia. It was used against urinary tract infections with the formaldehyde being bactericidal. 
Prodrugs are very useful to consider when designing a drug as they have many desirable 
properties, such as better lipophilicity or better solubility. An active drug can be converted to a 
prodrug by adding different functional groups to adapt its characteristics. There are many 
advantages to using this approach: drugs that were previously too toxic to administer can be 
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adapted so the prodrug is less toxic and once converted to the drug it will again be toxic or 
‘active’. If solubility is an issue, adding water soluble functionalities can improve the solubility 
and these groups can be metabolically cleaved after drug administration. Adding lipid soluble 
groups can improve absorption into certain cells depending where the active site is. How a 
prodrug works is shown in Figure 7.93  
 
The intended target site for the drug will influence which prodrug is used. There are two 
different categories: carrier and bioprecursor. The carrier-prodrug principle consists of the 
active drug being attached to the carrier group which will thus change its physiochemical 
properties.93 Bioprecursors are a result of a molecular modification of the active drug itself. 
This modification to a compound can enables the resulting compound to become the active 
principle, the ability to be transformed metabolically or chemically. There are several reaction 
mechanisms used on these drugs depending on which functional group is present. Oxidative 
Figure 7: A simplified diagram of the prodrug concept. Modified from ref. 93. 
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and reductive reactions are generally used in vivo but there are some functional groups which 
use reactions that do not alter their oxidative state.94,95 A well-thought-out prodrug satisfies the 
following criteria: 
1. The linkage between the drug substance and the transport moiety is usually a covalent 
bond 
2. It is inactive or less active then the active compound in its natural form. 
3. The linkage that connects the active drug and the carrier must be broken in vivo. 
4. The carrier once it has been released must be nontoxic in vivo. 
5. The generation of the active formula must take place with rapid kinetics to ensure 
effective drug levels at the target site and to minimise either direct prodrug 
metabolisation or gradual drug inactivation.93 
Carrier-linked prodrugs are further broken down into three categories: bipartite, tripartite and 
mutual. Bipartate prodrugs consist of one carrier attached to the active drug. Triparate prodrugs 
are different from the bipartate drugs as they contain a linker connecting the drug and transport 
molecule. Ampicillin 24 belongs to the penicillin family, and is able to penetrate both gram-
negative and gram-positive bacteria. It acts as an irreversible inhibitor of transpeptidase, so is 
an inhibitor of cell wall synthesis. Once administered, esterase attacks the prodrug 22 to create 
an intermediate 23 and a carboxylic acid. This then breaks down further to produce the active 
drug as exemplified in Scheme 5. Mutual prodrugs are two, usually synergistic, drugs attached 
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1.3 Carbohydrates in drug design 
1.3.1 Natural Carbohydrates and their presence in drugs 
 
Carbohydrates, also known as saccharides or sugars, are the most abundant biomolecule and 
come in many forms including monosaccharides, polysaccharides and oligosaccharides. They 
are involved with many processes in nature, with inflammation, cell growth and development, 
cell surface recognition, and bacterial infections as a few examples. There are many diseases 
and disorders that can occur when there is a problem with the metabolism of certain sugars. An 
example of this is galactosemia. This term refers to all disorders involving galactose 
metabolism. Some of the problems arising from these disorders include: hepatocellular damage, 
Scheme 5: An example of a tripartite prodrug.  
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Es. coli sepsis and liver failure.96 It has also been reported that glycosylations, particularly 
N-linked glycosylation, on a surface of the immunodeficiency virus limits the neutralising of 
the antibody response to simian immunodeficiency virus. This occurs due to sugar shielding 
the virus from immune recognition.97  
Carbohydrates have been used for medicinal purposes for many conditions such as honey for 
antibacterial properties.98 They are essential in glycoconjugates; these different drugs produce 
varying biological activities. They are found in many forms as drug conjugates. Figure 8 shows 
the most commonly used form of the sugar when attaching it to a drug. The data was compiled 
from the United States Pharmacopoeia/the National Formulary, European Pharmacopoeia, 
Japanese Pharmacopoeia sixth edition, and Chinese Pharmacopoeia 2010 (data was correct as 
of 2015).99 The most common forms are polysaccharides and their derivatives which includes 











Figure 8: Data analysis of the composition of carbohydrate drugs records from the     




A class of glycoconjugates are saponins. These are secondary metabolites which are found 
naturally in some plants and marine life. They are steroidal glycosides and can be used for a 
wide range of sicknesses. Some of these possess antimicrobial properties. Tigogenin 3-O-β-D-
xylopyranosyl- (1→2)-[b-D-xylopyranosyl (1→3)]-b-D-glucopyranosyl-(1→4)-[aL-
rhamnopyranosyl-(1→2)]-b-D-galactopyranoside  (TTS-12) 25 and tigogenin 3-O-b-D-
glucopyranosyl-(1→2)-[b-D-xylopyranosyl- (1→3)]-b-D-glucopyranosyl-(1→4)-b-D-
galactopyranoside (TTS-15) 26 both have excellent activities against Candida albicans with 
MIC80 10 and 2.3 mg mL
-1, respectively, and Cryptococcus neoformans with MIC80 1.7 and 6.7 









1.3.2 Glycosylations in chemistry 
 
Glycosylations involve the reaction between a glycosyl donor, usually protected, and a glycosyl 
acceptor. The donor usually has a leaving group at the anomeric centre which allows the 
accepter to attack the C-1 position.101 The bond formed is called a glycosidic bond, there are 
many forms of this bond, with the most common being O-glycosidic bonds. This type of 
Figure 9: The structures of TTS-12 (25) and TTS-15 (26). 
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glycosidic bond references the oxygen used to link the glycoside to the aglycone. This is the 
most common glycosidic bond as the most abundant disaccharides, sucrose, lactose and 
maltose, all contain this bond.102 There are also N- (common in N-glycans)103, S- and C- 
glycosidic bonds.  
Glycosylations are common reactions in nature; they result in glycosides, polysaccharides or 
glycoconjugates. There are, however, still difficulties when trying to perform these in a 
laboratory environment. They tend to be sensitive to water, especially if a halogenated leaving 
group is used; hydrolysis of the sugar tends to happen rather than the desired glycosylation.  In 
nature, there are many pathways by which glycosylations occur; all involve the use of one or 
more enzymes to produce the desired product. There are five main groups of enzymes that are 
used during glycosylations in nature, examples of these are shown in Figure 10; 
glycosyltransferase (A), reverse glycosidase (B), glycan donor transferase (C) 
transglycosylation (D), and lipid-linked donor transferase.104 Both examples of donor and 
acceptor pathways are shown. 
These types of reactions are important in biological systems. Glycans themselves function as 
an energy source, structural components, and recognition compounds for carbohydrate binding 










1.3.3 Carbohydrate uptake system 
 
The PEP: phosphotransferase system (PTS) is the overall process utilised by bacterial cells to 
uptake carbohydrates. It was first discovered in Es. coli by Kundig et al. in 1964.107 Equation 1 




→  𝑃 − 𝐻𝑃𝑟 + 𝑝𝑦𝑟𝑢𝑣𝑎𝑡𝑒 (1) 
𝑃 − 𝐻𝑃𝑟 + 𝑐𝑎𝑟𝑏𝑜ℎ𝑦𝑑𝑟𝑎𝑡𝑒 → 𝐶𝑎𝑟𝑏𝑜ℎ𝑦𝑑𝑟𝑎𝑡𝑒 − 𝑝ℎ𝑜𝑠𝑝ℎ𝑎𝑡𝑒 + 𝐻𝑃𝑟 (2) 
𝑃𝐸𝑃 + 𝐶𝑎𝑟𝑏𝑜ℎ𝑦𝑑𝑟𝑎𝑡𝑒 → 𝐶𝑎𝑟𝑏𝑜ℎ𝑦𝑑𝑟𝑎𝑡𝑒 − 𝑝ℎ𝑜𝑠𝑝ℎ𝑎𝑡𝑒 + 𝑝𝑦𝑟𝑢𝑣𝑎𝑡𝑒 (1 + 2) 
Equation 1: The general process used in PTS. 
 
The system consists of two enzymes (EI and EII), Phospho-histidine-protein (P-HPr) and PEP. 
The PEP is used as an energy source as well as a donor for the phosphoryl group for the 
carbohydrates phosphorylation. There are several steps involved in the system, beginning with 
enzyme I (EI). This autophosphorylates the histidine-protein (HPr) to create P-HPr. The 
Figure 10:  Four of the key enzymatic glycosylations in nature. Glycosyltransferase (A),   
         reverse glycosidase (B), glycan donor transferase (C) transglycosylation (D). 
         Adapted from 104.  
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phosphoryl group (P) is provided by PEP. The P group is then transferred onto the carbohydrate 
using enzyme II (EII). Unlike EI, EII are specific for one type of carbohydrate.109 There are 
three domains which are found in this enzyme: IIA, IIB and IIC. IIA first becomes 
phosphorylated and passes on the phosphate to IIB. The IIC domains allow the intracellular 
carbohydrate phosphorylation.110,111 
The phosphorylated carbohydrate is then used in glycosis, via the Embden-Meyerhof-Parnas 
pathway, which occurs in the cell.112 The glycosis pathway allows for the release of energy 
from the carbohydrates. This is not the only metabolic pathway used, although it is the most 
common. Entner-Doudoroff pathway is another route used to convert carbohydrates into 
pyruvate. Pseudomonas113 and Azotobacter114 both use this pathway in preference to glycosis. 
The uptake system is used to allow carbohydrates into the cell, which also includes drugs with 
carbohydrates attached. 
 
1.3.4 Carbohydrate prodrugs 
 
Glycosides have been used to create prodrugs for a variety of different biological activities. 
Carbohydrates are chosen as they can increase bioavailability, solubility, activity, and 
selectivity. For example, ciprofloxacin is an example of a fluoroquinolone, but since its 
introduction resistance to this compound has risen. Glycosides of the compound were 
synthesised and tested against various bacteria, these results are shown in Figure 11. The 
glycosides showed similar, but lower, activities to the parent compound, ciprofloxacin. These 




Another example is glycosylation of nadifloxacin. These glycosides were synthesised and 
tested against various bacteria. As seen with previous glycosidic prodrugs, their activities were 
less than that of the parent compound. In most gram-positive bacteria, the glycosides 




Figure 11: The structure of ciprofloxacin 27 with its glucose 28 and galactose 29    
        conjugates. The data shown is the diameter of the zone of inhibition in a disc 




Figure 12: The structure of nadifloxacin 30 with its glucose 31 and galactose 32                  
conjugates. The data shown is the MIC determined by the bioscreen method. 







1.4 Overall aims and objectives 
1.4.1 Overall aims of the project 
 
The overall aim of this project was to create novel carbohydrate prodrugs, with a focus on 
antimicrobial activity. These compounds were be designed to couple a sugar to an  antimicrobial 
compound, to produce a glycoside which inhibits the growth of certain bacteria to be potentially 
used in selective media. This was done through the design and synthesis of the prodrugs 
followed by biological testing, including enzyme hydrolysis and MIC data. This allowed 
structure-activity relationships (SARs) to be derived. Within this project there were three 
different series containing three different antimicrobial compounds (bisphenol, flavonoids, 
1,2,3-trizoles with the core that contains azidothymidine (AZT)).  
1.4.2 Overall objectives of the project 
 
The aims for the project have been completed by firstly using different synthetic pathways to 
create the various prodrugs, including glycosylations and click chemistry methods. These 
prodrug compounds were then tested using a variety of biological methods. The MIC100 data 
was collected using a bioscreen method, using different media, as well as using an agar method. 
The bacteria were chosen based on the pathogenicity, gram-positive and gram-negative bacteria 
were used.  Where applicable, cell assays were used to study and evaluate the cancer properties 
of the flavonoid containing compounds. AZT was originally released onto the market as an anti-
viral but was also found to have antimicrobial properties. A fitting model was used to explore 
the antiviral properties of the compounds that contain the 1,2,3-traizole core. AZT was 
originally released onto the market as an anti-viral but was also found to have antimicrobial 
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properties. This used Pymol to fit the compounds in the enzyme active site in HIV reverse 







































Chapter 2 – The synthesis and 
microbiological evaluation of carbohydrate 

















This series of compounds, the target molecules 33-34 which are shown in Figure 16, used a 
prodrug approach for drug design. The active drug would be released once the sugar moiety has 
cleaved in the target bacterial cell by glycosidase enzymes. Bacteria contain a range of these 
enzymes and different bacterial strains contain different glycosidase enzymes, as summarised 
Table 6. In this way, it has been hypothesised that it is possible to selectively deliver 
antimicrobial agents to specific bacterial strains by careful matching of glycoside prodrugs to 
the enzyme profiles present in the bacteria. In addition, the PTS, which is the transport protein 
system that is involved in bacterial carbohydrate uptake, will allow active uptake of the 
prodrugs within bacterial cells.108    
 
2.1.1 Polychlorinated compounds  
 
There are many poly-aromatic compounds which display excellent antimicrobial properties. 
Triclosan 38, 2,4,4’-trichloro-2’-hydroxydiphenyl ether, is a broad spectrum antimicrobial 
agent which is considered part of the bisphenol class, its structure shown in Figure 13. It has 
been shown to have good activity against S. aureus (ATCC 29213) and Es. coli (ATCC 25922), 
with moderate activity against MRSA.117 This compound 38 has good antimicrobial activity 
when compared to other antimicrobials which are also used as topical agents in dermatology, 
the data is presented in a table in Figure 13.118  It was discovered in the 1970’s, and has been 
used in a variety of different products, including deodorants, soaps and cosmetics119–121, and 
dermatological and topical preparations for protection of skin.118 It has been used in these 
products as it contains antimicrobial properties while still being gentle on skin.119 Using the 
right concentrations, triclosan 38 can also be used as a biocide.67 In recent years, however, there 
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have been concerns over the safety of this compound, in animal studies it is thought to affect 
thyroid functions.122 The major concern, however, is the resistance that bacteria have acquired 
to 38. Triclosan 38 at a low concentration is a fatty acid synthesis inhibitor, whereas as a biocide 
has multiple cytoplasmic and membrane targets.123 There are many mechanisms by which 









 Hexachlorophene (hex) 39, also known as 2,2'-methylenebis(3,4,6-trichlorophenol), is also 
another example of a bisphenol, structure shown in Figure 14. It was first patented as a 
broad-spectrum antimicrobial in 1941 by Gump.132  The mechanism of action for this compound 
Bacterium Mechanism of resistance Antibiotic cross-resistance Ref. 
Es. coli fabI mutations; efflux Yes 124–126 
P. aerginosa Multiple efflux systems Yes 127,128 
S. aureus fabI mutations No 129 





Figure 13: The structure of triclosan 38.  The MIC data is also shown; data collected using a      
micro-dilution assay.115 A table showing triclosan’s 38           




(39) involves inhibition of the membrane bound part of the electron transport chain, at higher 
concentrations it can cause protoplast lysis and inhibit respiration.133–135  It was used in soaps 
and cosmetics was taken off the market due to toxicity concerns, much like triclosan 38.136,137 
Hex, 39, was linked to brain lesions in infants before been taken off the market in 1975.138 The 
drug was found to have a cumulative effect and was absorbed through the skin.139,140   
Bromochlorophen (BCP) 40 and dichlorophene (DP) 41 are the anti-bacterial agents that have 
been used previously in cosmetics and deodorants, structures shown in Figure 14.141 Notably, 
they all possess phenolic groups that allow for easy attachment to carbohydrates, through 
glycosylations, to form a range of glycoside prodrugs. Use of Hex 39 and BCP 40 has declined 
due to their toxicity; however, using the prodrug design can reduce the compounds toxicity and 















2.1.2 Justification for drug design  
This series of compounds 35-37 has been designed based on previous work.142  Dr. Brierley’s 
work explored how attaching various bisphenolic compounds to a carbohydrate affected the 
activity of the phenolic compound. The glycosides of these compounds were synthesised and 
tested for the antibacterial efficacy and selectivity alongside the free anti-bacterial agents, the 
target compounds 35-37 are shown in Figure 15. 
Figure 14 : The structures of bromochlorophen (BCP) 40, dichlorophen (DP) 41 and         





Once compounds 35-37 were synthesised, their MIC values were determined and these are 
summarised in Table 9. The red lettered microbials are gram-positive bacteria, and the yellow 
highlighted values represent those with a MIC value of ≤ 32 µg/ml. In the table, the glycoside 
derivatives are compared with the underivatised compounds. For hex, 39, the MIC values for 
both gram-positive and gram-negative bacteria were under 32 µg/ml. Due to the outer 
membrane of lipopolysaccharides and proteins found in gram-negatives, the MIC values were 
generally higher in the gram-negative bacteria when compared to the gram-positive bacteria. 
The glucosides are generally more active than the galactosides, and the carbohydrate prodrugs 
are less active than the free anti-bacterial agents. This is due to the extra step of the enzyme 
cleaving the carbohydrate to release the compound, so under the same time conditions would 
have expected a lower MIC value.  
With all the above compounds there are halogens attached to the bisphenol moiety. The more 
halogens attached to the compound the lower its MIC. When designing the bisphenol 
compounds for preparation in this work, careful consideration was paid to which bisphenol 
moieties to use. In previous work, it was hypothesised that a free hydroxyl on the bisphenol 
moiety of the prodrug was responsible for the antibacterial activity. The hydroxyls in the ortho 




position on the rings are vital for activity, once the hydroxyl groups are moved to the para 
position on the ring the MIC activity in Es. coli decreased from >40 µg/mL with 
2(2-hydroxybenzyl)-phenol to >100 µg/mL with 4(4-hydroxylphenyl)-phenol. The hydroxyl 
forms hydrogen bond interactions with Y156 and with the 2’-hydroxyl group of NAD+ ribose 
ring. This allows for a stable enzyme-cofactor complex to form in FabI.118 This was also taken 
into consideration when designing the target compounds for this work. Thus, glycosides were 
designed that incorporated a free phenolic group alongside the non-phenol counterpart. By 
preparing derivatives that do not have halogens, it was hypothesised that it would also be 
possible to compare the activities of the halogenated and the non-halogenated compounds to 
see the extent of the influence of the halogen on anti-bacterial properties. In this way, SARs 














Table 9: A table showing the results of screening several bis-phenol compounds attached to 
various sugars against a range of bacterial strains, as performed by L. Brierley.142 It is 
highlighted in yellow where the value ≤ 32 µg/ml. The microbials labelled in red are 
gram-positive bacteria. The broth is CM5.  
 
 
Organisms MIC (µg/ml) of various bis-phenyl moieties attached to various sugars. 
39 40 41 
Hex 39 35a 35b BCP 40 36a 36b DP 41 37a 37b 
B. cereus <0.5 16 16 1 16 16 2 128 32 
E. facalis <0.5 32 16 4 32 32 8 >128 128 
E. faceium <0.5 64 16 4 32 32 8 >128 64 
S. aureus <0.5 32 16 1 32 32 4 >128 64 
S. epidermis <0.5 16 16 <0.5 16 32 4 >128 64 
St. agalactiae <0.5 16 8 <0.5 8 16 1 128 32 
St. pneumoniae <0.5 1 2 <0.5 8 8 <0.5 32 8 
St. pyogenes <0.5 64 2 <0.5 1 8 <0.5 128 8 
St. viridans <0.5 16 8 2 16 32 4 >128 >128 
C. freundii 16 >128 128 >128 >128 >128 32 >128 >128 
Cr. sakazakii 4 >128 128 >128 >128 >128 16 >128 >128 
En. cloacae 4 >128 128 >128 >128 >128 4 >128 128 
Es. coli 8 >128 128 >128 >128 >128 64 >128 >128 
K. pneumoniae 8 >128 64 >128 >128 >128 64 >128 >128 
P. mirabilis 2 >128 128 8 128 >128 8 >128 >128 
Ps. aeruginosa 8 >128 128 >128 >128 >128 128 >128 >128 
Sa. typhimurium 16 >128 128 >128 >128 >128 32 >128 >128 
Se. marcescens 8 >128 64 >128 >128 >128 64 >128 >128 
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2.2 Aims and objectives of the bisphenol containing compounds 
 
2.2.1 Aims for the bisphenol moiety containing prodrugs  
 
Previously, glycosides containing a bisphenol moiety have been synthesised and studied for 
their biological activity.143 These compounds, 35-37, are shown in Figure 16, they were used 
for the basis of the design of 33 and 34. This series of compounds that have been synthesised 













Figure 16: The previously synthesised compounds, 35-37,116 and the target structures, 33-34, 




These compounds were designed to probe the structure-activity relationships (SAR) with other 
bisphenolic compounds that have previously been investigated.142 Specifically, 33 and 34 were 
designed to probe whether the free hydroxyl, in the meta position the aromatic ring without a 
glycoside, had any bearing on the antimicrobial activity of the compounds. Also, compounds 
35-37 were used to investigate the influence of halogens present on the bisphenolic rings on the 
antimicrobial activity. 
2.2.2 Objectives of the bisphenol moiety containing prodrugs 
 
The aims for this chapter were achieved by utilising an aq. glycosylation method, a Michael 
style of reaction.  A base was used to deprotonate the bisphenol and this allowed the 
deprotonated moiety to attack the anomeric centre of the halogenated sugar. These compounds 
were then deprotected to give the target compounds 33 and 34. The MIC data was collected 
using a media method; using various media, namely Mueller-Hinton broth (MHB), CM5, and 















2.3 Results and discussion 
 
 2.3.1 Synthesis 
 
2.3.1.1 Synthetic route to synthesising the target molecules 33 and 34 
 
The target compounds 33-34 and the retrosynthetic route for these compounds are shown in 
Figure 17. As can be seen in the retrosynthetic analysis, the glycosidic bond between the 
carbohydrate and the bisphenol moiety was cleaved and this left the carbohydrate with a leaving 
group on the anomeric centre and hydroxylated bisphenol moiety. The difference between 
glucosides and galactosides is the stereochemistry of the hydroxyl position on the C-4 position 
on the carbohydrate ring. 
Figure 17: The target compounds 33-34. The retrosynthetic route is also shown beneath the 
         target compounds.  
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Scheme 6: The reaction scheme for the synthesis of 33 and 34. The compound in the   
        square bracket represents an intermediate that was partially purified. 
For the synthetic route, shown in Scheme 6, a glycosylation method involving NaOH was used. 
This reaction involved the aglycone (bisphenol) and the halogenated sugar. A brominated sugar, 
brominated at the anomeric centre, was used to provide a good leaving group in the sugar for 
the deprotonated aglycone to attack. A glycosyl halide was chosen as they are versatile and 
provide a halide, a good leaving group, in the anomeric position. The bromide was chosen in 
the anomeric centre as it is more reactive then its chloride and fluoride counterparts, it is also 
the most common halide used.144 The fluoride and chloride are more stable, which therefore 
makes them inferior glycosyl donors. The glycosyl iodide compounds are more reactive than 














The NaOH was added to the bisphenol firstly and allowed to stir for 20 min, to allow the 
deprotonation of one of the hydroxyls on the bisphenol compound before the sugar was added. 
The halogenated carbohydrate was then added to form the acetylated intermediate. The 
glycosylation only occurred at one of the free hydroxyls. This could be due to the ratios used 
in the reaction NaOH: bisphenol: sugar (1:1:1), so only one sugar molecule reacted with one 
bisphenol compound. Another theory could be that the oxygen present in the ring in the 
carbohydrate could hydrogen bond to the free hydroxyl, thus only single glycosylations are 




2.3.1.2 Optimisation of the glycosylation reaction   
 
As previously mentioned, there are different routes in which to perform glycosylations. In this 
work, different glycosylation methods were used to try and optimise the yield. Phase transfer 
catalysis (PTC) was a reaction method which was used. PTC involves the use of a catalyst to 
enable the migration of a reactant from one phase to another, this then allows the reaction to 
occur. The catalyst used was tetrabutylammonium hydrogensulfate (TBAHS), with the K2CO3 
deprotonating the aglycone. The tetrabutylammonium ion forms a complex with the 
deprotonated bisphenol compound. This, in turn, allows a transition state between the 
halogenated sugar and the bisphenol to form, the bromide then acts as a leaving group and gives 
Figure 18: The possible hydrogen bond present in the acetylated intermediates in for the   
        synthesis of 33b and 34b. 
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the glycosylated bisphenol. The results for these reactions are shown in Figure 19. The 















As can be seen in Figure 19, only one of the methods was successful. The PTC reaction did not 
afford the product; this could be due to the base not being able to deprotonate the bisphenol 






Figure 19: A table showing the different glycosylation methods used. NR = no reaction. 
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2.3.1.3 Mechanism by which the reaction occurs 
 
The aglycone attacked the C-1 carbon and produced the β-anomer. The lone pair on the oxygen 
in the ring activates the C-1 position, leading to the formation of the oxocarbenium ion. The 
oxygen in the carbonyl in the acetyl group then in turn attacks the C-1 position and pushes the 
electron from the double bond onto the oxygen in the ring. This reaction can be described as an 
SN1 mechanism, or unimolecular. The acetyl protecting group leads to the formation of the β-
anomer due to neighbouring group participation (NGP), as seen in Scheme 7. NGP, also known 
as anichermic assistance, is present in this mechanism due to acetyl groups being used as the 
protecting group. This phenomenon stabilises the intermediate produced by being bonded to 
the anomeric centre.147 Due to the steric hindrance around C-1 position the deprotonated 
aglycone can only form the β-anomer.  
 
 
To ascertain which anomer was formed 1H- nuclear magnetic resonance (NMR) spectroscopy 
was used. The J values between these two anomers changes drastically, with β-anomers having 
Scheme 7: The mechanism for the formation of the β-anomer.  
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Figure 20: 1H-NMR spectrum for 34a, the highlighted peak is the hydrogen present at the anomeric 
        centre. The J value highlights that’s it’s the β-anomer has been synthesised. The table 
        above shows the J values (Hz) for the four compounds, 33-34, as determined from their 
        respective 1H-NMR spectra. CBD – cannot be determined. 
a coupling constant of ~7 Hz and α- anomers ~4 Hz.148 For the glycosides synthesised in this 
project, the β-anomers were formed. The coupling constants for the H-1, anomeric centre, were 
between 6.0 – 7.5 Hz. In Figure 20, the 1H-NMR spectrum of 34a is displayed with the 
anomeric peak highlighted. This doublet has a J value of 7.5 Hz, indicative of the β glycoside. 































The value for 34b could not be distinguished as there was a water solvent resonance masking 
the anomeric peak. The anomeric effect is a term to describe the stereoelectronic effect that 
dictates the axial conformational preference of electronegative substituents in the C-1 position 
in a sugar or heterocycle; therefore it determines whether the α- or β-anomers of the target 
compounds 34-35 are synthesised. It is also known as Edward-Lemieux effect and was first 
described in 1958.149,150 There are two main models used to describe this effect: electrostatic 
and hyperconjugation model. The electrostatic model states that the preference for the α-anomer 
arises from local dipole-dipole interactions. These interactions can be seen in Figure 21. In the 
equatorial position, the dipole moments are aligned and this gives a greater net dipole. The axial 
position is preferred as the dipoles oppose each other and this reduces the net dipole. This model 
is in agreement with experimental data, which suggests that the solvent effect influences the 
stabilisation of the β-anomer and in turn reduces the anomeric stabilisation, example of this is 






There is much debate, however, with the hyperconjugation model. The model suggests that 
there is a stabilising effect asserted between the unshared electrons on the heterocycle (in 
glucose and galactose these are from an oxygen) and the σ* orbital in the C1 position, seen in 
Figure 22. In the axial position, these orbitals align which lowers the energy of the system and 
causes greater stability. When in the equatorial position, these orbitals do not align so this extra 
stability is not provided. This model is supported by the direct computations of the n→σ* and 
Figure 21: The dipole interactions shown on the α- and β- anomers. 
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σ*→σ* stabilisation energies, which are based on natural bond orbital (NBO) method.153 NBO 
uses orthogonal orbitals to describe the localised construct, using algorithms that enable 






When using the block-localised wavefunction (BLW) method, however, the electron 
delocalisation slightly favoured the trans conformator of dimethoxymethane and cis for the 
substituted tetrahydropyrans.155 This method is an ab initio valence bond (VB) theory: this 
approach combines molecular orbitals theory with VB theory.156 One school of thought is that 
the steric effect dominates the conformation formed.155  
Many conditions influence this effect, the main two conditions being substituent and solvent 
effect. Substituent effects can influence which anomer is formed. Alkyoxy, acetoxy and halogen 
substituents on the anomeric centre prefer the axial position, whereas hydroxyl prefers 
equatorial.157 The solvent effect shows that the solvent used will help dictate which anomer is 
formed. Computation studies have shown that the conformational preference is reduced in 
solution, and this increases as the polarity of the solvent increases.158  When designing the 
synthetic pathway for compounds 34-35 the above conditions had to be taken into consideration 
as the β-anomer was the target stereochemistry.  
Figure 22: The hyperconjugation model. This shows the lone pair orbital on the oxygen and       
the σ* orbital in C-1 position.  
60 
 
2.3.1.4 Optimisation of the purification for the target compounds 
 
After the acetylation reaction, the compounds were partially purified using column 
chromatography. The product was only partially purified as the acetylated compounds and the 
bisphenol starting materials had very similar Rf values on thin layer chromatography (TLC), 
0.46 in a solvent mixture of ethyl acetate: petrol ether   (3:2), and therefore had very similar 
retention times on the normal phase column. The protected glycosides were partially purified 
using normal phase (NP) column chromatography ethyl acetate: petrol ether   (3:2). The 
compounds were then deprotected using anh. MeOH and K2CO in a process called 
methanolysis, with the K2CO3 being used as a base catalyst. This crude mixture was then 
purified using reverse phase chromatography, using 0.1% formic acid in water: acetonitrile 
(3:7). When the final products were first purified it was performed using NP column 
chromatography, with solvent system of methanol: dichloromethane (DCM) (1:99 up to 1:9).  
In NP silica, compounds with hydrophilic properties contained within the mobile phase will 
have a high affinity to the stationary phase, in column chromatography that is the NP silica. 
Hydrophobic compounds have less affinity for the stationary phase and therefore are the first 
to be eluted. To counteract this, methanol (a polar solvent) was used to try and elute the 
hydrophilic target compounds. This, however, did not work on small scale reactions. When NP 
silica eluted the targeted molecules, the retention time was a prolonged and there will be more 
ineractions with the stationary phase. For these reasons, reverse phase (RP) silica column 
chromatography was used. The polar nature of the compounds meant that the compounds 




2.3.1.5 Yields and purity of the target compounds 
 
When synthesising these compounds there was a difference in yields between the glucosides 
and galactoside, as well as differences as to which bisphenol moiety was used. The compounds 
33b and 34b contained the extra hydroxyl on the aromatic ring. It is hypothesised that the 
hydroxyl hydrogen bonds to the oxygen in the carbohydrate ring. This provides more stability 
and has caused the yield to increase when compared to no extra hydroxyl present.  
 The purity for these glycosides was determined using a high performance liquid 
chromatography (HPLC) method, using a gradient solvent system. Each compound has >99% 
purity, with the results seen in Table 10. A solvent system of A=0.1% formic acid in H2O and 
B=MeCN was used, with a flow rate = 1.0 mL/ min. Compounds were eluted with a gradient 
of 5% B to 80% B for 30 min. Wavelengths 254, 280, and 210 nm were used. A gradient was 
used to expose any compounds that are less polar than the target compound, such as hydrolysed 
sugars. An evaporative light scattering detector (ELSD) was used in conjugation with UV in 
the HPLC as some of the side products could be ultra-violet (UV) inactive, an example is the 
hydrolysed sugar. The yields and purities for compounds 33-34 are shown in Table 10. 






Compound Yields (%) Purity (%) 
33a 9 99 
33b 15 99 
34a 7 99 
34b 11 99 
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2.3.2 Microbiology data for the bisphenol series  
 
2.3.2.1 Bioscreen method 
The bioscreen method is used to quantitatively measure bacterial growth in different broth 
mediums. The bioscreen method is described as turbidimetric. A bioscreen can measure the 
optical density (OD) of the bacterial cells in a broth at a certain temperature and wavelength. It 
allows for up to 18 bacterial organisms over 9 different concentrations to be measured. It can 
be applied to determine how an antibiotic may affect the growth of different bacterial cells, 
when compared to a control which contains no drug.  
As the bacteria grow in the bioscreen plates they follow a pattern; containing four phases or 
stages. These are shown in Figure 23. The first phase is the lag stage, also known as the latent 
period. In this phase, the bacteria are thought to adapt themselves to the growth conditions. This 
may be due to dilution of exoenzymes and nutrients that are given out by the growing cells. The 
dilutions means that these cells are not close to each other, which makes sharing these materials 
more difficult.159 They mature, with little to no cell division occurring.160  They then enter the 




=  𝜇𝑋 
Equation 2: An equation to express the exponential stage of growth in bacteria. 
Where X is the number of cells, or equally the mass of the cells, µ is the growth rate constant 
(1/time) and t is the time taken for the cells to grow. The specific growth rate constant depends 
on its surroundings, if unchanged it is equal to the same as the constant at time = 0.159 
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The third stage in the growth of the bacteria is the stationary phase. There is no net growth in 
this stage; therefore Equation 2 is equal to zero. The cells are still dividing at the same rate that 
they are dying.161 There are many reasons this could happen, one common reason is all the 
nutrients are used up. Another reason may be that the waste products which are produced when 
the cells grow are beginning to inhibit cell growth. Although, as stated earlier, the net growth 
is zero, there can sometimes be a small growth. This is caused by the dead cells lysing and 
providing a source of nutrients. The final phase in bacteria growth is the death stage. This is 
characterised as a net loss in cells. The death of cells is exponential, but often slower then cell 



































Figure 23: A graph showing the growth of a bacterium, in relation to time.  
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2.3.2.2 Justification for organisms used 
 
The tables display the bacteria that were chosen for these projects. Where they are naturally found and their pathogenicity are also shown, as a 




Bacteria chosen Naturally found Pathogenicity Refs. 
Bacillus cereus 
 
Decaying organic matter. Fresh and marine 
waters. Vegetables and fomites. Intestinal tract 
of invertebrates. 
Food poisoning and gastro-intestinal infections. 
Local and systematic infections in immunocompromised 




Gastro-intestinal and urinal tract in mammals. 
Wound and soft tissue infections. Meningitis 






Skin and nasal cavities. 
Adaptable to human flora conditions and can colonise easily. 
Sole cause of epidural abscess, acute endocarditis, 
botryomycosis, impetigo bullosa, pyomyositis, toxic shock 




Skin and mucous membranes of the human 
body. 
Colonises the skin. Predominant pathogen of sepsis in preterm 






Lower gastintestinal and vaginal flora. 
Affects babies, generally in the first 6 days of life. Been an 
increase in adults and elderly incidences (in the US), mostly 




Throat and skin. 
Exclusively affects humans, ranging from mild skin conditions 
to life threatening diseases. Infections include streotococcal 




Mucosal surfaces of the human upper 
respiratory tract. 





Most prevalent in the oral cavity but also 
found in the upper respiratory tract, the female 
genital tract, and the gastrointestinal tract. Can 
also be found on human skin flora. 
Causes endocarditis, bacteraemia, abscesses in the lungs, 




Gram negative bacteria 
 
Bacteria chosen Naturally found Pathogenicity Refs. 
Citrobacter freundii 
Water, soil, food, and the intestinal tracts of 
animals and humans. 
In immunocompromised people, can lead to such diseases as 




Water, soil, food and some foodborne sources 
including milk and meats. 
(Formally known as Enterobacter sakazakii) Affects neonates. 




Human gastro-intestinal tract. Also found in 
soil and sewage. 
Hospital-acquired sepsis, nosocomial pneumonias, nosocomial 





Human colon and other warm blooded 
animals. 
There are four types of Es. coli: B2 and D damage 
gastrointestinal barriers and cause infections such as urinary 




Transmitted by contaminated medical 
equipment, blood and from hospital personal. 
Responsible for community acquired pneumonia. 187,188 
Proteus mirabilis Human intestines 





Intestinal tracts of animals, including birds, 
and people. 





Soil and surface water 
Requires little nutrition. Infect the airway, urinary tract, burns 
and wounds. Also causes other blood infections 
192,193 
Serratia marcescens Soil and water 






2.3.2.3 Microbiological results 
 
As discussed earlier, a bioscreen method was used to obtain the MIC100 values for the 
compounds 33-34. Three different broths were used: MHB, CM5, and NB. Different broths 
were used to see if the broth had any effect on the bacterial growth. MHB is the standard by 
which the European committee on antimicrobial susceptibility testing (EUCAST) and the 
clinical and laboratory standards institute (CLSI) use, NB is a good general medium, supports 
the growth of most bacteria. The control measurement for these glycosides 33-34 are the free 
compound 2-benzyl phenol (BP, 42) and bis(2-hydroxyphenyl)methane) (HPM, 43). 
2.3.2.4 Microbiological results for β-2-benzylphenol glycosides and 
β-bis(2-hydroxyphenyl)methane glycosides  
 
In Table 11, the MIC values for the free drugs, BP 42 and HPM 43, are shown in two different 
media, NB and MH. As can be seen the media has very little effect on the MIC100 data for the 
same compound. The difference between these two compounds is an extra hydroxyl which is 
present in HPM in the ortho position on second ring. Firstly, there very little differences 
between the two different broths, NB and MH. Without the hydroxyl present, the MIC values 
were improved in Streptococcus agalactiae, Streptococcus pneumoniae and Streptococcus 
pyogenes, highlighted in yellow. 
A tool used preclinically to gain information about potential toxicity is ClogP. This is the 
measure of lipophilicity of a given compound, with the higher the ClogP value, the more 
lipophilic the compound. Many lipophilic antibiotics are less active against gram-negative 
bacteria. This is due to the structure of the outer membrane; it is composed of 
lipopolysaccharide molecules that form a hydrophilic environment. This gives the 
gram-negative protection against hydrophobic molecules.196 Lipophilic compounds are capable 
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of diffusing through the lipid bilayer, which is the main entry for drugs in gram-positive 
bacteria. In Table 11, the ClogP data is shown. When comparing these compounds, the ClogP 
value for BP is slightly higher than HPM. This could mean that BP is slightly more toxic than 
HMP, which is seen in the results against Streptococcus agalactiae, Streptococcus pneumoniae 
















Table 11: The MIC100 data for the underivised compounds, BP 42 and HPM 43. The NB and 
MHB refer to the media used in the bioscreen. NG – No growth. The ClogP data was     
calculated using Chem BioDraw Ultra software version 13.0. It is highlighted in yellow where 






MIC (µg/ml) of various bis-phenyl parent compounds 
 NB MHB 
OCC BP 42 HPM 43 BP 42 HPM 43 
ClogP 3.49 2.76 3.49 2.76 
B. cereus 754 128 256 128 256 
E. facalis 640 128 >256 128 >256 
E. faceium 220 128 >256 128 >256 
S. aureus 100 NG 256 128 256 
S. epidermis 691 128 256 128 256 
St. agalactiae 182 64 128 64 256 
St. pneumoniae  64 128 NG 256 
St. pyogenes 163 64 128 64 256 
St. viridans  128 256 128 256 
C. freundii 851 128 256 128 256 
Cr. sakazakii 1888 128 256 128 256 
En. cloacae 760 >128 128 64 256 
Es. coli 199 128 256 128 256 
K. pneumoniae 758 128 256 128 256 
P. mirabilis 2080 128 256 128 >256 
Ps. aeruginosa 201 >128 >256 >256 >256 
Sa. 
typhimurium 
854 128 256 128 256 





The results for the Streptococci bacteria could be a result from their uptake system which allows 
this compound 42 to be taken up when compared to the other bacteria that the bisphenolic 
compounds were analysed against. The glycosides, both glucosides and galactoside 33-34, were 

















Table 12: The MIC100 data for the glycosidic compounds, BP and HMP. The broth is NB. NG 
– No growth. The ClogP data was calculated using Chem BioDraw Ultra software version 




Organisms MIC (µg/ml) of various bis-phenyl moieties attached to various sugars. 
OCC 43 34b 34a 42 33b 33a 
CLogP 2.76 1.33 1.33 3.49 2.05 2.05 
B. cereus 754 256 >256 >256 128 >256 >256 
E. facalis 640 >256 >256 >256 128 >256 >256 
E. faceium 220 >256 >256 >256 128 >256 >256 
S. aureus 100 256 >256 >256 NG >256 >256 
S. epidermis 691 256 >256 >256 128 >256 >256 
St. agalactiae 182 128 >256 >256 64 >256 >256 
St. 
pneumoniae 
1548 128 >256 >256 64 >256 >256 
St. pyogenes 163 128 >256 >256 64 >256 >256 
St. viridans 1638 256 >256 >256 128 >256 >256 
C. freundii 851 256 >256 >256 128 >256 >256 
Cr. sakazakii 1888 256 >256 >256 128 >256 >256 
En. cloacae 760 128 >256 >256 >128 >256 >256 
Es. coli 199 256 >256 >256 128 >256 >256 
K. 
pneumoniae 
758 256 >256 >256 128 >256 >256 
P. mirabilis 2080 256 >256 >256 64 >256 >256 
Ps. 
aeruginosa 
201 >256 >256 >256 >128 >256 >256 
Sa. 
typhimurium 
854 256 >256 >256 128 >256 >256 
Se. 
marcescens 
217 256 >256 >256 128 >256 >256 
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The table shows the bioscreen results with the broth NB. As can be seen, the glycosides had the 
same MIC values. This could be due to the timescale over which the bioscreen ran, or that the 
concentrations used of the drug were too weak. The glycosides also had higher MIC values 
when compared to their underivatised counterparts when the same method was employed. This 
signifies that the glycosides are not as biological active against the bacteria in the same 
timescale as the parent compounds. This is not entirely unexpected as the cleaving of the sugar 
from the prodrug compound should delay the release of the drug; this in turn could make the 
glycosides less toxic on the same timescale as the parent compound. The ClogP values were 
also decreased in the glycosidic compounds when compared to their respective parent 
compounds.  As previously described in Section 1.2.1, prodrugs are converted to the active 
compound at the target compound, which may take an amount of time. This hypothesis is also 
shown in work on carbohydrate prodrugs performed by Dr. Brierley.142 
The glycosidic compounds 24-25 were also analysed in MHB and CM5. The results for these 
are shown in Table 13. The glycosides, again, had very high MIC values, similar values to that 
of them shown in NB.  
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Table 13: The MIC100 data for the glycosidic compounds, 33 and 34. The broth is MHB and CM5. NG – No growth. It is highlighted in yellow 





MIC (µg/ml) of various bis-phenyl moieties with their corresponding glycosides. 
OCC MHB CM5 
43 34b 34a 42 33b 43 34b 34a 42 33b 33a 
B. cereus 754 256 >256 >256 128 >256 256 >256 >256 128 >256 >256 
E. facalis 640 >256 >256 >256 128 >256 >256 >256 >256 128 >256 >256 
E. faceium 220 >256 >256 128 128 >256 >256 >256 128 128 >256 128 
S. aureus 100 256 >256 256 128 >256 256 >256 256 128 >256 256 
S. epidermis 691 256 >256 >256 128 >256 256 >256 >256 128 >256 >256 




256 NG NG NG NG 256 256 >256 64 256 >256 
St. pyogenes 163 256 256 >256 64 256 256 >256 >256 128 >256 >256 
St. viridans 1638 256 >256 >256 128 >256 256 >256 >256 128 >256 >256 
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C. freundii 851 256 >256 >256 128 >256 256 >256 >256 128 >256 >256 
Cr. sakazakii 1888 256 >256 >256 128 >256 256 >256 >256 128 >256 >256 
En. cloacae 760 256 >256 >256 64 >256 256 >256 >256 64 >256 >256 




256 >256 >256 128 >256 >256 >256 >256 128 >256 >256 





















2.3.3 Structure-activity relationships between the bisphenol moiety glycosides 
 
Using the data collected in Chapter 2, SAR can be deduced. Figure 24 shows a summary of the 
SAR collected. The addition of the carbohydrate to one of the free hydroxyls produced lower 
MIC values when compared to their respective parent compounds. This is to be expected as it 
will require additional time to cleave the sugar from the bisphenol moiety.  When referring to 
the prodrug approach this is one of these advantages, the carbohydrate was masking the drug 
producing a less toxic drug and the drug is released once enzymes cleave the sugar to produce 
the toxic compound. When comparing BP and HPM, the free compounds had the same MIC 
values in the different broths used. They also had very similar values, with BP being slightly 
more biologically active against Streptococcus agalactiae, Streptococcus pneumoniae, Proteus 
mirabilis and Streptococcus pyogenes. This is to be expected when ClogP is taken into 
consideration, with BP having a slightly higher ClogP value. 
When the glycosides were analysed, the glucosides and galactosides of BP and HPM had the 
same MIC values. They all had values over >258 µg/mL over a 24 h time period. The 
compounds 33-34 and 42-43 were compared to previously synthesised compounds 35-37, and 
the latter compounds had lower MIC values. In the compounds 35-37, both the parent 
compounds and the glycoside had lower MIC data. The only different between 33 and 35-37 is 
the amount of halogens present. The compounds 33 contained no halogens and had higher MIC 
values. As more halogens were added to the aromatic rings, the lower the MIC obtained, with 
39, as a parent compound, having values of <0.5 µg/mL for all the gram-positive bacteria tested. 
The glycosides of this compound, 42a and 42b, had similar activity to 49a and 49b which were 
higher values then their respective parent compounds.  
For 33-34 there were no difference between the glucosides and galactosides, all had the same 




trend was also seen in 39a and 39b. However in 39a and 39b, the glucosides had the same 













2.4 Conclusion  
 
The target compounds 33-34, found in Figure 25, were synthesised using an aq. NaOH 
glycosylation method. The β-anomers were synthesised, as can be seen form the 1H-NMR 
spectra, by analysing the J values of doublet for the anomeric centre. The compounds 33-34 




Figure 24: A diagram showing the SAR collected from the different bisphenol          












Figure 25: The target structure 33-34, with their respective yields and purities shown. 
 
When synthesising these compounds, 33-34, there was a slight difference between the yields. 
Compounds 33b and 34b may have had hydrogen bonding stability with the extra hydroxyl 
present in the aromatic ring not involved with the glycosylation. This led to slightly greater 
yields in 33b and 34b.  
The MIC data was collected and compared to their respective parent compounds, as well as to 
previously synthesised compounds that contain various bisphenol moieties, 35-37. Thus, SAR 
data could be deduced. In the underivatised compounds, 42 and 43, there was a correlation 
between ClogP values and MIC data. Against the bacteria Streptococcus agalactiae, 
Streptococcus pneumoniae and Streptococcus pyogenes, 42 had MIC values of 64 μg/mL and 
a ClogP value of 3.49. In comparison, 43 had a ClogP value of 2.76 and observed no notable 
MIC values against all the bacteria tested. Once a glycoside was added to the bisphenol moiety, 




SAR data was collected from comparisons between compounds 35-37, 33-34 and 42-43. The 
extra hydroxyl that is present in all the compounds other than 43 was shown to not be essential 
for biological activity. Once halogens were added to the aromatic rings, in varying amounts and 
what halogens were present, the MIC values decreased. Hex 39 was found to be particularly 
active against gram-positive bacteria, with all the ones it was tested against had MIC values of 
>0.5 μg/mL. Compared to 43, once these chlorine groups were removed the values for the 





























Chapter 3 – The synthesis and 
microbiological evaluation of triazole 















This group of compounds, structures shown in Figure 26, was designed to probe the biological 
activities of 1,2,3-triazoles derived from AZT, also known as Zidovudine. AZT was first 
marketed as an antiviral agent, but activity against gram-negative bacteria has also been 
reported.197 As the 1,2,3-triazole functionality is also reported to enhance antibacterial activities 
of compounds, this work sought to determine any benefits from combining the AZT moiety 













3.1.2 The history and further development of AZT 
 
 
AZT 52 is an antiretroviral used for the prevention and treatment of human immunodeficiency 
virus (HIV) and acquired immune deficiency syndrome (AIDS). AZT is described as a 
nucleoside derived HIV reverse transcriptase drug, and is a potent inhibitor of HIV replication 
due to an inhibition of HIV reverse transcriptase for DNA synthesis.198 There have also been 
Figure 26: The basic structures for this series of compounds. In 44-51, the R groups are   




other nucleoside based drugs released, shown in Figure 27. They are shown with their ID50 
(infectious dose) values, AZT has the lowest values of the nucleosides tested, in both HIV type 
1 and 2.148 After it was released as an anti-HIV therapy, it was discovered that 52 also had 
antimicrobial properties.197 The structure of AZT 52 is close to that of thymidine 53, which is 
a DNA base. The two structures can be seen in Figure 27, the only difference between them is 









































52 0.05 0.08 
54 1.2 2.8 
55 3 3.5 
56 2.1 5.6 
57 0.2 0.35 
58 0.7 1.3 
59 0.4 - 
Figure 27: The structure of Azidothymidine 52 and thymidine 53. The hydroxyl on the 3’                          
position of the thymidine is replaced with an azido group in AZT 52.  The ID50 is   





Whilst AZT 52 was first tested and used for the treatment of HIV and AIDS, nucleosides have 
also been tested for use as antibiotics.199 An example of a synthetic nucleoside with antibacterial 
properties is 2’,3’ dideoxyadenosine. This has a similar structure to adenosine, with the absence 
of the two hydroxyls present at the 2’ and 3’- positions. This was found to inhibit DNA synthesis 
in most gram-negative bacteria, as there is no hydrogen bond donor in the 3’ position and this 
contributes to the compound inhibiting DNA. It was found to be lethal against Es. coli,200 with 
inhibitory effects at 0.1 µmol/mL.201 This result, among others, started the interest into synthetic 
nucleosides as antimicrobial compounds. There was a high-throughput screen (HTS) performed 
on compounds for potential antimicrobial properties and AZT 52 was observed to be potent. 
The HTS assay was based on a screen-counterscreen approach and used Klebsiella pneumonia 
BIDMC12A.202 It was found to have bactericidal properties against various Enterobacteraceae 
members, with a MIC range of 0.3-2.0 µg/mL against Enterobacter aerogenes.197 Later, it was 
discovered that its mechanism of action involves phosphorylation at the 5’ hydroxyl position. 
It is metabolically activated to the nucleotide, using deoxythymidine (dThd) kinases. This 
enzyme phosphorylates the 5’ position to AZT-triphosphate 62; this can then in turn act as a 
DNA chain terminator. It was discovered that the di- 61 and mono- 60 phosphate compounds 
were less potent.197 There are several enzymes involved to create the potent AZT-triphosphate; 
namely dThd, thymidylate (dTMP) and nucleoside-diphosphate (NDP) kinases.203 Thymidine 
kinases are present in many organisms, including viruses. Cellular cytoplasmic thymidine 
kinase 1 (TK1) catalyses the intracellular phosphorylation of AZT 52 into the corresponding 
monophosphate compound. Further kinases are used to catalyse the additional 
phosphorylations.204 These enzymes are not found in gram-positive bacteria and are also not 
present in Pseudomonas aeruginosa.205 AZT-triphosphate 62 is then incorporated into DNA 
causing it to terminate the azide in the 3’-position stops the hydrogen bonding within the DNA. 





Figure 28: The mechanism of action for AZT 52. The use of enzymes allows for the        
active metabolite (AZT-triphosphate 62) to be synthesised and used as a DNA      
chain terminator. Adapted from ref. 203.  
 
Although AZT 52 is still used today for treating HIV and AIDS, there are still many side effects 
associated with the drug which result in limited clinical use. It is a known bone marrow 
suppressant, causes severe anaemia, as well as hepatic abnormalities and myopathy.206,207 




3.1.3 Nucleoside based prodrugs 
 
Prodrugs have proven to be effective for providing more pharmacokinetically or bioavailable 




position, by using different functional groups. There are two main groups of prodrugs that have 
been studied: ester derivatised and masked phosphate compounds.  
Ester prodrugs of AZT have been the main focus of most studies into prodrugs of AZT 52. 
Esters as a functional group have ideal features, they can enhance lipophilicity and oral 
absorption, but can be chemically broken down in the body by uses of the enzyme esterase. 
These prodrugs have been tested for a variety of different biological activities; including 
anti-HIV, anticancer and antimicrobial. The prodrugs shown in Figure 29 have been tested 
against a variety of different bacteria, compounds 63-66 were tested against fifteen different 
bacteria and among them different strains of the same bacteria. As expected, the compounds 
were not active against gram-positive bacteria but were all active against Klebsiella pneumoniae 
and Klebsiella oxytoca. 63 performed better than the parent compound, with 64 having the same 
MIC value. The prodrugs present in 60 and 61 contain an antibiotic, norfloxacin and 
ciprofloxacin, respectively. These prodrugs performed better when compared to 67 and 68, 
which did not contain an antibiotic attached to AZT. They worked well in both gram-positive 





Figure 29: Examples of ester prodrugs of AZT. 63-70 are reported in ref. 209, 67-70 in ref. 210. 
The MIC data is presented below each compound. 63-66 MIC was assayed              
using MHB against Klebsiella pneumoniae ATCC 10031. 63-70 were assayed using 
Mueller-Hinton broth against Klebsiella pneumoniae. *             
compared to the parent compound, AZT 52, which had an MIC= 2 µg/mL. **         
compared to commercial antibiotics: Norfloxacin MIC = 0.0381 µg/mL and         





3.1.3.1 1,2,3-Triazoles  
 
There are many triazole containing compounds with a range of different properties: examples 
of these include anti-HIV,211 anti-influenza agents,212 anti-cancer,213and antimicrobial 
compounds.214–217 Due to these properties, the triazole functional group is being explored as an 
avenue for novel antibiotics. Another avenue being explored as drug modifications for AZT is 
adding a 1,2,3-triazole moiety. Promising results for some 1,4-isomers are shown in Figure 
30.218  
  
Figure 30: The structures 71-78 which were tested against various bacteria. These are from ref. 





The compounds were tested against 4 different bacteria, two gram-negative and two 
gram-positive. The addition of a halogen to the phenyl group increased its activity against 
S. aureus. The addition of a fluoride, 75, also increased the activity in Es. coli when compared 
to 77. The addition of two halogens to the phenyl group increased the activity in B. subtilis and 
performed better than the standard it was tested against, streptomycin 5.  
The prodrugs shown in Figure 31 were all tested to assess their efficiencies to inhibit 
Ureaplasma parvum thymidine kinase (UpTK) and human thymidine kinase 1 (hTK1). 
Ureaplasma parvum are bacteria belonging to the family Mycoplasmataceae found in the 
human urinary and genital tracts with a gram-positive shape. All the compounds 79-84 
phosphorylated more efficiently with UpTK when compared to hTK1. Compound 80 was also 
5 times more potent with UpTK than hTK1 in vitro.75  The higher efficiency with UpTK the 
















Figure 31: Compounds 79-84, which all contain a 1,2,3-triazole in the 3’ position.         
        The data is showing the phosphorylation by UpTK and hTK1, with 100 M        
        ATP and the nucleosides, respectively. The data is presented as relative         





In the previous section, compounds 68-84 all contained triazoles and were used to explored 
anti-HIV and antimicrobial activities. Cefatrizine 85 is an example of a clinically used drug that 
contains a triazole moiety. It is a broad spectrum antibiotic and inhibits the final cross-linking 
stage of peptidoglycan production, thus it is a bacterial cell wall synthesis inhibitor. It is used 
in some gram-positive infections, the exception being Enterococci bacteria. The MIC data is 
shown in Figure 32. The drug is well tolerated with limited toxicity being detected in the liver 
or renal area.219,220 
 
Other examples of antimicrobial 1,2,3-triazole containing compounds are shown in Table 14. 
The precursor 86 was tested for its inhibitory activity and was found to have no activity. The 
triazole attached to an aromatic moiety drastically enhanced the activity thus providing some 
evidence that the triazole is of biological significance.217 Isonicotinylhydrazine 88 (INH), is an 
active oral drug that is highly active against Mycobacterium tuberculosis and bacteriostatic on 
the Bacillus family. Its mechanism of action is the interference with a pathway that is 
responsible for cell wall synthesis. It is, however, toxic to the liver so there was a need to design 
a different drug. The 1,2,3-triazoles exhibited similar  MIC values as INH for mycobacterial 
Figure 32: Cefatrizine 76 is a commercial drug that contains a 1,2,3,-triazole. The MIC data 





activity. Compound 89 exhibited lower toxicity and fewer side effects compared to INH this 
could be because the hydrazine is protected using the triazole.214 There has already been interest 
in carbohydrates tethered to a triazole for the purposes of antimicrobial agents. Triazole 90, a 
xylose tethered to a 1,2,3-triazole, was synthesised with a multitude of alkynes to incorporate 




















Table 14: Antimicrobial compounds containing 1,2,3-triazole moieties. MIC (µg/mL) for compounds 86 and 87 were determined by two-fold serial                   




MIC100 Data (µg/mL) 
Ref. 













64 128 16 128 16 n.d. n.d. 
88 
 






n.d. n.d. n.d. n.d. n.d. n.d. 0.62 
90A 
 




n.d. n.d. n.d. n.d. n.d. >12.5 >12.5 
90C 
 
n.d. n.d. n.d. n.d. n.d. >12.5 >12.5 
90D 
 
n.d. n.d. n.d. n.d. n.d. >12.5 12.5 
90E 
 




3.1.4 Justification for drug design 
 
This series of compounds used ‘click’ chemistry to create a 1,2,3-triazole moiety in the 
3’ position on the AZT ring. An advantage is that libraries of compounds can be quickly 
assembled, using a ‘click’ reaction. This allows many compounds to be generated and tested 
for their antimicrobial properties. From this, SARs can be defined and this can inform the 
synthesis of further libraries of triazoles. The proposed compounds are shown in Figure 33 . 
The 2 different isomers, 1,4- and 1,5-, were synthesised to explore the possibility of the position 
of the functional group affecting the activity.  
As can be seen in Figure 33, the hydroxylated moiety was synthesised to explore whether the 
phosphorylation of the hydroxyl in the 5’ position on the AZT ring (blue circle) is affected if 
the hydroxyl on the 4- or 5-position on the 1,2,3-triazole ring (red circle) is present. Compounds 
45 and 49 contain a benzyl group , it was found that a benzyl containing compounds gave lower 
MIC values than their alkyl counterparts.217 A fluorine group attached to the benzyl group in 
different positions attached to the 1,2,3-traizole ring (pink circle) can interfere with its 









3.2.1 Aims for the triazole based compounds 
 
The aim of these triazole containing compounds was to create a family of prodrugs that contain 
AZT. This drug is a nucleoside based drug, whose mechanism of action involves enzymatic 
phosphorylation of the 5’-O position to produce AZT-triphosphate. This compound is then 
incorporated into DNA, with the azide present in the 3’ position not allowing for hydrogen 
bonding between AZT and the DNA base pairs, hence causing DNA replication to terminate. 
This causes the death of the microbe as they are not able to produce DNA.  There is, however, 
limited use of this drug as an antiviral or antimicrobial due to its severe side effects. To 
overcome these problems, compounds have been designed to try and mask AZT’s activity until 
it is at the target site, to try and limit its side effects. These designed compounds 44-51 were 
synthesised to try and overcome the side effects by forming a triazole at the 3’-N position. These 
were then tested to see if they are viable and effective as antibacterials using various biological 
activity tests.  
 
3.2.2 Objectives of the triazole based compounds 
 
These aims will be achieved using synthetic methods to create the compounds 44-51. A 
synthesis of the 1,2,3- triazoles was proposed using ‘click’ chemistry, which involves reactions 
between an azide and an alkyne, in a process that is expected to be high yielding, produce by-
products (different by-products depending on the reactants used) which can be easily separated 
from the product, be stereospecific, simple to form and conducted in solvents that can be easily 
removed or are benign. This started to become popular after Sharpless described ‘click 
chemistry’ and its reactions.223 Triazoles as an additional functional group are attractive for 




synthesise using the ‘click chemistry’ methods. The 1,4-isomer for the 1,2,3-triazole is formed 
by forming CuII in situ. The 1,5- isomer is produced by using a ruthenium catalyst. The MIC100 
data was collected using a bioscreen method, using different media. A preliminary fitting model 





























Figure 34: Three different ‘click’ reactions. (A) is the Huisgen 1, 3-Dipolar Cycloaddition, 
          stereocontrol is achieved. (B) uses CuAAC and (C) uses RuAAC.  
 
 
3.3 Results and discussion 
 
3.3.1 Synthesis  
 
3.3.1.1 Synthetic route 
 
‘Click’ chemistry has proven invaluable for the formation of 1,4- and 1,5- isomers of 
1,2,3-triazoles using an azide, alkyne and different metal catalysts, dependant on which isomer 
is preferred. Originally, the ‘click’ reaction was performed using heat and stirring, also known 
as Huisgen 1,3-dipolar cycloaddition. This afforded a mixture of the 1,4- and 1,5- isomers. With 
the introduction of a metal catalyst either isomer can be selectively synthesised, the reaction 
schemes are shown in Figure 34. A copper catalyst is used in a copper-catalysed azide-alkyne 
cycloaddition (CuAAC) to produce the 1,4- isomer. A ruthenium catalyst is used to produce the 






A general reaction scheme for the formation of the different isomers is shown in Figure 35, as 




Figure 35: The general reaction schemes for the synthesis of the 1,4- and 1,5- isomers of the 





As previously mentioned, for the 1,4- isomer, a copper catalyst is used. The copper first forms 
a complex with the alkyne, which allows the carbon to attack the negatively charged nitrogen 
in the azide. In the azide, the terminal nitrogen is electrophilic, or Lewis basic, which allows it 
to interact with the Cu1. The σ-bonded copper (I)–acetylide interacts with the terminal nitrogen. 
This complex then contracts and forms a 6-membered metallacycle, which constrains the sp-
hybridised carbon present. This requires a lot of energy to activate, so there is a current theory 
that two copper ions are used to alleviate this constraint. This intermediate then forms the 1,4-
triazole with the copper in the 5’ position. This forms the final 1,4- product, and copper is then 
free to be reused, this can be seen in Figure 36. CuI  is used as the copper catalyst; this is 





























A different catalyst is used to create the 1,5-isomer. Commonly used catalysts for these 
formations contain ruthenium. In the ‘click’ reactions using RuCp*Cl(PPh3)2 it has been 
observed that the active component of the catalyst is [Cp*RuCl].225 The first part of this cycle 
starts with the alkyne and azide displacing the PPh3 groups on the ruthenium, then the strained 
intermediate is formed using oxidative coupling of the alkyne group and the azide.  Due to the 
Figure 36: The copper catalytic cycle for the formation of a 1,4-isomer. Adapted from ref. 




complex being bulky, the new bond is formed using the less sterically hindered carbon 
(containing the moiety present in the alkyne) and the terminal nitrogen in the azide. To form 
the triazole, the third compound undergoes reductive elimination, then the triazole is released 
















Figure 37: The ruthenium catalytic cycle for the formation of the 1,5-isomer. Adapted   




3.3.1.2 Optimisation of the formation of the 1, 4 isomer 
 
Several experimental conditions were initially explored to synthesise the 1,4-isomer of the 
1,2,3-triazole ring. Compound 91was first synthesised for method development. It allowed to 
obtain which synthetic pathway was greater yielding, and therefore could be used for the AZT 
containing compounds, 44-51. These conditions are summarised in Table 15. These are all an 
one-pot synthesis, meaning that the azides are generated in situ, from the sodium azide and 
corresponding halide (3-bromo-1-propanol).  
 
Table 15: The different experimental condition used to synthesis 91. The reaction can be      






Conditions Materials used Yield Ref. 
Stirring- 
65 ̊C, 18 h, 
H2O:THF 
 
77 % 226 
Microwave – 
125 ̊C, 20 
mins, 100 W, 
H2O:THF 
 
68 % 227 
Sonication- 
RT, 25 mins, 






For the sonication method, the Cu1 catalyst was added to the reactions, whereas in the other two 
methods the Cu1 was formed in situ. The sonication method is seen as an environmentally 
friendly method for chemical synthesis as it can significantly reduce the reaction time to 
minutes compared to traditional stirring. Ultrasound induces chemical or physical changes 
during cavitation, a phenomenon involving the formation, growth, and instantaneous implosive 
collapse of bubbles in a liquid.229 There was no reaction, however, with the sonication method. 
This could be due to the frequency of the sonication being insufficient to allow bubbles 
formation and subsequent implosion to occur.  
The other two methods, microwave and stirring, did afford the triazole product in very good 
synthetic yield. Microwave irradiation has been well-documented as a useful method for 
triazole synthesis, which often gives better reaction times and yields when compared to tradition 
heating methods. The heating in a microwave vessel is different to that of stirring. The reaction 
absorbs the microwave energy from the interior to the exterior of the vessel. This dielectric 
heating allows the reaction times to be shortened as it is a more effective way of heating. In the 
reaction, the polar component causes the absorption of these waves as a dipole moment is 
needed. The dipole is sensitive to the changes in the electric field, trying to realign once one is 
applied. The alternating field causes rotation in these molecules; this in turn causes heat to 
dissipate from these molecules. The heating directly correlates to the dielectric properties of the 
components. The vessel itself is not heated in the process, leading to better homogeneity and 
better selective heating of the polar compounds.230,231 
In the reactions shown in Table 15, the stirring method afforded a higher yield when compared 
to the microwave. The stirring method was used in future reactions due to this method providing 





3.3.1.3 Chemical analysis of the triazole containing compounds 44-51 
 
In this series of compounds there are two possible isomers of the 1,2,3-triazole that can form, 
specifically 1,4- and 1,5- isomers, and when analysing the product there were noticeable 
differences in the 1H NMR spectra between these two isomers. The VB theory approach can 
help explain as to why the hydrogen on the triazole, in the 5-position on the 1,4 isomer and in 
the 4-position on the 1,5 isomer, is shifted upfield in the 1,4 isomer, the positions are seen in 
Figure 38. Some of the key resonance forms are shown for both the 1,4 and 1,5 isomers, the 
upfield position on the 1H NMR spectra of the hydrogen in the ring, 5’ position in the 1,4-isomer 
and 4’ position in the 1,5-isomer (hydrogens coloured pink in Figure 38), can be accredited to 
resonance donation from the nitrogen with a function group attached. A positive charge is 
formed on the nitrogen which leaves the more electronegative nitrogen with a negative charge. 
This charge is then transferred to the hydrogen. The negative charge on that carbon causes an 
increase in electron density. This in turn causes a strong shielding effect for the hydrogen and 
hence why the resonance on the NMR spectra is upfield. The resonance peaks for the target 






Figure 38: The key resonance forms on the 1,2,3-triazole ring. The 1,4 and 1,5 isomers are 
       shown. The hydrogen coloured is the hydrogen resonance peak on the 1H NMR 





Table 16: A table summarising the resonance peaks for the hydrogens in the 1,2,3-triazole 
ring. 
Compound 
Resonance peak for the correspond hydrogens in the 
1,2,3-triazole ring (ppm) 
H-5 H-4 
44 8.24 -- 
45 8.78 -- 
46 8.88 -- 
47 8.79 -- 
48 -- 7.83 
49 -- 7.82 
50 -- 7.91 
51 -- 7.90 
 
The 1,2,3-triazoles also demonstrate characteristic features that are commensurate with the 
formation of the triazole, and loss of the alkyne and azide functionalities. An example of a 
spectrometric analysis technique that can be used in determining the formation of the 
1,2,3-triazole ring is Infrared spectroscopy. Phenylacetylene is the alkyne starting material for 
the 1,4 (45) and the 1,5 (49) isomer. There is a peak present at 3289 cm-1, this corresponds the 
CH bond present in the alkyne. This peak, however, is absent in both the spectra for 45 and 49. 




It was noted that there was also differences in solubilities between the two isomers. The 
1, 4- isomers were only soluble in dimethyl sulfoxide (DMSO), whereas the 1,5- isomers were 
soluble in methanol and acetone as well as DMSO.  
 
3.3.1.4 Yields and purity of the target compounds 44-51 
 
There were two different catalysts used in the synthesis of these compounds. They had 
drastically different yields, with the copper CuAAC reactions producing the better yields. There 
was also a difference depending on which alkyne was used. The 1,4-isomers, 44-47, gave a 
range of yields from 75-93%, whereas the RuAAC reactions that produced the 1,5-isomers 48-
51 yields range from 38-50%. This could be due to the RuAAC reactions requiring the 
production of a strained intermediate, whereas in the CuAAC reactions the strained 
intermediate is alleviated using two copper ions.  
In general, alkynes that contained a benzyl group afforded better yields for the 1,4- and 
1,5- isomers. These aromatic groups are more electron withdrawing when compared to the 
alcohol on the alkyne. As previously reported in the literature the efficacy of the process 
depends on the electronic factors on the alkyne, with the introduction of electron withdrawing 
groups enhancing yields of 1,2,3-triazole formations.232  
The purity of these compounds was determined using a developed HPLC method, using a 
gradient solvent system. Each compound was shown to have > 99% purity. A solvent system 
of A = H2O and B = MeCN was used, with a flow rate = 1.0 mL/min. Compounds were eluted 
with a gradient of 5% B to 100% B for 25 min. Detection at wavelengths of 254, 280, 210 nm 
was used. A gradient was used to expose any compounds that are less polar than the target 




as some of the side products could be UV inactive. The yields and purities for compounds 44-
51 are shown in Table 17. 












3.2.1 Microbiology data for the triazole containing compounds 
3.2.1.1 Microbiological results 
As previously discussed (Section 2.3.2.1), a bioscreen method was used to obtain the MIC100 
values for the triazole containing AZT compounds. Two different broths, MHB and NB, were 
used to understand whether the broth had any effect on bacterial growth. The control 
measurement for these compounds 44-51 is AZT 52.  
 
Compound Yields (%) Purity (%) 
44 75 >99 
45 80 >99 
46 93 >99 
47 89 >99 
48 38 >99 
49 42 >99 
50 50 >99 




3.2.1.2 Microbiological results for AZT 52 using the bioscreen method  
 
Data for the control drug, AZT 52, is shown in Table 18. As expected, the MIC values were 
high, >128 µg/mL, for the gram-positive bacteria and Pseudomonas aeruginosa.197 It was 
shown in Section 3.1.3, that the mechanism of action for AZT needs dThd kinases to activate 
52, which are not present in these bacteria. In Table 19, the dThd levels in certain bacteria are 
shown.205 In Klebsiella pneumoniae, the levels are elevated which is consistent with the 
MIC100 results as that bacterial strain had values of 0.5 µg/mL.  
There was very little difference in MIC values between the two media, with 
Enterobacter cloacae and Escherichia coli being the only two bacteria that showed slight 
differences. This is to be expected as both broths ingredients should not interfere with the 


















Table 18: MIC100 data for AZT 52 in two different media; MHB and NB. The values    
highlighted yellow show MIC100 ≥64 µg/mL. NG – No growth. The bacteria in red       
refer to gram-positive strains. 
 
Organisms 
MIC100 (µg/ml) of AZT 52 in two different broths 
OCC MHB NB 
B. cereus 754 >128 >128 
E. facalis 640 >128 >128 
E. faceium 220 >128 >128 
S. aureus 100 >128 >128 
S. epidermis 691 >128 >128 
St. agalactiae 182 >128 >128 
St. pneumoniae 1548 >128 >128 
St. pyogenes 168 >128 >128 
St. viridans 1683 >128 >128 
C. freundii 851 128 128 
Cr. sakazakii 1888 8 8 
En. cloacae 760 1 2 
Es. coli 199 4 8 
K. pneumoniae 758 0.5 0.5 
P. mirabilis 2080 >128 >128 
Ps. aeruginosa 201 >128 >128 
Sa. typhimurium 854 NG NG 










Table 19: Cell extracts of the bacteria were examined for TK activity at a protein    
concentration of 50 pg mL- in the reaction mixture. Adapted from data in ref. 205. 
Strain of bacteria 
Relative specific dThD 
kinase activity in cell 
extract (%) 
Relative dThD kinase 
production in cell extract 
(%) 














Proteus mirabilis (IFO3849)c 34 39 
 
3.2.1.3 Microbiological results for the 1,4-1,2,3-triazole derived compounds 44-47 using 
the bioscreen method  
 
The MIC values for the 1,4-1,2,3-triazole isomers of the triazole based compounds, 44-47, had 
similar MIC values to AZT 52 for the gram-positive bacteria, >128 g/mL, as well as in 
Pseudomonas aeruginosa and Proteus mirabilis. The broth used was NB. Compound 37 lost 
activity compared to the parent AZT and gave MIC values of >128 µg/mL. This was similar to 
44 and 47, where the only bacterium where MIC activity was seen was Klebsiella pneumoniae, 






Table 20: The MIC100 data for the underivised compound AZT and the 1,4-isomers 44-47. The 
broth is NB. NG – No growth. The values highlighted yellow show MIC100   
≥64 µg/mL.  The ClogP data was calculated using Chem BioDraw Ultra software version 13.0. 
Organisms 




44 45 46 47 
CLogP  0.04 -2.48 0.66 0.84 0.84 
B. cereus 754 >128 >128 >128 >128 >128 
E. facalis 640 >128 >128 >128 >128 >128 
E. faceium 220 >128 >128 >128 >128 >128 
S. aureus 100 >128 >128 >128 >128 >128 
S. epidermis 691 >128 >128 >128 >128 >128 
St. agalactiae 182 >128 >128 >128 >128 >128 
St. 
pneumoniae 
1548 >128 >128 >128 >128 >128 
St. pyogenes 168 >128 >128 >128 >128 >128 
St. viridans 1683 >128 >128 >128 >128 >128 
C. freundii 851 128 128 128 >128 128 
Cr. sakazakii 1888 8 >128 16 >128 >128 
En. cloacae 760 2 >128 128 >128 >128 
Es. coli 199 8 >128 64 >128 >128 
K. 
pneumoniae 
758 0.5 64 4 >128 64 
P. mirabilis 2080 >128 >128 >128 >128 >128 
Ps. 
aeruginosa 
201 >128 >128 >128 >128 >128 
Sa. 
typhimurium 
854 NG >128 8 >128 >128 
Se. 
marcescens 






Compound 44 contained an extra hydroxyl handle on the triazole ring, and had a CLogP value 
of -2.48. This could help to explain why its MIC value was increased in certain gram-negative 
bacteria, as its lipophilicity is decreased and as previously mentioned this affects gram-negative 
bacteria in an undesirable manner. The ClogP values, however, for the other compounds do not 
follow the same pattern, i.e. parent compound, AZT has a lower ClogP value when compared 
to 45-47 but demonstrated lower MIC data for certain gram-negative bacteria. The structure 44-
47 and 52 are shown in Table 21, the ClogP values and select gram-negative bacteria’s MIC100 

















Table 21: The structure 44-47 and 52 shown with their ClogP and select gram-negative bacteria’s 
MIC100 values. 











0.04 8 2 8 0.5 
44 
 
-2.48 >128 >128 >128 64 
45 
 
0.66 16 128 64 4 
46 
 
0.84 >128 >128 >128 >128 
47 
 




Of the 1,4-isomers, 45, with the benzyl group in the 4- position on the triazole ring, still retained 
activity against the same bacteria as AZT 52. It had similar MIC values in Klebsiella 
pneumoniae, 4 µg/mL when compared to 0.5 µg/mL for AZT, and Cronobacter sakazakii, 
16 µg/mL when compared to 8 µg/mL. This compound, 45, was also the only compound to 
possess activity against Salmonella typhimurium. No growth was detected by the control AZT, 
and 44-47 all displayed values >128 µg/mL. Once a fluoride atom was added to the benzyl ring 
on the triazole ring the values for MIC100 increased.  
 
3.2.1.4 Microbiological results for the 1,5-1,2,3-triazole derived compounds 48-51 using 
the bioscreen method 
 
 
The 1,5-isomers, 48-51, were also tested against the same species of bacteria. The MIC100 data 











Table 22: The MIC100 data for the underivised compound AZT and the 1,5-isomers 48-51. 
The broth is NB. NG – No growth. The values highlighted yellow show MIC100 ≥64 µg/mL.  









48 49 50 51 
ClogP  0.044 -2.48 0.66 0.84 0.84 
B. cereus 754 >128 >128 >128 >128 >128 
E. facalis 640 >128 >128 >128 >128 >128 
E. faceium 220 >128 >128 >128 >128 >128 
S. aureus 100 >128 >128 >128 >128 >128 
S. epidermis 691 >128 >128 >128 >128 >128 
St. agalactiae 182 >128 >128 >128 >128 >128 
St. 
pneumoniae 
1548 >128 >128 >128 >128 >128 
St. pyogenes 168 >128 >128 >128 >128 >128 
St. viridans 1683 >128 >128 >128 >128 >128 
C. freundii 851 128 >128 128 >128 >128 
Cr. sakazakii 1888 8 16 4 >128 >128 
En. cloacae 760 2 4 64 >128 >128 
Es. coli 199 8 8 32 >128 >128 
K. 
pneumoniae 
758 0.5 0.5 4 >128 64 
P. mirabilis 2080 >128 >128 >128 >128 >128 
Ps. 
aeruginosa 
201 >128 >128 >128 >128 >128 
Sa. 
typhimurium 









For these 1,5-isomers, there was no activity against gram-positive bacteria, Pseudomonas 
aeruginosa and Proteus mirabilis, with MIC values of >128 µg/mL for the respective bacteria.  
This is again due to a lack of dThd kinases in these species. Relatively high MIC100 values were 
also found in Citrobacter freundii and Serritia marcescens, in both the parent drug and the 1,5- 
compounds. In all but one of the bacteria (C. freundii), AZT gave better activity. When 
compound 49 was tested against Cronobacter sakazakii, a MIC100 of 4 µg/mL was recorded. 
This is similar than the MIC value obtained for AZT, 8 µg/mL. This compound was also the 
only compound that was found to have activity against Salmonella typhimurium, this was also 
similar to the activity of the 1,4- isomers. The compound containing the hydroxyl handle, 48, 
and benzyl group, 49, displayed similar activity against Enterobacter cloacae and Escherichia 
coli, which was in turn similar to 51. The lowest MIC100 values were found in Klebsiella 
pneumoniae, with compound 48 having the same MIC values as the parent drug. As previously 
mentioned, K. pneumoniae contains a high percentage of the dThd kinases, which allows the 
compound to be incorporated into the DNA.  
When comparing the two different isomers compounds 50 and 51 gave the same activity as 
their 1,4-counterparts an example being the position of the fluorinated benzyl group on the 
triazole ring did not change the MIC100 values. With four bacteria (Cr. sakazakii, En. cloacae, 
Es. coli, and K. pneumoniae) both the hydroxylated 48 and benzylated 49 rings gave lower MIC 
values with the 1,5- isomer. For compound 48, there is a hydroxyl group at the 5, position of 
the triazole ring. Both the hydroxyl on the O’-5 membered ring and the hydroxyl attached to 
the triazole ring are spaced by a methyl chain. The 1,5-isomer group could be positioned closer 
to the active site for dThd kinases, therefore could potentially be phosphorylated. In the 1,4- 
isomer, this hydroxyl chain is positioned further away and this could explain why the 1,5-isomer 
has better MIC100 values for a select gram-negative bacteria. Compound 49 demonstrated 




µg/mL in the 1,5- isomer 49. Overall, the 1,5-isomers gave lower MIC100 values for the bacteria 
against which the compounds were active, with a significant difference between 44 and 48, the 
hydroxylated triazole rings.    
The MIC values of the triazole containing compounds 44-51 were also determined in MHB. 









Table 23: The MIC100 data for the underivised compound AZT and both the 1,4- the 1,5-isomers 44-51. The broth is MHB. NG – No growth. 





MIC100 (µg/mL) of various 1,4- and 1,5- 1,2,3-triazole moieties attached to AZT. 
OCC 
MHB 
52 44 45 46 47 48 49 50 51 
B. cereus 754 >128 >128 >128 >128 >128 >128 >128 >128 >128 
E. facalis 640 >128 >128 >128 >128 >128 >128 >128 >128 >128 
E. faceium 220 >128 >128 >128 >128 >128 >128 >128 >128 >128 
S. aureus 100 >128 >128 >128 >128 >128 >128 >128 >128 >128 
S. epidermis 691 >128 >128 >128 >128 >128 >128 >128 >128 >128 
St. agalactiae 182 >128 >128 >128 >128 >128 >128 >128 >128 >128 
St. 
pneumoniae 
1548 >128 >128 >128 >128 >128 >128 >128 >128 >128 
St. pyogenes 163 >128 >128 >128 >128 >128 >128 >128 >128 >128 




C. freundii 851 128 128 128 >128 128 >128 128 >128 >128 
Cr. sakazakii 1888 8 >128 16 >128 >128 16 4 >128 >128 
En. cloacae 760 1 >128 128 >128 >128 4 64 >128 >128 
Es. coli 199 4 >128 64 >128 >128 8 32 >128 >128 
K. 
pneumoniae 
758 0.5 64 4 >128 64 0.5 4 >128 64 
P. mirabilis 2080 >128 >128 >128 >128 >128 >128 >128 >128 >128 
Ps. 
aeruginosa 
201 >128 >128 >128 >128 >128 >128 >128 >128 >128 
Sa. 
typhimurium 
854 NG >128 8 >128 >128 NG 4 >128 >128 
Se. 
marcescens 






3.3 SAR for the target compounds in the triazole containing compounds 
 
Using the data collected in Chapter 3, SAR’s can be deduced. Figure 39 shows a summary of 
the SAR data collected. The addition of a triazole moiety to AZT 52 saw a loss in antimicrobial 
activity; this is for the 3- and 4- position on the ring. The bacteria strain which was most 
responsive to these compounds 44-51 was Klebsiella pneumoniae, this bacteria is responsible 
for community acquired pneumonia.188 This is unsurprising considering the level of dThd 
kinases that are found in this strain.205 MIC100 values collected for 48 and AZT were 
comparable. This was not true of the 1,4-isomer of the same product, 44. The addition of a 
hydroxyl chain to the 1,5- position seemed to have very little effect on the activity of the 
compound, this could be due to the smaller group being able to fit in the active site of the 
kinases, which are needed to activate the compound to become a DNA terminator. Compounds 
48 and 49 had similar activities against select gram-bacteria strains, again very similar to the 
values found for the parent drug AZT.  
The addition of a benzyl ring to the 1,5- position gave slightly higher MIC values for the 
gram-negative bacteria, but 49 was the only compound which saw growth and activity of 
Sa. typhimurium. Salmonellosis is a disease in humans and animals caused by Sa. typhimurium, 
it is characterised by fever, acute intestinal inflammation, and diarrhoea within 24 h after 
infection.191 Once a fluoride was added to the 4’ or 3’ position on the benzyl ring there was a 








3.4  Antiviral properties of AZT and its modifications 
 
As previously mentioned, AZT 52 was first designed as an antiviral for HIV. Antiretroviral 
drugs are used to combat diseases caused by retroviruses, with AZT 52 being the first drug 
discovered and used for treating AIDS through inhibition of HIV. It was found to inhibit the 
HIV-1 replication in vitro at a concentration of >0.37 µg/mL.233 Although this was the first drug 
discovered and used in the treatment of this virus, its history is unique and subject to 
controversy. For example, there were problems with the controls in the trials used to approve 
AZT, as well as issues surrounding patient confidentiality and the stocks of drugs leading to 
limited supply.234 The compound inhibits HIV reverse transcriptase by incorporating itself into 
DNA and acting as a chain terminator. In order for this to occur AZT 52 has to first be 
phosphorylated by several kinase enzymes. The triphophosylated chain chelates to the 
magnesium ion in the transcriptase enzyme active site, this can be seen in Figure 40. The figure 
shows AZT triphosphate being incorporated into the DNA of the HIV, causing the DNA chain 
Figure 39: A diagram showing the SAR collected from the different triazole containing      





to terminate. In Figure 40, the structure is taken from the reverse transcriptase enzyme present 








To primarily investigate the potential antiviral properties of the 1,2,3-triazole containing 
compounds, the target compounds were fitted into the biological target (HIV reverse 
transcriptase) was used. This involved fitting the compounds into the HIV reverse transcriptase 







Figure 40: A computer model of AZT triphosphate chelating to the magnesium ion. AZT     





3.4.1 HIV reverse transcriptase 
  
AZT inhibits DNA synthesis by acting as a chain terminator. This occurs in HIV reverse 
transcriptase. The compounds previously synthesised (44-51) were fitted into the mentioned 
enzyme active site to determine whether the compounds with the extra triazole ring would fit 
and therefore would, in theory, be able to inhibit the DNA synthesis in HIV. There were a 
number of assumptions that were made; the most important of these is that the original 
compounds would be phosphorylated with the prior enzymes (kinases). 
The compounds 44-51 were fitted into the active site of the HIV reverse transcriptase, these are 
shown in Figure 41.The model of the new derivatised compounds where fitted to the biological 
structure which contained the underivatised parent compound, AZT 52. As can be seen, the 
compound needs to be tri-phosphorylated to allow it to chelate to the magnesium, which in turn 
allows it to be incorporated into the DNA of the virus. The figures have been generated using 
an existing model (PDB : 3V4I) and fitting the triazole compounds in the active site using 























Figure 41: The fitting of the compounds 44-51 with the active site of HIV reverse transcriptase.          







In this model, the compounds fit in the active site. When fitting the compounds, there was space 
for either the 1,4- or 1,5- isomers. In Figure 42, there is an example of both isomers on the 1,2,3 
triazole with a benzyl moiety attached to the ring, overlapped around the cyclic AZT core, 
showing the space they both occupy in the active site. As there is free rotation around the bond 
between nitrogen in the triazole and carbon in the AZT ring, the different isomers could in 
theory move around until they could fit. In the active site, the azido moiety on AZT 52 does not 
hydrogen bond to any residues. These models are limited, however. These are crude models 
and can be used to potentially indicate is any of the compounds was more likely to fit into the 
enzymes active site. More experimental data is needed to say with certainty of the triazole based 









Figure 42: The overlapped view of 45 and 49 (45=blue and 49 = green) in the active site of 






The target compounds 44-51, shown in Figure 43, were successfully synthesised using ‘click’ 
chemistry. This involved using two different metal catalysts to synthesise the two different 
isomers; 1,4-1,2,3-triazole isomers were synthesised using a copper catalyst and 
1,5-1,2,3,-triazole isomers were synthesised using a ruthenium catalyst. The 1,4- 1,2,3-triazole 
containing compounds, 44-47, were synthesised in greater yields when compared to the 
1,5-1,2,3-triazole isomers, 75-93% for the 1,4-isomers as compared to 38-50% for the 
1,5-isomers.  
 




These compounds were tested using a bioscreen method to obtain MIC100 data. All compounds 
displayed no biological activity against gram-positive bacteria; this is to be expected when the 
parent, AZT 52, is also inactive against these bacteria. Compounds 47 and 51, containing a 
fluoride in the 4’ position in the benzyl ring, had MIC values of >128 µg/mL. When the fluoride 
was in the 3’ position on the benzyl ring, 46 and 50, similar MIC values were recorded, with 
the exception of Klebsiella pneumoniae which the MIC value was 64 µg/mL. The 
1,5-1,2,3-triazoles , 48-51, generally had smaller MIC values when compared to their 
1,4-1,2,3-triazole isomer counterparts, with compound 48 having comparable MIC values 
against Escherichia coli and Klebsiella pneumoniae. 
Preliminary antiviral models where performed using a fitting model, with all the compounds 
44-51 found to fit in the HIV reverse transcriptase active site. In vitro studies will be needed to 
be conducted to fully evaluate their potentials as antivirals. These crude models have their 
limitations, as they are just an indicator as to which compounds could potentially give the 
















Chapter 4 – The synthesis and 
microbiological evaluation of carbohydrate 
















4.1.1 Introduction to Flavonoids 
  
Flavonoids are a family of compounds consisting of two benzene rings linked through a 
heterocyclic pyrene ring.236 This group of compounds can be split into further sub-groups, the 
most common known as flavones, isoflavones, flavonols and chalcones (structures can be seen 
in Figure 44). They are a naturally occurring secondary metabolite from plants, with many 
health benefits.237   
 
 
4.1.2 Flavonoid as antimicrobial agents 
 
Figure 44: The general structures of the different flavonoids. The general flavonoid structure 




As well as the previously discussed biological activities, some flavonoids contain antibacterial 
activities. Without people realising, they have been using flavonoids found in plants to improve 
their health. An example of this is the use of Tagetes minuta. This plant was used by individuals 
as a hot tea to treat diseases as an Argentinian folk medicine. The active compound in this tea 
is quercetagetin-7-arabinosyl-galactoside 98, a glycosidic flavonoid which has good 
antimicrobial activity.238 The structure and chloramphenicol equivalent concentrations are 
shown in Figure 45. Chloramphenicol equivalent concentration was used to compare how the 









Huang qin is a herb used in Chinese medicine, it is from the Scutellaria baicalensis plant. It 
contains many flavonoids, including chrysin. Other flavonoids also present in this plant are 
baicalein 99 and wogonin 102. Baicalin 101 is baicalein 89 with a glycoside, glucuronide, 
present at the hydroxyl on the C (7) position on the A ring. Interestingly, when the MIC data 
for 99 and 100 are compared there is only a slight difference, data shown in Figure 46.239 This 
Figure 45: Quercetagetin-7-arabinosyl-galactoside 98 equivalent concentrations against   




was also found true for 101 and 102. The MIC and minimum bacterial concentration (MBC) 
were measured. The MBC data was defined as minimum concentration at which no growth was 
observed on the bacto tryptic soya agar (TSA) plates. 
 
 
















































Figure 46: The structures of the flavonoids and their glycosidic counter parts found in                        
        Scutellaria baicalensis. The MIC and MBC were determined using methods                
        described by Hansen et al.312   S. aureus (ATCC 19115), and L. monocytogenes         






Chrysin 103 is a flavone, which is distributed in many plants. Examples of where this flavone 
103 can be found include honey and honeycomb, as well as the passion flowers, 
Passiflora caerulea and Passiflora incarnata.240 This compound 103 has a variety of different 
biological activities; including antiviral,241–243 antiinflammatory,244,245 anticancer,246,247 
antioxidant,248,249 and antibacterial.250,251 The structure of chrysin 103 and select MIC values 










Figure 47: Chrysin 103 MIC values against selective gram-positive and gram-negative   
        bacteria. Four gram-negative (Agrobacterium tumefaciens (ATCC 11158),   
        Escherichia coli (ATCC 29425), Pseudomonas lachrymans (ATCC 11921) and 
       Xanthomonas vesicatoria (ATCC 11633)) and three gram-positive (Bacillus   
       subtilis (ATCC 11562), Staphylococcus aureus (ATCC 6538) and Staphylococcus 
       haemolyticus (ATCC 29970)). The method used was a modified broth dilution-




4.2.1 Mechanism of action  
 
Chrysin 103 has been reported to be a FabH inhibitor.250 FabH is used to catalyse the fatty acid 
synthesis in bacteria and is considered one of the β-ketoacyl-acyl carrier protein (ACP) 
synthases. These catalyse the Claisen condensation of the fatty acid thioesters and 
malonyl-ACP, this initial elongation is performed by FabH. The fatty acid synthesis pathway 







4.2.2 Derivatives of chrysin 
 
Modifications have been made to chrysin 103 and the antibacterial properties of these 
derivatives were tested. One such example is shown in Figure 49.251 In these compounds, the 
C (7) position was changed. Alkyl amines were added with varying chain lengths to enhance 
the compounds lipophilicity. The compounds with the lower MIC values were the compounds 
with a 4-carbon spacer on the alkyl chain. These compounds were effective in inhibiting 
gram-positive and gram-negative bacteria, and outperformed chrysin, the parent compound.  
Figure 48: Part of the elongation stage in the fatty acid synthesis in bacteria which involved 
















Further examples of modifications made at the C (7) position are shown in Figure 50.  These 
derivatives contained different alkyl chains with differing functional groups to explore their 
SAR against different bacteria as determined through their FabH inhibitory activity. FabH 
proteins are found in both gram-positive and gram-negative bacteria and are not similar to those 
found in humans. They regulate fatty acid synthesis and have been previously mentioned in 
Section 1.1.3.2. Most of the compounds showed better MIC values when compared to 103; 
Figure 49: The structures of C (7) derivatives. The MIC were determined using broth dilution 
        methods. B. subtilis (MTCC 441), B. sphaericus (MTCC 11), S. aureus (MTCC 96), 
        K. aerogenes (MTCC 39), C. violaceum (MTCC 2656), and                        
        Ps. aeruginosa (MTCC 741). The n refers to a=1, b= 2 and c=4.Data adapted from 





however the MIC data was only measured up to 50 µg/mL. The molecule, 109g, was the most 
potent and was a potent inhibitor of Es. coli FabH.250 
 
Figure 50: The structures of C (7) derivatives. The MIC values were determined using the MTT 






4.3 Justification for design 
 
Although chrysin 103, and numerous other flavones, have many significant biological 
properties, they have poor bioavailability. Chrysin 103 is limited as a therapeutic drug as it has 
a compromised oral delivery.253 Other flavones also suffer from modest to poor bioavailability. 
Phenolics, including chrysin 103, undergo glucuronidation via UDP-glucuronosyltransferases 
(UGTs), which adds a glucuronide moiety to the nucleophilic hydroxyl on the phenolics. In 
chrysin 103 and 7,8-dihydroxyflavone 111, the hydroxyl, which attacks the C (1) position on 
the glucuronide moiety, is found in the C (7) position on the A ring.254 The mechanism by which 
this occurs is shown in Figure 51. In a previous study, it was shown that chrysin was rapidly 
metabolised by glucuronidation.255 Sulfation and methylation in the liver also leads to the poor 
oral bioavailability.256 
 
Along with glucuronidation, the solubility of flavonoids, including chrysin 103, is an issue. 
These polyphenolic compounds are quite polar, however are poorly water soluble.257 





The hypothesis is that attaching a glycoside to chrysin 103 and 7,8-dihydroxyflavone 111 will 
aid with the solubility in aq. environments of the compounds, as well as blocking the 
7-O-position on the A ring, which should reduce the glucuronidation process, making this 
prodrug more bioavailable. As can be seen in Figure 52, a glucoside and galactoside have been 














To also gain SAR information for these flavones, with respect to their antimicrobial activity, 
another sub-set of compounds were selected for synthesis. These compounds contain a 
7-hydroxyflavone 110 attached to either a glucose or galactose. There are no free hydroxyls 
present in these glycosides, whereas in 94-95 a hydroxyl is present in the C (5) position at the 





4.3.1  Aims for the glycosidic flavonoid compounds 92-97 
 
Flavonoids are naturally occurring polyphenolic compounds which have a plethora of different 
biological activities; including antimicrobial,258,259anti-inflammatory,260,261,262,263 
antioxidant,264,265antithrombotic,266,267 antiviral,268 and anti-carcinogenic269,270 agents. 
Although flavonoids have all these beneficial biological activities, they are for the most part 
also insoluble in aq. solutions. The objective for this programme was to synthesise more soluble 
flavonoids, through the design and synthesis of glycosidic prodrugs. Glycosylating at a free 
hydroxyl position should allow the compounds to become more soluble in an aq. 
environment.271 Once at the target site in the body, the glycosides in the compounds will be 
cleaved and this will allow the desired drug to be delivered at the active site. The target 
compounds are shown in Figure 54. 
 

























4.4 Results and discussion 
 
4.4.1 Synthesis 
4.4.1.2 Synthetic route 
 
There are many different methods for glycosylations, for this series a different approach was 
used; PTC (previously mentioned in Section 2.3.1.4). This involves using a catalyst to enable 
the migration of a reactant from one phase to another where the reaction occurs. It was first 
devised to bring reactants that have incompatible solubilities together so a reaction may 
occur.272  




Figure 55: The target compounds 92-97. The retrosynthetic route is also shown beneath the 




















In PTC, the reaction precedes via an SN2 style of reaction, a transition state is formed as can be 
seen in Figure 56. The reaction was left for 24 h with the PTC. Methanolysis was used to 












When this reaction was performed on chrysin 103 to produce the per-O-acetylated intermediates 
for 114 and 115, a mono-glycosylated compound was formed, with the O-glycosylation having 
occurred at the C (7) position. The 1H-NMR spectra for 94 is shown in Figure 57. This displays 
a resonance at 12.83 ppm which refers to the hydroxyl present in the A ring (C (5) labelled as 
Figure 56: The catalytic cycle for the formation of the glycosidic flavonoids. The transition 




20). The free hydroxyl for the C (7) position is found further downfield (~10 ppm) due to 
resonance effects present at the C (20) position. 
 
Figure 57: The 1H-NMR spectra for compound 94. 
  
The acetylated intermediates are shown in Figure 58. These are first synthesised by the PTC 





















Only the mono-glycosylated compounds are synthesised possibly due to hydrogen bonding 
between the carbonyl and hydroxyl present in the C (5) position. This would hinder this position 
for glycosylation, therefore the glycosylations occurred in the C (7) position. This has been 




Figure 59: The possible hydrogen bond present in the acetylated intermediates in the synthesis 
      for 84 and 85. 




4.4.1.3 Yields and purity 
 
Three different parent flavonoids were used to synthesise glucosides and galactosides. There 
was a difference in yields dependant on which carbohydrate was used, with the galactosides 
being produced in better yields. The parent flavonoid compound had very little impact on the 
yield of the glycosylation reaction as can be seen in Table 24. The di-glycosylated compounds 
96 and 97 were formed in lower yields due to the mono-glycosylated product also forming. 
The acetylated intermediates, 112-117, were purified using NP-column chromatography. 
Following the deprotection, the products (92-97) were firstly filtered from the reaction mixture. 
This crude solid was washed with methanol and the resultant mixture was purified using RP-
column chromatography. RP- silica was used to as the resultant target compounds (92-97) were 
polar. 
The purity of these compounds was determined using a developed HPLC method, using a 
gradient solvent system. Each compound was shown to have >97% purity. The chrysin based 
glycosides, 94 and 95, had purities of >99%.  A solvent system of A = H2O and  B = MeCN 
was used, with a flow rate = 1.0 mL/ min. Compounds were eluted with a gradient of 10% B to 
80% B for 25 min. Detection at wavelengths of 254 and 210 nm was used. A gradient was used 
to expose any compounds that are less polar than the target compound, such as hydrolysed 
sugars. An ELSD was used in conjunction with UV in the HPLC as some of the side products 






Table 24: A table showing the yields and purity of the target compounds 92-97 and the 











4.4.1.4 Optimisation of the synthetic route  
 
There are many synthetic pathways that can be employed to O-glycosylate a compound.  PTC 
is just one synthetic route that has been explored. As previously mentioned, an aq. NaOH 
method can be utilised to synthesise glycosidic target compounds. Both the reaction pathways 












112, 92 62 65 97 
113, 93 71 68 98 
114, 94 68 51 99 
115, 95 69 53 99 
116, 96 40 64 97 















There was a big difference in yields between these two reactions.  This could possibly be caused 
by solubility issues, chrysin 93, the parent compound, is not soluble in aq. solutions. The 
solubility of chrysin is shown in Table 25. The aq. mixture was basic, with the use with NaOH, 
which would have aided the solubility. However, with poor solubility and the hydrolysis of the 
brominated carbohydrate the yield was extremely low at 2%. The solvents used in the PTC 
route were a mixture of anh. solvents; acetone and dimethylformamide (DMF), which are 
solvents in which chrysin is soluble. The use of anh. solvents also could have aided in the yield 
as less opportunity for the carbohydrate to hydrolyse. 
 
 
Figure 60:A table that summeries the different conditions used for glycosylation of 114. The 




Table 25: A table summarising the solubility of chrysin. A concentration of 1 mg/mL was 
used.  





MeOH Partially soluble 
Chloroform Partially soluble 
 
 
There are many compounds which are classified as phase transfer catalysts. The most common 
catalysts used in O-glycosylations of aromatic compounds are tetrabutylammonium salts, with 
some relevant examples included within Table 26. As can be seen tetrabutylammonium 
bromide (TBAB), under the right conditions, can produce a greater yield when used as a phase 
transfer catalyst compared to benzyltriethylammonium chloride (TEBA). TBAB was therefore 
chosen as the phase transfer catalyst in this work, with the added advantage that the solvents 











Table 26: The starting material for these reactions was acetobromo-α-D-glucose. All 
































4.4.1.5 Chemical analysis 
Confirmation of the stereochemistry at the anomeric centre was determined through the use of 
1H-NMR spectroscopic analysis. As previously discussed in Section 2.3.1.5., the 
stereochemistry at C-1 could be determined by analysing the J values for the anomeric 
hydrogen, H (1). The values for these are summarised in Table 27.  
Table 27: The J values (Hz) for the six compounds 92-97, as determined from their respective 













For compounds 96 and 97, one of the anomeric H peaks for the carbohydrates are under another 
peak so a J value cannot be distinguished. 




92 8.0 β 
93 8.0 β 
94 7.5 β 
95 8.5 β 
96a 7.5 β 
96b CD (cannot be distinguished) β 
97a CD β 




There is a difference in resonance shifts for the anomeric hydrogen between the acetylated 
intermediates and the deprotected final products. In Table 28, the anomeric H resonance peaks 
are shown for the acetylated intermediates and the final target compounds 92-97, with the peaks 
from the acetylated intermediates being further upfield. There are also resonance peaks found 
between 2-3 ppm, these are not present in the final compounds.  
 
Table 28: A table showing the differences between the resonance peaks using 1H-NMR spectra. 
* = The resonance peaks are under other peaks 
Compound 
Resonance peak at the 
anomeric H (ppm) 
Acetylated intermediate 
resonance peak at the anomeric 
H (ppm) 
92 5.09 5.25 
93 5.12 5.32 
94 5.03 5.20 
95 5.04 5.13-5.18* 
96a 5.04 5.27-5.41* 
96b 4.97-5.01* 5.52 
97a 4.92-4.99* 5.27 







4.4.2 Microbiology data for the flavonoid containing compounds 
 
4.4.2.1 Microbiological results 
A bioscreen method was used to obtain the MIC100 values for the glycosylated flavonoid 
compounds 92-97. Two different broths were used: NB and MHB.  
 
4.4.2.2 Microbiology data for the parent flavonoid compounds 103, 110 and 111 in agar 
 
Due to the poor solubility of the parent flavonoid compounds (103, 110 and 111), the bioscreen 
method could not be used to gain MIC100 information. When the compounds 103, 110 and 111 
were dissolved in the maximum percentage of DMSO (3%)278 in the two respective broths (NB 
and MHB), precipitation occurred once the aq. media was added. In Table 29, the conditions 
that were used to try and overcome these solubility issues are summarised.  
Table 29: A table showing the different conditions used to try and solubilise the parent 








Method used Result 
Aq. Media, 3% DMSO Precipitation occurred 
Tween 80 (emulsifier) Precipitation occurred 






Precipitation occurred in all the conditions, which led to an agar method being used, an example 
of the plates is shown in Figure 61. The agar chosen was Mueller-Hinton agar (MHA), the 
results are still comparable to the MIC100 values collected using the bioscreen method.






Figure 61: MHA with the target bacteria. A = 111 at 100 μg/mL. B = MHA control 
 
During the agar method, different solvents were used to improve solubility in the agar. The 
parent flavonoid was firstly dissolved in the selected solvent. The solvents used were present 
in literature and would not affect the bacterial growth. These were then added to the agar and 
set on a plate before bacteria was added to the top of the agar. The solvents used are summarised 
in Table 30.  
Table 30: A summary of the different conditions in which the agar was prepared 
Solvent used Percentage used Result Ref. 
DMSO 0.5-1.5% 
Precipitation visible 




for 110 and 103 
Acetone 30% 
Precipitation visible 
before adding agar 
252 
Methanol 10% Precipitation visible 
279 
Once water was added to the acetone stock solution to create 30% concentrations, precipitation 







methanol before the aq. media was added. In DMSO, all the flavonoids are soluble, however 
once the aq. media is added to 103 and 110 precipitation occurred. DMSO, at 2%, was used 
although precipitation still occurred at concentrations 100-50 µg/mL for 103 and 110. The MIC 
values reflect this with the maximum concentration of compound that fully dissolved into agar, 
25 µg/mL. The MIC100 values for the parent flavonoids 103, 110 and 111 are shown in Table 
31.  
Table 31: The MIC100 data for the underivised parent compounds 93, 100-101. The agar is 
MH. NG – No growth. The values highlighted yellow show MIC100 ≥50 µg/mL.  The ClogP 
data was calculated using Chem BioDraw Ultra software version 13.0. 
Organisms 
MIC (µg/ml) of various parent flavonoids (103, 110, and 111). 
OCC 110 103 111 
CLogP 3.21 3.56 2.73 
B. cereus 754 >25 >25 100 
E. facalis 640 >25 >25 >100 
E. faceium 220 >25 >25 >100 
S. aureus 100 12.5 >25 50 
S. epidermis 691 6.25 NG 25 
St. agalactiae 182 25 >25 100 
St. pneumoniae 1548 NG NG NG 
St. pyogenes 168 NG NG NG 
St. viridans 1683 NG NG NG 
C. freundii 851 >25 >25 >100 
Cr. sakazakii 1888 >25 >25 >100 
En. cloacae 760 >25 >25 >100 
Es. coli 199 >25 >25 >100 
K. pneumoniae 758 >25 >25 >100 
P. mirabilis 2080 >25 >25 >100 
Ps. aeruginosa 201 >25 >25 >100 
Sa. typhimurium 854 >25 >25 >100 
Se. marcescens 217 >25 >25 >100 
 
As to be expected, the MIC values for the gram-negative bacteria were all high, >25 µg/mL for 




C (7) position, there were MIC values collected for Staphylococcus aureus, 
Staphylococcus epidermidis and Streptococcus agalactiae, 12.5, 6.25, and 25 µg/mL 
respectively. Staphylococcus epidermidis, when present in blood, can lead to sepsis especially 
in preterm infants. In 2010, sepsis accounted for 5.1% of deaths in England.280 Staphylococcus 
aureus is a sole contributor to toxic shock syndrome, acute endocarditis and botryomycosis. 
This bacteria also acquires resistance to produce MRSA, which recently has gained a lot of 
media attention as named as the superbug. A potential mechanism of action, as seen with 
various other flavonoids, for these compounds could involve inhibiting Staphylococcus aureus 
β-Ketoacyl acyl carrier protein synthase III (saKASIII). The enzyme saKASIII is responsible 
for initiating the fatty acid synthesis in bacteria, and is seen as a key target enzyme to overcome 
the antibiotic resistance problem. The hydroxyl present in the C (7) position can participate in 
hydrogen bond interactions with the backbone oxygen of Phe298 and Ser152.281 
The flavone 111 has hydroxyls present in the C (7) and (8) positions. Against 
Staphylococcus aureus and Staphylococcus epidermidis was found to have MIC values of 
50 µg/mL and 25 µg/mL, respectively. These values are less than those recorded for 110, 
suggesting the hydroxyl present in the C (8) position may slightly affect the MIC values. When 
a hydroxyl was added to the C (5) position in 103, the values were higher at >25 µg/mL.  
There was no growth shown for Streptococcus pneumoniae, Streptococcus pyogenes and 
Streptococcus viridians. There were difficulties when culturing these strains of bacteria, with 
little growth in the cultures overnight.  
4.4.2.3 Microbiology data for the parent flavonoid compounds (103, 110 and 111) and 
their respective glycosides 92-97 
 
The glycosides, 92-97, of the various parent flavonoids (103,110 and 111) were tested using 




to the agar results for their respective flavonoid parent compounds. All the glycosylated 
flavonoid compounds, 92-97, could be analysed using an aq. media broth method. The 
solubilities of flavonoids increased when glycosylated to either glucose or galactose. DMSO, 
at 3%, was used to solubilise the glycosylated compounds, 92-97, during the bioscreen 
technique. Precipitation did not occur during the testing unlike their parent counterparts.  
The glycosides 92 and 93 of 7-hydroxyflavone 110 were tested against gram-negative and 

















Table 32: The MIC100 data for the underivised parent compounds 110 and its respective 
glycosides 92 and 93. The agar is MHB; with the broth shown NB (92-93). NG – No growth. 
The values highlighted yellow show MIC100 ≥50 µg/mL.  The ClogP data was calculated 
using Chem BioDraw Ultra software version 13.0. 
Organisms 
MIC (µg/ml) of the 110 moiety attached to various sugars. 
OCC 110 92 93 
CLogP 3.21 1.51 1.51 
B. cereus 754 >25 >128 >128 
E. facalis 640 >25 >128 >128 
E. faceium 220 >25 >128 >128 
S. aureus 100 12.5 >128 >128 
S. epidermis 691 6.25 >128 >128 
St. agalactiae 182 25 >128 >128 
St. 
pneumoniae 
1548 NG >128 >128 
St. pyogenes 168 NG >128 >128 
St. viridans 1683 NG >128 >128 
C. freundii 851 >25 >128 >128 
Cr. sakazakii 1888 >25 >128 >128 
En. cloacae 760 >25 >128 >128 
Es. coli 199 >25 >128 >128 
K. pneumoniae 758 >25 >128 >128 
P. mirabilis 2080 >25 >128 >128 
Ps. aeruginosa 201 >25 >128 >128 
Sa. 
typhimurium 
854 >25 >128 >128 
Se. 
marcescens 
217 >25 >128 >128 
 
The glycosides, 92 and 93, had values of >128 µg/ml for all bacteria strains tested against in 
NB. The glycosides also had higher MIC values when compared to their parent compound, 110. 






Table 33: The MIC100 data for the underivised parent compounds 93 and its respective 
glycosides 84 and 85. The agar is MHB; with the broth shown NB (94-95). NG – No growth. 
The values highlighted yellow show MIC100 ≥50 µg/mL.  The ClogP data was calculated 
using Chem BioDraw Ultra software version 13.0. 
Organisms 
MIC (µg/ml) of the 103 moiety attached to various sugars. 
OCC 103 94 95 
CLogP 3.56 2.07 2.07 
B. cereus 754 >25 >128 >128 
E. facalis 640 >25 >128 >128 
E. faceium 220 >25 >128 >128 
S. aureus 100 >25 >128 >128 
S. epidermis 691 NG >128 >128 
St. agalactiae 182 >25 >128 >128 
St. 
pneumoniae 
1548 NG >128 >128 
St. pyogenes 168 NG >128 >128 
St. viridans 1683 NG >128 >128 
C. freundii 851 >25 >128 >128 
Cr. sakazakii 1888 >25 >128 >128 
En. cloacae 760 >25 >128 >128 
Es. coli 199 >25 >128 >128 
K. 
pneumoniae 
758 >25 >128 >128 
P. mirabilis 2080 >25 >128 >128 
Ps. 
aeruginosa 
201 >25 >128 >128 
Sa. 
typhimurium 
854 >25 >128 >128 
Se. 
marcescens 
217 >25 >128 >128 
 
The results shown above are results in NB. Similar to 92-93, the glycosides 94 and 95 had 
values of >128 µg/ml. When compared the 103, the parent compound, they all had values that 





The glycosides 96 and 97 of 7,8-dihydroxyflavone 111 were tested against gram-negative and 
gram-positive bacteria, the MIC values are shown in Table 34.  
 
Table 34: The MIC100 data for the underivised parent compounds 111 and its respective 
glycosides 96 and 97. The agar is MHB; with the broth shown NB (96-97). NG – No growth. 
The values highlighted yellow show MIC100 ≥50 µg/mL.  The ClogP data was calculated 
using Chem BioDraw Ultra software version 13.0. 
 
Organisms 
MIC (µg/ml) of the 111 moiety attached to various sugars. 
OCC 101 96 97 
CLogP 2.73 -0.89 -0.89 
B. cereus 754 100 >128 >128 
E. facalis 640 >100 >128 >128 
E. faceium 220 >100 >128 >128 
S. aureus 100 50 >128 >128 
S. epidermis 691 25 >128 >128 
St. agalactiae 182 100 >128 >128 
St. 
pneumoniae 
 NG >128 >128 
St. pyogenes 163 NG >128 >128 
St. viridans  NG >128 >128 
C. freundii 851 >100 >128 >128 
Cr. sakazakii 1888 >100 >128 >128 
En. cloacae 760 >100 >128 >128 
Es. coli 199 >100 >128 >128 
K. 
pneumoniae 
758 >100 >128 >128 
P. mirabilis 2080 >100 >128 >128 
Ps. 
aeruginosa 
201 >100 >128 >128 
Sa. 
typhimurium 
854 >100 >128 >128 
Se. 
marcescens 






The results from 96-97 are >128 µg/mL for all bacteria tested in NB. Similarly to 92-93, 96-97 
had higher MIC values for Staphylococcus aureus and Staphylococcus epidermis.  
For all the glycosides tested, 92-97, had values of >128 µg/mL. This could be due to many 
factors; including transport issues and enzyme issues. Further testing is needed to exploring the 
kinetics of the enzyme cleaving the glycoside to release the drug.  
For all the measured MIC100 values using the bioscreen method, 92-97, there were no 
differences between the two different media employed during the bioscreen method (NB and 





Table 35: The MIC100 data for the glycosidic flavonoid compound 92-97. The broth is MHB. NG – No growth.  
Organisms 
MIC100 (µg/mL) of various flavonoid moieties attached to glycosides, 92-97. 
OCC MHB 
92 93 94 95 96 97 
B. cereus 754 >128 >128 >128 >128 >128 >128 
E. facalis 640 >128 >128 >128 >128 >128 >128 
E. faceium 220 >128 >128 >128 >128 >128 >128 
S. aureus 100 >128 >128 >128 >128 >128 >128 
S. epidermis 691 >128 >128 >128 >128 >128 >128 
St. agalactiae 182 >128 >128 >128 >128 >128 >128 
St. pneumoniae 1548 >128 >128 >128 >128 >128 >128 
St. pyogenes 168 >128 >128 >128 >128 >128 >128 
St. viridans 1683 >128 >128 >128 >128 >128 >128 
C. freundii 851 >128 >128 >128 >128 >128 >128 
Cr. sakazakii 1888 >128 >128 >128 >128 >128 >128 
En. cloacae 760 >128 >128 >128 >128 >128 >128 
Es. coli 199 >128 >128 >128 >128 >128 >128 
K. pneumoniae 758 >128 >128 >128 >128 >128 >128 
P. mirabilis 2080 >128 >128 >128 >128 >128 >128 
Ps. aeruginosa 201 >128 >128 >128 >128 >128 >128 
Sa. typhimurium 854 >128 >128 >128 >128 >128 >128 





4.4.3 SAR of the target compounds 103, 110 and 111 and their respective glycosides 92-97 
 
Using the data collected in Chapter 4, SAR can be deduced. Figure 62 summarises the SAR 
collected. The addition of the carbohydrate produced lowered MIC values when compared to 
their respective parent compounds, with the exception of 103 and 96-97. Chrysin 103 and its 
glycosides (96-97) had values that could not be determined using the concentrations used, 
>128 µg/mL for 96-97 and >25 µg/mL for 103. For the double glycosylated compounds, 94-95, 
they had the same values as the mono-glycosidic compounds. When the glycosides were 
analysed, the glucosides and galactosides of 103, 110 and 111 had the same MIC values, >128 
µg/mL over a 24 h time period. When applying the prodrug approach to the glycosides 
synthesised, the carbohydrate was masking the drug producing a less toxic drug. Further kinetic 
analysis is needed to determine whether the sugar is cleaved or if the compound remains as a 
glycoside. The glycosides had better solubility in aq. media, so therefore were analysed using 
a bioscreen method. Whereas the parent compounds an agar method was utilised.  
For the parent flavonoid 110 and 111, there were lower MIC values recorded for 
Staphylococcus aureus and Staphylococcus epidermis. Both of these bacteria can lead to death, 
sepsis from S. epidermis and toxic shock syndrome, acute endocarditis, and epidural abscesses 
to name a few for S. aureus. The ‘superbug’ (MRSA) is also associated with S. aureus.  For 
compound 103, the MIC values were >25 µg/mL for all bacteria tested. The hydroxyl present 
in the C (5) position hindered antimicrobial activity when compared to 110. The extra hydroxyl 















The target compounds 92-97, found in Figure 63, were successful synthesised using a PTC 
method. The β-anomers were synthesised, as can be seen for the 1H-NMR spectra, using 







Figure 62: A diagram showing the SAR collected from the different flavonoid moieties 


















There were slight differences in the yields for the acetylated intermediate compounds, 112-117, 
with lower yields recorded for the double glycosylated compounds 116-117. PTC was utilised 
for the glycosylation as the parent compounds, 103, 110 and 111, were soluble in the solvents 
used, DMF and acetone. The deprotection of the acetylated compounds was performed using 
K2CO3 in anh. methanol.  
Figure 63: The target structures 92-97, with their respective yields and purities shown. The 




The MIC data for the parent compounds were collected using an agar method, due to solubility 
issues. For compounds 103 and 110, precipitation still occurred at 2% DMSO in aq. media, 
therefore the results recorded were limited to 25 µg/mL. Against the bacteria 
Staphylococcus aureus and Staphylococcus epidermis, 110 and 111 had MIC values of 12.5 and 
50 µg/mL for S. aureus and 6.25 and 25 µg/mL for S. epidermis, respectively. Compound 110 
also had an MIC value of 25 µg/mL for St. agalactiae, which is comparable to fusidic acid 
which has a MIC value of 32 µg/mL.282Fusidic acid is used as a topical cream and eye drops 
for Staphylococci and Streptococci infections. The glycosides of the respective flavonoid parent 
compounds were more soluble in the 3% DMSO in aq. media, therefore a bioscreen method 
was used to analyse these compounds for MIC values. The MIC values collected for all the 
glycosides, 92-97, were >128 µg/mL.  
SAR data was collected from comparisons between compounds 92-97, 103, 110, and 111. The 
hydroxyl present in the C (7) position appears to be essential for antimicrobial activity against 
Staphylococci. This is in agreement with literature, which suggests that this hydroxyl hydrogen 
bonds to inhibit the enzyme saKASIII. The hydroxyl present in the C (5) position is not essential 
for antimicrobial activity, 103 had MIC values of >25 µg/mL for all bacteria tested against. The 
hydroxyl present in the C (8) position seemed to increase the MIC values slightly, as seen in 





































5.1 Overall summary of this project 
 
The research presented in this project concentrated on the design, synthesis, and biological 
testing of novel antimicrobials. The moieties were all selected to probe SAR of the various 
classes of compounds. The target compounds were synthesised using various synthetic 
methods; namely glycosylations or ‘click’ chemistry. These were then screened against various 
bacteria that are seen as a threat to human and animal health to ascertain their antimicrobial 
properties. In Chapter 3, the triazole containing compounds were fitted in the HIV reverse 
transcriptase enzyme active site to probe the compounds 44-51 antiviral properties. In Chapter 
4, the flavonoid containing compounds were also tested to explore their anticancer properties. 
All the glycosides tested had MIC values above that of their respective parent compounds. 
5.2 The carbohydrate prodrugs containing a bisphenol moiety 
 
Four novel β-glycoside containing compounds, 33-34 (Figure 64), were synthesised. This route 
used the corresponding per-O-acetylated carbohydrate and NaOH to create the acetylated 
glycoside intermediates. These were then deprotected using K2CO3 in anh. methanol.  All 





The MIC100 data for these compounds were then determined using a bioscreen method. There 
was a correlation between the ClogP values and the MIC100 values; the higher the ClogP value 




the lower the MIC100 value. The addition of a glycoside to the parent compounds led to higher 
MIC values when compared to their respective parent compounds. In Streptococcus agalactiae, 
BP 42, the parent compound, had a MIC value of 64 μg/mL whereas the glucoside 33a and the 
galactoside 34a had MIC values of >256 μg/mL. 
When compared with other data in the literature,142,283 SAR could be found. The additional 
hydroxyl which is present in 43, the underivised compound for 33b and 34b, was not required 
to improve the MIC values. BP 42 had MIC values of 64 μg/mL for Streptococcus agalactiae 
and Streptococcus pyogenes, whereas HMP 43 had MIC values of >256 μg/mL for the 
respective bacteria. There was also a positive correlation between an increase in halogens 
present and an increase in MIC values, the MIC values for the underivised compounds are 
shown in Table 36. 
Table 36: The MIC values (μg/mL) for St. agalactiae and Es. coli the underivised compounds. 
Compounds 39-41 data was adapted from ref. 103. 
Compound Halogens present 
Hydroxyls 
present 




Hex 39 6 x Cl 2 <0.5 8 
BCP 40 
2 x Br 
2 x Cl 
2 <0.5 >128 
DP 41 2 x Cl 2 1 64 
BP 42 0 1 64 128 
HMP 43 0 2 128 256 
 
A summary of the MIC values for clinically available antimicrobial compounds is shown in 




bisphenol compounds (42 and 43) and their respective glycosides (33-34). BP (42) had similar 
MIC values as cefaclor and cefadroxil in Streptococcus pneumoniae. 
Table 37: A comparison of clinically available antimicrobials MIC values with the bisphenol 
parent compounds 42 and 43 and their respective glycosides 33-34 MIC values. The values are 
reported by EUCAST for the clinically used compounds.  














2-benzyl phenol (42) 64 
bis(2-hydroxyphenyl)methane (43) 128 
2-benzyl phenol-β-D-glucopyranoside (33a) >256 
2-benzyl phenol-β-D-galactopyranoside (33b) >256 
bis(2-hydroxyphenyl)methane-β-D-glucopyranoside (34a) >256 
bis(2-hydroxyphenyl)methane-β-D-galactopyranoside (34b) >256 
 
The MIC values collected for the glycosides 33-34 were all higher than that of the 





5.2.1 Future work for the carbohydrate prodrugs containing a bisphenol moiety 
 
As previously mentioned in Section 2.2.3, other bisphenols have been previously studied to 
determine their MIC against Es. coli (wild type). These compounds could also be converted to 








The β-glycosides derivatives of these compounds could be synthesised and their MIC100 
determined. These can then be compared to 33-34 and 35-37 to gain SAR information.  In the 
compounds presented above, 118-122, there is an oxygen present in the bridge between the two 
aromatic rings. SAR data can be collected when compared to 33-34 and 35-37 where it is a 
methyl bridge.  The analysis of the SAR data could enable the determination of the chemical 
group responsible for evoking a target biological effect in the organism. This in turn allows for 
the modification of the effect or the potency of a bioactive compound by changing its chemical 
structure. 




5.3 The triazole containing compounds based on azidothymidine 
 
Eight novel 1,2,3-triazole containing compounds, 44-51, were synthesised using ‘click’ 
chemistry methods, the compounds are shown in Figure 66. Different metal catalysts were used 
to synthesis the two different isomers; the 1,4-1,2,3-traziole isomers were synthesised using a 
copper catalyst and the 1,5-1,2,3-triazole isomers were synthesised using a ruthenium catalyst. 
The 1,4-1,2,3-triazole containing compounds, 44-47, were synthesised in greater yields when 
compared to the 1,5-1,2,3-triazole isomers, 48-51. All compounds had >99% purity as 
determined by HPLC. 
 
These compounds’ MIC100 values were obtained using the bioscreen method. Compounds 
44-51 all displayed no biological activity against gram-positive bacteria. The 




1,5-1,2,3-triazoles, 44-47, generally had lower MIC values when compared to their 
1,4-1,2,3-triazole isomer counterparts, with compound 48 having comparable MIC values to 
AZT 52 against Escherichia coli, 8 μg/mL, and Klebsiella pneumoniae, 0.5 μg/mL. The 
compounds AZT (52) and 3’-deoxy-3’-(5-Hydroxymethyl-1,2,3-triazol-1-yl)-β-D-thymidine 
(48) had comparable MIC values when compared to clinically used antimicrobials, summarised 
in Table 38. Compounds 45 and 49 also had comparable MIC values, 4 µg/mL, when compared 





















Table 38: A comparison of clinically available antimicrobials MIC values with the AZT 52 
and its triazole containing compounds 44-51 MIC values. The values are reported by 
EUCAST for the clinically used compounds. 















AZT (52) 0.5 
3’-deoxy-3’-(4-hydroxymethyl-1,2,3-triazol-1-yl)-β-D-thymidine (44) 64 
3’-deoxy-3’-(4-benzyl-1,2,3-triazol-1-yl)-β-D-thymidine (45) 4 
3’-deoxy-3’-(4-4’’-fluoro-benzyl-1,2,3-triazol-1-yl)-β-D-thymidine (46) >128 
3’-deoxy-3’-(4-3’’-fluoro-benzyl-1,2,3-triazol-1-yl)-β-D-thymidine (47) 64 
3’-deoxy-3’-(5-Hydroxymethyl-1,2,3-triazol-1-yl)-β-D-thymidine (48) 0.5 
3’-deoxy-3’-(5-benzyl-1,2,3-triazol-1-yl)-β-D-thymidine (49) 4 
3’-deoxy-3’-(5-4’’-fluoro-benzyl-1,2,3-triazol-1-yl)-β-D-thymidine (50) >128 
3’-deoxy-3’-(5-3’’-fluoro-benzyl-1,2,3-triazol-1-yl)-β-D-thymidine (51) 64 
 
Preliminary antiviral studies where performed using a fitting model. All the compounds 44-51 
were found to potentially fit in the HIV reverse transcriptase active site. This could lead to 




5.3.1 Future work for the triazole containing compounds based on azidothymidine 
 
The mechanism of action for AZT involves phosphorylating at the 5’-O position to allow the 
compound to be integrated into DNA and causes the DNA replication to terminate. To mask 
the active hydroxyl, a carbohydrate could be used. This would provide target specificity, the 
bacterial cell wall recognises the carbohydrate; it acts as a guidance mechanism for certain 
bacteria, so allows the drug to arrive there precisely. Enzymes within the bacterial cell will 
cleave the sugar before the kinases can phosphorylate the hydroxyl present in the 5’ position. 







The β-glycosides 123 and 124 could be synthesised using a glycosylation method such 
Koenings-Knorr. This synthetic pathway uses acetylated sugar with a good leaving group on 
the anomeric centre, usually a chloride or bromide, a promotor such as silver triflate or silver 
carbonate and an acid scavenger. The acid scavenger, an example being tetramethyl urea, 
ensures that the acid that is produced in the last step of the mechanism does not cleave the new 
glycosidic bond that has just formed. Their MIC100 values would also be determined. Then 
kinetic studies could be performed to determine whether the sugar is cleaved, to determine their 
value as prodrug compounds.  




To further investigate the antiviral properties for compounds 44-51, further computer fitting 
models could be used. These could ascertain as to whether the compounds fit in the active site 
for the enzymes responsible for phosphorylations (dThd’s). Antiviral assays can also be 
performed. These could use tissue culture lines infected with HIV-1 and a control being healthy 
cells. This would help determine which compounds possess antiviral properties against HIV-
1.284,285  
5.4 The carbohydrate prodrugs containing flavonoids 
 
Six novel compounds, 92-97, were synthesised using a PTC synthesis method to create 
per-O-acetylated β-glycosidic flavonoids. These acetylated glycosides were then deprotected 





















The bioscreen method was used for compounds 92-97 to collect the MIC100 values against 
various gram-positive and gram-negative bacteria. This method, however, could not be used 
for the parent compounds (103, 110 and 111) due to solubility issues, so an agar method was 
used to gain MIC100 values for the parent compounds. The addition of a glycoside to the parent 
flavonoid led to higher MIC values when compared to their respective parent compounds. In 
Table 39, the MIC values for the underivatised flavonoid compounds are shown. This displays 
how the positioning of the hydroxyls on the A ring on the flavonoid affect the MIC values.   











on A ring 
MIC100 values (µg/mL) 
S. aureus S. epidermidis St.  agalactiae 
7-hydroxyflavone 110 1 C (7) 12.5 6.25 25 
chrysin 103 2 C (7), C (5) >25 NG >25 
7,8-dihydroxylflavone 
111 
2 C (7), C (8) 50 25 100 
 
The MIC values collected for the glycosides 92-97 were all higher than that of the 
antimicrobials already available, shown in Table 40. The compound 7-hydroxyflavone, 110, 
had lower MIC for both S. aureus and S. epidermidis when compared to chloramphenicol and 

















Table 40: A comparison of clinically available antimicrobials MIC values with the parent 
flavonoids (103, 110-111) and their glycoside derivatives 92-97 MIC values. The values are 
reported by EUCAST for the clinically used compounds. NG – no growth 
Compound 
Bacterial strain MIC 
values (μg/mL) 
S. aureus S. epidermidis 
amikacin 8 0.5-32 
ampicillin 0.12-32 0.12-32 
benzylpenicillin 0.125 0.03-32 
cefepime 8 -- 
cefotaxime 4 2 
chloramphenicol 16 16 
ciprofloxacin -- 1 
erythromycin 1 1 
fosfomycin 32 -- 
gentamycin 2 0.5 
linezolid 4 2 
7-hydroflavone (110) 12.5 6.25 
chrysin (103) >25 NG 
7,8-doihydroxyflavone (111) 50 25 
7-hydroxyflavone-β-D-glucopyranoside (92) >128 >128 
7-hydroxyflavone-β-D-galactopyranoside (93) >128 >128 
chrysin-β-D-glucopyranoside (94) >128 >128 
chrysin-β-D-galactopyranoside (95) >128 >128 
7,8-dihydroxyflavone-β-D-glucopyranoside (96) >128 >128 









5.4.1 Future work for the carbohydrate prodrugs containing flavonoids 
 
For the parent flavonoids, 103, 110-111, different methods need to be used to try and solubilise 
the compounds therefore allowing their MIC values can be tested at over 25 µg/mL. There has 
been reported in literatures the synergistic effect flavonoids have with different flavonoids. 
Combination therapies are used in many situations, an example being in immunocompromised 
patients. In these patients, identification of the pathogen is more difficult so a combination 
therapy allows the pathogen to be treated without exactly knowing what bacteria are causing 
the problem.286 This therapy is also used in polymicrobial infection, to cover all potential 
pathogenic bacteria.287,288 The combination of two different classes may result in a greater 
bacterial activity than either agent used alone, this is described a synergistic.289 Most 
importantly, this therapy prevents emergence of resistance.290,291  
Flavonoids have been studied for their synergetic properties with various antibiotics. An 
example investigates three flavonoids (rutin, morin and quercetin) in synergy with various 
antibiotics to see how their MIC values against S. aureus and MRSA were affected. The results 
are shown in Table 41.292 The activity of flavonoids was further enhanced against S. aureus 










Table 41: A table showing the MIC values as a result of using combination therapy against 
S. aureus and MRSA. R – rutin, M – morin, Q - quericetin 
Compound 
MIC values (µg/mL) 
S. aureus MRSA 










Amoxicillin 256 256 64 8 128-256 128-256 32-64 2-8 
Ampicillin 128 16 128 4 64-256 8-32 64-256 2-8 
Cephradine 256 32 64 8 128-256 16-32 32-64 4-8 
Imipenem 32 4 8 1 32-256 4-32 8-64 1-4 
Methicillin 64 8 16 2 64-256 8-32 16-64 2-8 
Ceftriaxone 64 16 16 2 32-128 4-16 8-64 1-4 
 
The flavonoids, both the parent (103, 110-111) and the glycosides (92-97), could be explored 
as potential synergy compounds with various antibiotics and various bacterial strains, both 
gram-positive and gram-negative.  
5.4.1.2 Anticancer and in vitro toxicity for the glycosidic flavonoids 92-97 
 
As previously mentioned flavonoids possess many biological activities, including 
anti-cancer.246,247,269,270 Cancer is defined as a group of diseases that involve the abnormal 
growth in cells, with the potential to invade and spread to other parts of the body other than its 
original site. It can affect anyone, with an estimated 2.5 million people living with cancer in 




increased by almost half a million people within 5 years.293 The most prevalent cancers in the 
UK in 2015 were breast (female), prostate, lung, bowel and skin cancers.294  There are many 
factors which affect the risk of developing cancer; lifestyle factors include age, smoking, 
alcohol consumption, diet, obesity and sunlight as well as genetic factors. 
There is a need to develop new therapies to try and overcome challenges presented in treatment 
of the diseases. The problem with treating cancers is that cancer is complex with many pathways 
that could potentially cause the mutation in cells to allow them to grow uncontrollably. It is also 
the host’s own DNA which mutates. There is also an added complexity as the tumour can 
metastasize and move around the body. The current treatments that could be used, namely 
radiotherapy and chemotherapy, often have toxic side effects.  
 
5.4.1.3 Glycosidic compounds used in cancer therapy  
 
As the tumour mass grows they require more nutrients to survive and expand. Cancer cells alter 
themselves to allow for a greater uptake in glucose and fermentation into lactate. To transport 
the glucose, glucose transporters (GLUTs) are utilised, with cancer cells having an elevated 
level of these proteins, in particular GLUT1 when compared to normal human cells.295 
Glycoconjugate compounds are therefore an interesting class of compounds to explore for 
cancer therapies. In one study, radio-labelled 2-deoxy-2-(18F)-D-glucose was used to further 
study as to what categories of cancers would be possibly effected by carbohydrate prodrugs. 
Using PET screening, with the radio-labelled sugar, preferential uptake of this radiolabelled 
glucose analogue compared to non-cancerous cells was seen with lung, breast, colorectal, and 





There are examples of carbohydrate prodrugs being used clinically in cancer treatments. An 
early example is glufosfamide 125. The compound 125 was designed as a cancer targeting 
agent, to decrease the toxicity and increase the selectivity to cancer cells of its aglycone, 
















5.4.1.4 In vitro toxicity experiment 
 
In vitro testing offers long-term safety data for drugs in their early stages of development. 
Specific properties can be identified including carcinogenic and mutagenic effects. It allows for 
an initial determination of toxicity before in vivo studies. It can be problematic as the translation 
between in vitro and in vivo can be difficult. The compound maybe toxic in vitro but due to 
different pathways being used it can have very little to no effect in vivo. First pass metabolism, 
also referred to as first pass effect, is an example of a pathway in which drugs can be inactivated 
and excreted.  
Figure 69: The structures of glufosfamide 125 and ifosfamide 126 with their LD50 data for rats 




The breast cancer cell line MCF-7, was chosen as it contains β-glycosidases which are needed 
to cleave the sugar from the aglycone.298Breast cancer is a prevalent cancer; in 2015 it was the 
most predominant cancer in females in the UK. Males are also affected by this cancer. The  
MCF-7 cell line was first isolated in the 1970’s , and became the first hormone receptor-positive 
breast cancer.299 It is also estrogen receptor positive, therefore it is a useful cell line when 
reviewing the toxicity of compounds that may interact with this receptor. The cell line MDA-
MB231 was also selected for study and this cell line does not have the estrogen receptors that 
are present in MCF-7.  
The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide  (MTT) assay is a metabolic 
assay which can be used to elude to the toxicity of the compounds 92-97 and their parent 
compounds. This method is a colorimetric assay that assesses the cell metabolic activity. Firstly, 
the cell lines, MCF-7 and MDA-MB231, were incubated at 37 ̊C in RPMI 1640 media. The 
compounds were prepared in DMSO to a concentration of 2 mM. This made the stock solution. 
From this, a fraction was taken and added to complete media to make a final concentration of 
20 µM. The cell suspension was added to 96-well plate and then the compounds were added. 
These were incubated for 48 h. MTT was then added to the wells and the plate was further 
incubated for 4 h. The MTT is reduced in living cells with the use of NAD (P) H-dependant 
cellular oxidoreductase enzymes. The yellow compound MTT is reduced to its insoluble form 
formazan, which is purple. A solubilising solution, DMSO, is added to the formazan and the 
absorption is measured a 570 nm by a spectrophotometer.300 
The IC50 values for the parent compounds 103, 110 and 111 were studied and these have been 
compared to their respective glycosidic compounds, 92-97. This allowed the cell viabilities to 





The graph shown in Figure 70 was produced using cell assay techniques by Az Natji 
(University of Reading). It summarises the % cell viability for compounds 110-111, 92-97. The 
MCF-7 cell lines were performed in duplicate and the MBA-MB231 was performed once. 
Further work includes performing these cell assay analyses in triplicate. Error bars show 








The cells were still viable (MCF-7 and MDA-MB231 cell lines). Further investigation is needed 
to draw any conclusions. The assay was only performed at one concentration so would need to 



























Figure 70: The graph summarising the % cell viability of the target compounds against cell 
lines MCF-7 and MDA-MB231.  1 - 111, 2 - 96, 3 - 97, 4 - 110, 5 - 92, 6 - 93, 
7 - 95, 8 - 96. n=2 for MCF-7, and n=2 for MDA-MB. Control sample was the 




5.5 Future work  
5.5.1 Kinetic studies 
 
To further investigate the SAR of the compounds containing the bisphenol or flavonoid moiety, 
kinetic studies could be performed. The Michaelis-Menton equation could be used to determine 
the mechanism of the enzymatic release of the parent compound. This would be useful to 
ascertain, as the design of the prodrugs relies on the glycoside being cleaved to release the target 
drug. A double reciprocal plot, Lineweaver-burke plot, could be used as a representation of 
enzyme kinetics; this is based on a rearrangement of the Michaelis-Menton equation, shown in 












𝑌 =  𝑀    𝜘 +   𝐶 
Equation 3: The Lineweaver-burke rearrangement and how it relationship to Y=M𝝒+C 
 
Where ʋ is the reaction rate, [S] is the substrate concentration and Kmax is the Michaelis 
constant. Various concentrations of the target compound could be measured to obtain the initial 
rate. Kmax is the measure of the affinity of the enzyme for the substrate; a smaller Kmax indicates 
an increased affinity of the enzyme for a certain substrate.  
 
5.5.2 Analysis with resistant bacteria 
 
The glycosides and 1,2,3-traizole compounds that were synthesised could also be analysed 




resistant strains further studies could be performed using combination therapies. Different 
antimicrobial compounds could be used with the synthesised glycosides to discover whether 
they have synergetic properties.  
5.5.3 Possible future glycoside strategies 
 
There are many antimicrobials that possess a free hydroxyl which could undergo a 
glycosylation reaction to synthesise carbohydrate prodrugs.  
5.5.3.1 Pleuromutilin compounds 
 
This class of antibiotics was first isolated in 1951 from Pleurotus mutilus (Fr.) Sacc. and 
P. passeckerianus pilat.301 Pleuromutilin 127 was extracted from the fungi and was found to 
have excellent activity against Staphylococcus aureus. Many derivatives have been designed, 
synthesised and tested using the pleuromutilin backbone. Retapamulin 128, valnemulin 129 and 
tiamulin 130 are examples of some of these derivatives; their structures are shown in Figure 13. 
Retapamulin 128 was first developed by GlaxoSmithKline and is the only one of this family to 
be approved for human use, while 129 and 130 are for animal use only. These compounds were 


















This family of compounds is of interest as it is stated in the literature that the free hydroxyl on 
the pleuromutilin backbone is needed for its antibacterial activity.304,305 Masking the hydroxyl 
with an acetate functionality decreased the MIC data for the bacteria shown in Figure 72. The 
results shown in Figure 72 were collected using NB in a bioscreen method.  
 
 
Figure 71: The MIC100 data for four compounds in the pleutmultin class: Pleuromutilin 127, 
retapamulin 128, valnemulin 129 and tiamulin 130. Data was collected using a 

















Synthesising β-glycosides of 127-130 would mask the free hydroxyl functionality and would 
potentially allow a non-toxic prodrug to be created, with a more targeted release of the drug.  
Figure 72: The MIC100 values for 128 and 131, displaying how masking the hydroxyl          
moiety lowers the biological activity. The reaction scheme and yield for the 




5.5.3.2 Carvacrol compounds 
 
Monoterpenes are a class of terpenes which consist of two isoprene units. Carvacrol 132 is a 
compound which belongs to this class. This monoterpenic phenol is isomeric to thymol and is 
found in a plethra of different plants; including Thymus vulgaris and Thymus zygis (thyme), 
Thymus serpyllum (white thyme), and Satureja montana (winter savoury).306 This natural 
compound 132 possesses a hydroxyl which is vital for its mechanism of action. This phenolic 
hydroxyl potentially could decrease the pH of the bacterial membrane, which could cause the 
destabilisation of  the bacterial membrane and decrease the membrane potential.307 In Figure 
73, the MIC100 data for carvacrol 132 and carvacrol acetate 133 is shown. There was a decrease 













A carbohydrate could be used to mask the hydroxyl and would allow the glycoside to be cleaved 
in the bacteria by glycosidase enzymes. This will also provide a more targeted approach to 
using 132 as an antimicrobial.  
Figure 73: The MIC100 data for 132 and 133. The data was collected using a liquid broth 




5.5.3.3 Azido moiety containing antimicrobials 
 
Azidamfenicol 134 is a phenicol antibiotic, under the same class as chloramphenicol 135, 
structures are shown in Figure 74. Compound 134 is a water soluble compound and found in 
eye drops.309 It has the same mechanism of action as chloramphenicol, inhibiting peptide 
synthesis by interacting with the 23S RNA of the 50S ribosomal subunit in bacteria. As 
previously described, antibiotic resistance is an emerging problem amongst antibiotics, with the 
phenicol antibiotics being no exception. Chloramphenicol acetyltransferases are able to 
inactivate chloramphenicol 135 but also azidamfenicol 136.310 To try and overcome this 
problem the azido moiety could be used in a ‘click’ style reaction to create 1,2,3-triazoles. As 
previously mentioned, the 1,2,3-traizole is a pharmacophore and could potentially enhance the 
MIC values of the compound, as well as masking the parent compound from resistance 







5.5.4 Further biological analysis 
 
With the compounds suggested previously, 127-135, further analysis could be performed to 
ascertain their potentials as other biological relevant compounds, such as antiviral and 
anticancer. There has been a study previously into monoterpenes and their antiviral activity 
against herpes simplex virus type 1 (HSV-1).311 The glycosidic compounds of the monoterpenes 




could be investigated for their antiviral potential. All newly synthesised glycosidic compounds 























































6.1 Equipment and Materials 
6.1.1 NMR Spectroscopy  
The NMR spectra were measured in either MeOD, CDCl3 or DMSO at room temperature on 
the Nano400 which is a two-channel NMR instrument running ICON NMR 4.2 under 
TOPSPIN 2.4. It incorporates a 9.39 T Ultrashield Plus Long Hold Time Magnet and is 
equipped with a 5mm indirect observation z-gradient inverse (1H/13C)- BBI probe and a 60-
position BACS sample changer. δ units are ppm relative to the internal standard, 
trimethylsilane. All coupling constants are quoted to the nearest 0.5 Hz. 
6.1.2 Mass Spectrometry 
The mass spectra were measured using fourier transform mass spectroscopy (FTMS) on a 
Thermo Scientific LTQ Orbitrap XL and was run in positive ion mode. The detector used was 
the Orbitrap (this mass spectrometer has two detectors), an Orbitrap which is very high 
resolution and mass accuracy, and an LTQ ion trap. The sample dissolved in methanol to give 
a concentration of 1 mg/mL, each sample was then diluted 30 fold in 0.1% formic acid in 
methanol (LCMS grade). The scan range was 150-2000 m/z and resolution level was 30,000.  
6.1.3 HPLC 
High Performance Liquid Chromatography (HPLC) was performed on an Agilent 1100 series 
machine using a Hypersil Gold aQ column (150mm x 4.6 μm x 5), unless otherwise stated. 
Each of the chromatography conditions for each individual experiments are listed accordingly. 
6.1.4 Infrared Spectroscopy 
The IR spectra were recorded on a Thermo Scientific Nicolet iS5 FT-IR spectrophotometer 
equipped with a Thermo Scientific™ iD5 ATR Accessory. The method used a sample loaded 





The optical rotations were recorded on a Perkins Elmer 341 polarimeter. They were recorded 
using the Na lamp in Methanol. 
6.1.6 Thin layer Chromatography  
These were performed using Merck TLC silica gel 60 plates. Spots were visualised using UV 
light (λmax 254 nm) and staining with either 5% H2SO4 in ethanol, or ninhydrin with 3% acetic 
acid in n-BuOH. 
6.1.7 Column Chromatography 
For normal phase chromatography Sigma Aldrich silica gel (particle size 35-79 µm) was used. 
For reverse phase chromatography, the Reveleris X2 flash chromatography system was used. 
The different conditions and columns used are stated for the individual experiments.  
6.1.8 Melting points 
The melting points were recorded using a Gallenkamp melting point machine and are 
uncorrected. 
6.1.9 Chemicals 
2-Benzyl phenol, zidovudine (AZT), and 7-hydroxyl flavone were purchased from Alfa 
Aesar,Heysham, UK. Bis(2-hydroxyphenyl)methane and chrysin were purchased from Sigma 
Aldrich, Dorset, UK. 7,8-Dihdroxyflavone hydrate was purchased from TCI, Oxford, UK. 
The anhydrous solvents were all Sureseal from Sigma Aldrich. The other chemicals used were 
purchased from Sigma Aldrich, Fisher Scientific or Acros. 
 
6.1.10 Microorganism strain list 






Organism name Oxoid 
culture 
collection  
number     
(OCC) 
Other Culture Collection 
References 
Isolation 
NCTC ATCC NCIMB 
Bacillus cereus 754 2599 14579 9373  
Enterococcus faecalis 640 12697 29212  Urine 
Enterococcus faecium 220 7171 19434 11508  
Staphylococcus aureus V. 
Oxford 
100 6571 9144   
Streptococcus epidermis 691 11047 14990 12721 Nose 
Streptococcus agalactiae 182     
Streptococcus pneumoniae 1548  6305   
Streptococcus pyogenes 163     
Streptococcus viridans 234     
Citrobacter freundii 851     
Cronobacter sakazakii 1888 11467 29544  Childrens 
throat 
Enterobacter cloacae 760 10005 13047  Cerebrospinal 
fluid 
Escherichia coli 199  25922 12210  
Klebsiella pneumoniae 758 9633 13883   
Proteus mirabilis 2080  12453   
Pseudomonas aeruginosa  201  27853   
Salmonella typhimurium 854     





6.1.11 Preparation of bacteria 
The organisms were inoculated from a stock plate into 10 mL of the desired broth (NB, MHB, 
and CM5). The cultures were grown for 18 h at 37 ̊C. The overnight cultures were the diluted 
in maximum recovery diluent (MRD) (Thermofisher, UK) (1 mL culture into 9 mL MRD). 
6.1.12 Preparation of broths 
All the broths were prepared in accordance to the manufacturer’s instructions and autoclaved. 
The broths were all cooled to room temperature before use.  
6.1.13 Preparation of plate media 
Mueller Hinton agar (Thermofisher, UK) was prepared as per the manufacturing protocol.  
6.1.14 Determination of MIC of desired compounds using the bioscreen method 
A stock solution of the desired compound was made using 3 % DMSO in the desired broth (NB, 
MHB, and CM5) to a concentration of either 128 µg/mL or 256 µg/mL. These stock solutions 
were filtered and sterilised before use.  
The stock solutions were then diluted down to give final concentrations of 256, 128, 64, 32, 16, 
8, 4, 2, and 1 µg/mL or 128, 64, 32, 16, 8, 4, 2, 2, 1 and 0.5 µg/mL. Each concentration of the 
compound (300 µL) was added to the wells of the bioscreen plates. This was followed by the 
culture in broth (30 µL).  
The optical density (OD) for each well was measured every 15 min for 24 h. It was read at 600 
nm wavelength in an automatic bioscreen reader machine at 37 ̊C.  
6.1.15 Determination of MIC of desired compounds using the agar method.  
A stock of the desired compounds was prepared to a final concentration of 100,000 µg/mL in 




The Mueller Hinton agar was prepared as described in Section 6.1.13. The required 
concentration of compound was added to the agar to give final concentrations of 100, 50, 25, 
12.5, 6.25, 3.125, 1.5625 and 0.78125 µg/mL. A plate containing no compound was poured and 
used as a control. The plates were poured and dried for 20 min at 37 ̊C prior to use.  
A 36 pin multipoint inoculator (Thermofisher, UK) was utilised to seed the plates with bacteria. 
Each bacterial strain was incubated overnight, and then these strains were diluted in MRD, to 
about 104 CFU. These were applied to each well. The organisms were inoculated onto the plates 
and incubated for 24 h at 37 ̊C. The MIC were determined as whether growth occurred on the 
plate, this was determined as to whether the growth was viable upon examination.  
6.1.16 Cell culture 
All techniques were performed in a biological safety cabinet under sterile conditions. The MCF-
7 cells were cultured in RPMI 1640 media (Fisher, UK) supplemented with 5% bovine serum, 
MDA-MB231 cells were cultured in DMEM media (Fisher, UK) and supplemented with 10% 
bovine serum (heat inactivated). Both were incubated at 37 ̊C under 5% CO2 atmosphere. The 
cells were grown until 75% confluent.  
ATCC code: MCF-7 (ATCCâ HTB-22™), MDA-MB-231 7 (ATCCâ HTB-26™). 
ECACC code: MCF-7 (MCF7 (ECACC 86012803)), MDA-MB-231 (MDA-MB-231 (ECACC 
92020424)) 
  
MCF-7, provided by Tenovus centre for Cancer research (Cardiff, UK), the triple negative 
breast cancer cell line MDA-MB-231 was purchased as a frozen stock from the European 
Collection of Cell Cultures (ECACC). 





For media, for MCF-7: RPMI (with L-glutamine) REF: 21875-034 (supplied by Gibco), and 
5% FBS, REF: 10270-106 (supplied by Gibco). For MDA-MB-231: DMEM (with L-glutamine, 
low glucose, pyruvate) REF: 31885-023 (supplied by Gibco), and 10% FSB, REF: 10270-106 
(supplied by Gibco). For trypsin: Trypsin-EDTA (0.25%), Phenol red, REF: 25200-056 
(supplied by Gibco). Gibco can be found in Fisher. 
 
6.1.17 Cell sub-culturing 
Once the cells were 70-80% confluent, the growth medium for the cultured cells was removed 
from the cell culture flask and washed with 10 mL phosphate-buffered saline (PBS). Trypsin 
(2-3 mL) was then added and the flask was incubated at 37 ̊C for 5 min. The complete growth 
media (7-8 mL) was added to the flask, and the cell suspension was centrifuged at 215 xg for 5 
min. The media was removed and the pellet was resuspended in 10 mL fresh complete growth 
media. 0.5 mL of the suspension was transferred to 5 mL complete growth media. To each 
suspension, 4 or 8 mL of the corresponding media was added, these were then incubated at 37 ̊C  
6.1.18 Preparation of MTT 
The MTT (Sigma-Aldrich, UK) was prepared. Briefly, the MTT was dissolved in PBS at a 
concentration of 5 mg/mL. The solution was sonicated for 30 min under dark conditions, and 
then filtered through a sterile filter and stored in a fridge until use.  
For MTT, MTT solution was prepare in at 5 mg/mL in PBS pH 7.4. The code of MTT: M2128-
1G Thiazolyl Blue Tetrazolium Bromide  98% (Sigma Aldrich) 
  
The seeding densities of the cells: For MCF-7: 4 X 104 cells/mL, for MDA-MB-231: 2 X 





6.1.19 MTT assay 
A stock solution of 2 mM of the desired compound in DMSO was prepared. These were further 
diluted in complete growth media so that the concentration of DMSO is 1% (as to not affect the 
cell growth).  
The cell suspension (100 µL) was added to 96-well plate and the cells were grown for 24 h. 
Then the compounds were added to make the final concentration (10 µM). Controls were 
employed also. These were incubated at 37 ̊C in a 5% CO2 atmosphere for 67 h. The plates were 
then treated with MTT and further incubated for 5 h. The MTT and media were then removed 
and the formazan crystals were dissolved in DMSO. The plated were further incubated for 30 
min to ensure that all the formazan had dissolved. The OD was then measured. The absorbance 
was used to determine cell viability.  
6.2 The glycosidic compounds with a bis-phenol moiety 33-34  
 
6.2.1 General procedure for the synthesis of 33-34 
 
The bis-phenol (1 eq.) was suspended in deionised H2O (30 mL), and NaOH (1 eq.) was added 
and the solution was left to stir for 20 min. Anh. acetone (21 mL) was added to the flask. In a 
separate flask, the acetobromosugar (1 eq.) was dissolved in acetone (26 mL) and added 
dropwise to the stirred bis-phenol solution and the solution was left to stir at room temperature 
(RT) for 2 h. The progress of the reaction was monitored using TLC (ethyl acetate: petrol 
ether    (3:2)).  
The crude mixture was extracted using DCM (3 x 70 mL). The organic layers were combined 
and the solvent removed in vacuo. The crude compound was partially purified by column 
chromatography using silica (ethyl acetate: petrol ether    (3:2)). The partially purified product 




suspension was stirred for 20 h. The reaction was concentrated and chloroform was added. The 
crude filtrate was filtered using a sintered funnel and the solid was purified using reverse phase 
column chromatography. (0.1% formic acid in water: acetonitrile (3:7)). 
The purity of these compounds was measured using a HPLC method. A solvent system of 
A=0.1% formic acid in H2O and B=MeCN was used, with a flow rate = 1.0 mL/ min. 
Compounds were eluted with a gradient of 5% B to 80% B for 30 min. Wavelengths 254, 280, 
and 210 nm were used. A hypersil column (Thermofisher, Hypersil GOLD, 5μm, 150 × 4.6mm, 






























Following the general method outlined in Section 6.2.1: 2-benzylphenol (0.66 g, 3.57 mmol) 
was suspended in water (30 mL) and 1 M NaOH (0.14 g, 3.57 mmol, 3.57 mL) along with anh. 
acetone (21 mL) was added. Acetobromo-α-D-glucose (1.47 g, 3.57 mmol) was dissolved in 
acetone (26 mL) and added dropwise to the bis-phenyl solution and left to stir at RT for 2 h. 
The crude mixture was partially purified using silica (ethyl acetate: petrol ether    (3:2)). The 
crude product was dissolved in anh. methanol (30 mL) and K2CO3 (90 mg) was added and 
stirred for 20 h. The reaction was concentrated and purified using column chromatography to 
obtain the desired product 33a (Yield: 9%, white powder, Purity: >99%).  
1H-NMR (400 MHz, MeOD): δ = 3.87-4.02 (4H, m, H-2, H-3, H-4, H-5), 4.15 
(1H, dd, J = 5.5 Hz, J = 12.0 Hz, Ha-6), 4.33 (1H, app.d, J = 12.0 Hz, Hb-6), 4.43 (1H, d, 
J = 14.5 Hz, Ha-11), 4.55 (1H, d, J = 14.5 Hz, Ha-11), 5.39 (1H, d, J  = 7.0 Hz, H-1), 7.39 
(1H, t, J  = 7.0 Hz, H-9), 7.55-7.64 (4H, m, H-7, H-8, H-10, H-14), 7.70 (2H, t, J  = 7.5 Hz, 
H-13, H-15), 7.76 (2H, d, J  = 7.5 Hz, H-16, H-12) ppm.13C-NMR (100 MHz, MeOD): δ = 3
8.4 (C-11), 64.4 (C-6), 73.3 (C-4), 76.6 (C-2), 79.6 (C-3,C-5), 104.2 (C-1), 117.4 (C-14), 125.
0 (C-9), 130.1 (C-7, C-8), 130.8 (C-13), 131.7 (C-12, C-16), 132.9 (C-10), 133.4 (C-18), 144.
1 (C-17), 158.5 (C-19)  ppm. FTMS (ESI) m/z : 369.1416 ([M+Na]+, 99%), found 396.1315 













Following the general method outlined in Section 6.2.1: Bis (2-hydroxyphenyl) methane 
(0.7 g, 3.57 mmol) was suspended in water (30 mL) and 1 M NaOH 
(0.14 g, 3.57 mmol, 3.57 mL) along with anh. acetone (21 mL) was added. 
Acetobromo-β-D-glucose (1.47 g, 3.57 mmol) was dissolved in acetone (26 mL) and added 
dropwise to the bis-phenyl solution and left to stir at RT for 2 h. The crude mixture was partially 
purified using silica (ethyl acetate: petrol ether    (3:2)). The crude product was dissolved in 
anh. methanol (30 mL) and K2CO3 (90 mg) was added and stirred for 20 h. The reaction was 
concentrated and purified using column chromatography to obtain the desired product 33b 
(Yield: 15%, white powder, purity: >99%). 
1H-NMR (400 MHz, MeOD): δ = 3.86-3.99 (4H, m, H-2, H-3, H-4, H-5), 4.14 
(1H, dd, J  = 5.0 Hz, J = 12.0 Hz, Ha-6), 4.32 (1H, dd, J = 2.0 Hz, J = 12.0 Hz, Hb-6), 4.43 
(1H, d, J  = 15.0 Hz, Ha-11), 4.50 (1H, d, J  = 15.5 Hz, Hb-11), 5.37 (1H, d, J = 6.0 Hz, H-1),
 7.20 (1H, t, J = 7.5 Hz, H-9), 7.31 (1H, d, J  = 8.0 Hz,  H-7), 7.35 (1H, t, J = 7.5 Hz, H-15), 
7.47 (1H, t, J  = 8.0 Hz, H-8), 7.56 (3H, d, J = 8.5 Hz, H-10, H-13, H-16), 7.60 (1H,t, 
J = 8.0 Hz, H-14) ppm.13C-NMR (100 MHz, MeOD): δ = 31.6 (C-11), 64.5 (C-6), 73.1 (C-4),
 77.0 (C-2), 79.9 (C-3,C-5), 105.1 (C-1), 117.8 (C-7), 118.0 (C-13), 122.3 (C-9), 124.7 (C-8, 




12)  ppm. FTMS (ESI) m/z : 385.1263 ([M+Na]+, 99%), found  384.1259 [M + Na]+. Melting 
point: 145-47  ̊C. FT-IR (ATR): 34344 (O-H, br), cm-1. 
 









Following the general method outlined in Section 6.2.1: 2-benzylphenol (0.66 g, 3.57 mmol) 
was suspended in water (30 mL) and 1 M NaOH (0.14 g, 3.57 mmol, 3.57 mL) along with anh. 
acetone (21 mL) was added. Acetobromo-β-D-galactose (1.47 g, 3.57 mmol) was dissolved in 
acetone (26 mL) and added dropwise to the bis-phenyl solution and left to stir at RT for 2 h. 
The crude mixture was partially purified using silica (ethyl acetate: petrol ether   (3:2)). The 
crude product was dissolved in anh. methanol (30 mL) and K2CO3 (90 mg) was added and 
stirred for 20 h. The reaction was concentrated and purified using column chromatography to 
obtain the desired product 34a (Yield: 7%, white powder, purity: >99%). 
1H-NMR (400 MHz, MeOD): δ = 4.07 (1H, dd, J  = 3.5 Hz, J = 9.5 Hz, H-3), 4.16-4.22 (1H, 
m, H-5), 4.23-4.27 (2H, m, H-6), 4.31 (1H, t, J = 8.5 Hz, H-2), 4.41-4.58 (3H, m, H-4, H-11), 
5.33 (1H, d, J = 7.5 Hz, H-1), 7.37 (1H, t, J = 7.5 Hz, H-9), 7.52-7.65 (4H, m, H-7, H-8, H-10
, H-14), 7.70 (2H, d, J  = 7.5 Hz, H-13, H-15), 7.75 (2H, t, J  = 7.5 Hz, H-12, H-16) ppm. 
13C-NMR (100 MHz, MeOD): δ = 38.1 (C-11), 64.0 (C-6), 71.8 (C-4), 74.3 (C-2), 76.6 (C-3),
 78.4 (C-5), 105.2 (C-1), 118.3 (C-7, C-8, C-14), 124.9 (C-9), 129.4 (C-18), 130.9 (C-12, C-1




m/z : 369.1416 ([M+Na]+, 99%), found 369.1318  [M + 2Na]+. Melting point: 142-47 ̊C. FT-
IR (ATR): 3364 (O-H, br) cm-1.  










Following the general method outlined in Section 6.2.1: Bis (2-hydroxyphenyl) methane 
(0.7 g, 3.57 mmol) was suspended in water (30 mL) and 1 M NaOH 
(0.14 g, 3.57 mmol, 3.57 mL) along with anh. acetone (21 mL) was added. 
Acetobromo-β-D-glucose (1.47 g, 3.57 mmol) was dissolved in acetone (26 mL) and added 
dropwise to the bis-phenyl solution and left to stir at RT for 2 h. The crude mixture was partially 
purified using silica (ethyl acetate: petrol ether   (3:2)). The crude product was dissolved in anh. 
methanol (30 mL) and K2CO3 (90 mg) was added and stirred for 20 h. The reaction was 
concentrated and purified using column chromatography to obtain the desired product 34b 
(Yield: 11%, white powder, Purity: >99%). 
1H-NMR (400 MHz, MeOD): δ = 3.58 (1H, dd, J = 3.5 Hz, J = 9.5 Hz, H-3), 3.67 (1H, t, 
J = 6.5 Hz, H-5), 3.72-3.79 (2H, m, H-6), 3.83 (1H, app. t, J = 9.0 Hz, H-2), 3.90 (1H, d, 
J = 4.0 Hz, H-4), 4.02 (2H, app. t, J = 17.0, H-11), 5.40 (1H, d, J = 7.5 Hz, H-1), 7.25 (1H, t, 
J  = 7.0 Hz, H-9), 7.31 (1H, d, J  = 8.0 Hz, H-7), 7.43 (1H, t, J = 7.5 Hz, H-15), 7.51-7.59 (3H
, m, H-8, H-10, H-16), 7.67 (1H, t, J  = 8.0 Hz, H-14), 7.72 (1H,t, J  = 8.0 Hz, H-13) ppm. 




76.5 (C-5), 104.1 (C-1), 116.0 (C-7), 116.5 (C-13), 120.8 (C-9), 123.4 (C-15), 128.3 (C-14), 1
28.6 (C-8), 131.3 (C-16), 131.8 (C-10), 144.3 (C-17, C-18), 157.5 (C-19), 158.5 (C-12)  ppm. 
FTMS (ESI) m/z : 384.1259 [M + Na]+. found  384.1257 [M + Na]+. FT-IR (ATR): 3253 

























6.3 The compounds based on azidothymidine containing a triazole moiety 41-48 
 
6.3.1 General Procedure for synthesis of 1,4 triazoles via click reactions 
3’-Azido-3’-deoxythymidine (AZT) (1 equivalence (eq.)) and the alkyne (1 eq.) were added to 
a solution of THF: water (3:1). Freshly prepared sodium ascorbate (1M, 0.1 eq., in H2O) was 
then added followed by CuSO4.5H2O (1M, 0.06 eq., in H2O). The reaction was left to stir for 
18 h at room temperature, monitored using TLC. The mixture was then evaporated in vacuo. 
Water was then added to the crude mixture and filtered through a sintered funnel. The solid 





























Following the general method outlined in Section 6.3.1: AZT (0.3 g, 1.12 mmol) and propargyl 
alcohol (0.066 mL, 1.12 mmol) were added to a solution of THF: water (3:1, 12 mL). Freshly 
prepared sodium ascorbate (0.112 mL, 1 M, 0.112 mmol) was then added followed by 
CuSO4.5H2O (0.067 mL, 1 M, 0.067 mmol). The reaction was left to stir for 18 h at room 
temperature, monitored using TLC. The mixture was then evaporated to dryness. Water 
(20 mL) was then added to the crude mixture and filtered. The precipitate was then purified 
using reverse phase chromatography (0.1% Formic acid: MeCN, starting at 9:1, until 7:3) to 
produce 44 (Yield: 56%, white powder, Purity: >99%).  
1H-NMR (400 MHz, (CD3)2SO): δ = 1.88 (3H, s, H-1), 2.66-2.83  (2H, m, H-8), 3.68 (1H, dt,
 J = 12.5 Hz, J = 4.5 Hz, Ha-11), 3.76 (1H, dt, J  = 12.5 Hz, J = 4.5 Hz, Hb-11), 4.24-4.29 
(1H,m, H-10), 4.60 (2H, d, J = 6.5 Hz, H-15), 5.30 (1H, t, J = 5.5 Hz, H-12), 5.36 (1H, t, 
J = 5.5 Hz, H-16), 5.45 (1H, dt, J = 6.0 Hz, J = 8.5 Hz,  H-9), 6.48  (1H, t, J = 6.5 Hz, H-7), 
7.89 (1H, s, H-6), 8.24 (1H, s, H-13), 11.44 (1H, s, H-4), ppm.13C-NMR (100 MHz, 
(CD3)2SO): δ = 12.5 (C-1), 37.1 (C-8), 55.9 (C-15), 58.8 (C-9), 60.9 (C-11), 83.9 (C-7), 84.4 




m/z : 346.1126 [M + Na]+, found  346.1120 [M + Na]+. Melting point: 179-183 ̊C. FT-IR 
(ATR): 3673 (O-H, br), 3469 (O-H, br), 1670 (C=O) cm-1. 
 










Following the general method outlined in Section 6.3.1: AZT (0.5 g, 1.8 mmol) and 
phenylacetylene (0.2 mL, 1.8 mmol) were added to a solution of THF: water (3:1, 12 ml). 
Freshly prepared sodium ascorbate (0.18 mL, 1 M, 0.18 mmol) was then added followed by 
CuSO4.5H2O (0.108 mL, 1 M, 0.108 mmol). The reaction was left to stir for 18 h at room 
temperature, monitored using TLC. The mixture was then evaporated to dryness. Water 
(20 mL) was then added to the crude mixture and filtered. . The precipitate was then purified 
using reverse phase chromatography (0.1% Formic acid: MeCN , starting at 9:1, until 7:3) to 
produce 45 (Yield: 62%, white powder, Purity: >99%).  
1H-NMR (400 MHz, (CD3)2SO): δ =  1.83 (3H, s, H-1), 2.64-2.88  (2H, m, H-8), 3.64-3.79 
(2H, m, H-11), 4.26-4.36 (1H, m, H-10), 5.40-5.46 (1H, m, H-9),  5.36 (1H, at, J = 3.5 Hz, 8.5
 Hz, H-12), 6.47  (1H, t, J =7.0 Hz, H-7), 7.36 (1H, at, J = 7.5 Hz, H-18), 7.47 (2H, t, J = 7.5 




(1H, s, H-4), ppm.13C-NMR (100 MHz, (CD3)2SO): δ = 12.4 (C-1), 37.1 (C-8), 54.9 (C-9), 
60.8 (C-11), 83.3 (C-7), 84.4 (C-10), 110.7.8 (C-2), 121.1 (C-13), 124.8 (C-16), 128.0 (C-18),
128.9 (C-17), 129.2 (C-15), 136.3 (C-6), 147.0 (C-14), 151.7 (C-5), 165.2 (C-3) ppm. FTMS 
(ESI) m/z: 370.1437 [M + H]+, found  370.1515 [M + H]+.  392.1437 [M + Na]+, found          
392.1327 [M + Na]+.  Melting point: 218-221 ̊C. FT-IR (ATR): 3418 (O-H, br),3029 (C-H), 
1685 (C=O) cm-1. 
 










Following the general method outlined in Section 6.3.1: AZT (0.5 g, 1.8 mmol) and 1-
ethynyl-3-fluorobenzene (0.21 mL, 1.8 mmol) were added to a solution of THF: water (3:1, 
16 mL). Freshly prepared sodium ascorbate (0.18 mL, 1 M, 0.18 mmol) was then added 
followed by CuSO4.5H2O (0.108 mL, 1 M, 0.108 mmol). The reaction was left to stir for 18 h 
at room temperature, monitored using TLC. The mixture was then evaporated to dryness. Water 
(30 mL) was then added to the crude mixture and filtered to produce 46 (93%, Yellow powder, 




1H-NMR (400 MHz, (CD3)2SO): δ = 1.83 (3H, s, H-1), 2.66-2.87  (2H, m, H-8), 3.72 (2H, q, 
J  = 12.5 Hz, H-11),  4.24-4.35 (1H,m, H-10), 5.32-5.36 (1H, m, H-12),  5.38-5.46 (1H, m, H-
9), 6.45 (1H, t, J = 7.0 Hz, H-7), 7.20 (1H, t, J  = 8.0 Hz, H-18), 7.53 (2H, q, J  = 7.5 Hz, 
H-16), 7.73 (2H, d, J  = 7.5 Hz, H-17), 7.85 (1H, s, H-6), 8.88 (1H, s, H-13), 11.41 (1H, s, 
H-4) ppm. 13C-NMR (100 MHz, (CD3)2SO): δ = 12.3 (C-1), 37.2 (C-8), 59.6 (C-9), 60.8 
(C-11), 83.9 (C-7), 84.4 (C-10),109.8 (C-2), 111.7 (C-20), 114.6 (C-18), 121.2 (C-16), 121.7 
(C-13), 131.2 (C-17), 133.2 (C-15), 136.3 (C-6), 145.6 (C-14), 150.5 (C-5),161.9 (C-19), 
164.0 (C-3) ppm. FTMS (ESI) m/z: 388.1343 [M + H]+, found 388.1417 [M + H]+.  
410.1343 [M + Na]+, found 410.1230 [M + Na]+. Melting point: 230-233 ̊C. FT-IR (ATR): 
3431 (O-H, br), 1692 (C=O),1278 (C-F) cm-1. 
 










Following the general method outlined in Section 6.3.1: AZT (0.5 g, 1.8 mmol) and 1-
ethynyl-3-fluorobenzene (0.21 mL, 1.8 mmol) were added to a solution of THF: water (3:1, 
16 mL). Freshly prepared sodium ascorbate (0.18 mL, 1 M, 0.18 mmol) was then added 




at room temperature, monitored using TLC. The mixture was then evaporated to dryness. Water 
(30 mL) was then added to the crude mixture and filtered to produce 47 (89%, white powder, 
Purity: >99%).  
1H-NMR (400 MHz, (CD3)2SO): δ = 1.82 (3H, s, H-1), 2.65-2.84  (2H, m, H-8), 3.63-3.77 
(2H, m, H-11), 3.28 (1H, q, J   = 4.0 Hz, H-10),  5.33 (1H, t, J   = 5.0 Hz, H-12), 5.42 (1H, dt,
 J  = 9.0 Hz, J = 5.5 Hz, H-9),  6.47  (1H, t, J = 8.0 Hz, H-7), 7.32 (2H, t, J = 9.0 Hz, H-6, 
H-17), 7.85 (1H, s, H-20), 7.89 (1H,d, J = 7.0 Hz, H-16), 7.92 (1H, d, J  = 7.0 Hz, H-18), 8.79 
(1H, s, H-13), 11.39 (1H, s, H-4), ppm. 13C-NMR (100 MHz, (CD3)2SO): δ = 12.2 (C-1), 37.3
 (C-8), 59.4 (C-9), 60.7 (C-11), 83.8 (C-7), 84.4 (C-10), 109.9 (C-2), 115.9 (C-17), 120.91 (C-
13), 127.2 (C-16), 127.5 (C-15), 136.2 (C-6), 146.4 (C-14), 150.4 (C-5), 164.0 (C-3) ppm. 
FTMS (ESI) m/z: 388.1343 [M + H]+, found  388.1421 [M + H]+.  410.1343 [M + Na]+, 
found 410.1232 [M + Na]+.  Melting point: 241-243 ̊C. FT-IR (ATR): 3472 (O-H), 1676 
















6.3.2 General Procedure for synthesis of 1,5 triazoles via click reactions 
3’-Azido-3’-deoxythymidine (AZT) (1 eq.) and the alkyne (1 eq.) were added to anh. THF. A 
catalytic amount of RuCl*Cp(PH3)2 (0.05 eq.) was added and the mixture was stirred for 1-2 
days at 60 ̊C. The reaction was monitored using TLC. Upon completion, the reaction was 

































Following the general method outlined in Section 6.3.2: AZT (0.15 g, 0.5 mmol) was added to 
stirred anh. THF (20 mL). Propargyl alcohol (0.48 mL, 0.05 g, 0.84 mmol) and 
RuCp*Cl(PPH2)3 (20.3 mg, 0.028 mmol) where added to the solution.  The reaction was left to 
stir for 2 days at 60 ̊C, monitored using TLC. The mixture was then evaporated to dryness. The 
precipitate is then purified using reverse phase chromatography (0.1% Formic acid: MeCN , 
starting at 9:1, until 7:3) to produce 48 ( 38%, white powder, Purity: >99%).  
1H-NMR (400 MHz, MeOD): δ = 1.84 (3H, s, H-1), 2.68-2.88  (2H, m, H-8), 3.75 (1H, dd, 
J = 12.5 Hz, J  = 3.5 Hz, Ha-11), 3.76 (1H, dd, J  = 12.5 Hz, J  = 3.5 Hz, Hb-11), 
4.44-4.45 (1H, m,  H-10), 5.25 (2H,  s,  H-15), 5.40-5.45 (1H,  m,  H-12),  6.06 (1H, t, 
J   = 6.0 Hz, H-16), 6.69-7.02 (2H, m, H-6, H-9, H-7), 7.29  (1H, t, J   = 7.0 Hz, H-7), 7.83 (1
H, s, H-14) ppm.13C-NMR (100 MHz, MeOD): δ = 12.4 (C-1), 39.2 (C-8), 58.6 (C-15), 59.9 
(C-9), 62.1 (C-11), 85.8 (C-7) 87.2 (C-10), 123.2 (C-2), 135.6 (C-13), 138.6 (C-6), 152.4 
(C-14), 160.2 (C-5),  166.6 (C-3)  ppm. FTMS (ESI) m/z : 346.1230.[M + Na]+, found 















Following the general method outlined in Section 6.3.2: AZT (0.3 g, 1.12 mmol) was added to 
stirred anh. THF (20 mL). Phenylacetylene (1.8 mL, 16.5 mmol) and RuCp*Cl(PPH2)3 
(0.04 g, 0.055 mmol) where added to the solution.  The reaction was left to stir for 2 days at 
60 ̊C, monitored using TLC. The mixture was then evaporated to dryness. The precipitate is 
then purified using reverse phase chromatography (0.1% Formic acid: MeCN , starting at 9:1, 
until 7:3) to produce 49 (42%, white solid, Purity: >99%).  
1H-NMR (400 MHz, (MeOD)): δ = 1.83 (3H, s, H-1), 2.53- 2.64  (1H, m, Ha-8), 2.73- 2.81   
(1H, m, Hb-8), 3.54 (1H, dd, J   = 12.0 Hz, J   = 3.0 Hz, Ha-11), 3.73 (1H, dd, J   = 12.5 Hz, 
J   =  3.5 Hz, Hb-11), 4.46 (1H, q, J   = 3.5 Hz,  H-10),  5.26-5.31 (1H, m, H-9), 6.61 (1H, t, 
J   = 7.5 Hz, H-7), 7.45-7.54 (5H,m, H-16, H-17, H-18), 7.78 (1H, s, H-6), 7.82 (1H, s, H-14) 
ppm.13C-NMR (100 MHz, (MeOD)): δ = 12.5 (C-1), 39.9 (C-8), 59.9 (C-9), 62.8 (C-11), 86.8
 (C-10), 86.8 (C-7), 130.4-131.1 (C-16,C-17, C-18), 133.9 (C-6), 138.3 (C-14), 152.7 (C-3), 1
66.4 (C-5) ppm. FTMS (ESI) m/z: 370.1437 [M + H]+, found  370.1520 [M + H]+.  392.1437 
[M + Na]+, found  392.1332 [M + Na]+.  Melting point: 216-219 ̊C. FT-IR (ATR): 3462 














Following the general method outlined in Section 6.3.2: AZT (0.3 g, 1.1 mmol) was added to 
stirred anh. THF (20 mL). 1-ethynyl-3-fluorobenzene (1.91 mL, 1.98 g, 16.5 mmol) and 
RuCp*Cl(PPH2)3 (39 mg, 0.06 mmol) where added to the solution.  The reaction was left to stir 
for 2 days at 60 ̊C, monitored using TLC. The mixture was then evaporated to dryness. The 
precipitate is then purified using reverse phase chromatography (0.1% Formic acid: MeCN , 
starting at 9:1, until 7:3) to produce 50 (50%, white solid, Purity: >99%).  
1H-NMR (400 MHz, MeOD): δ = 1.77 (3H, s, H-1), 2.49-2.59  (2H, m, H-8), 3.68 (1H, dd, J  
 = 3.0 Hz, 12.0 Hz, Ha-11), 3.75 (1H, dd, J   = 3.0 Hz, 12.0 Hz, Hb-11), 4.40 (1H, m, H-10), 
5.34-5.39 (1H, m, H-9), 6.52 (1H, t, J = 6.5 Hz, H-7), 7.16-7.27 (2H,m, H-16), 7.42-7.47 (2H,
 m, H-17), 7.87 (1H, s, H-6),  7.91 (1H, s, H-14) ppm.13C-NMR (100 MHz, MeOD): δ = 12.3 
(C-1), 37.2 (C-8), 59.4 (C-9), 61.8 (C-11), 83.2 (C-7), 88.4 (C-10),115.8 (C-2), 115.0 (Ca-16),
 115.2 (Ca-16), 121.2 (C-15), 130.5 (Ca-17), 131.2 (Cb-17), 134.7 (C-6), 136.5 (C-14), 145.6 
(C-14), 151.2 (C-5), 161.8 (C-18), 167.1 (C-3) ppm. FTMS (ESI) m/z: 388.1343 [M + H]+, 
found 388.1442 [M + H]+. 410.1343 [M + Na]+, found 410.1430 [M + Na]+.   Melting point: 












Following the general method outlined in Section 6.3.2: AZT (0.3 g, 1.1 mmol) was added to 
stirred anh. THF (20 mL). 1-ethynyl-4-fluorobenzene (1.91 mL, 1.98 g, 16.5 mmol) and 
RuCp*Cl(PPH2)3 (39 mg, 0.06 mmol) where added to the solution.  The reaction was left to stir 
for 2 days at 60 ̊C, monitored using TLC. The mixture was then evaporated to dryness. The 
precipitate is then purified using reverse phase chromatography (0.1% Formic acid: MeCN , 
starting at 9:1, until 7:3) to produce 51 (48%, white powder, Purity: >99%).  
1H-NMR (400 MHz, MeOD): δ = 1.79 (3H, s, H-1), 2.48-2.62  (2H, m, H-8), 3.47 (1H, dd, J  
 = 3.0 Hz, 12.0 Hz, Ha-11), 3.59 (1H, dd, J   = 3.0 Hz, 12.0 Hz, Hb-11), 4.28 (1H, q, J   = 3.5 
Hz, H-10), 5.36 (1H, dt, J = 4.0 Hz, 8.5 Hz H-9), 6.51 (1H, t, J  = 7.5 Hz, H-7), 7.10 (1H, t, J 
= 8.5 Hz, H-17), 7.35 (1H, s, H-6), 7.70 (1H, s, H-14), 7.82 (1H, s, H-20), 7.92-7.99 (2H, m, 
H-16, H-18)  ppm.13C-NMR (100 MHz, MeOD): δ = 12.2 (C-1), 39.6(C-8), 59.7 (C-9), 62.5 (
C-11), 86.7 (C-10) 87.3 (C-7), 111.7 (C-2), 117.3 (Ca-16), 117.5 (Cb-16), 123.7 (C-15), 132.9
 (Ca-17), 133.0 (Cb-17), 134.0 (C-14), 138.3 (C-6), 139.4 (C-13), 152.6 (C-5), 163.7 (C-18), 
166.3 (C-13) ppm.  FTMS (ESI) m/z: 388.1343 [M + H]+, found 388.1366 [M + H]+. 
410.1343 [M + Na]+, found 410.1326 [M + Na]+.   Melting point: 236-239 ̊C. FT-IR (ATR): 





6.4 The glycosidic flavonoid containing compounds 92-97 and 112-117 
 
6.4.1 General Procedure for synthesis of O-acetylated flavonoid glycosides 112-117 
 
To a mixture of DMF: acetone (5:3), K2CO3 (21 eq.) was added. This was followed by the 
addition of the flavonoid (1 eq.), tetrabutylammonium bromide (TBAB) and the sugar (10 eq.). 
The reaction was stirred for 18 h at room temperature. Upon completion, the acetone was 
removed in vacuo and the remaining solution was washed with a saturated LiCl solution. Ethyl 
acetate was added and the organic layers were separated and combined. The organic layer was 
dried with MgSO4 and the solvent was removed in vacuo. The precipitate was then purified 


























Following the general method outlined in Section 6.4.1: To a mixture of DMF: acetone (100:60 
mL), K2CO3 (11.5 g, 84.0 mmol) was added. This was followed by the addition of 
7-hydroxyflavone (0.952 g, 4.0 mmol), TBAB (100 mg) and the acetobromoglucose 
(10 g, 20.0 mmol). The reaction was stirred for 18 h at room temperature. Upon completion, 
the acetone was removed in vacuo and remaining solvent washed with a saturated LiCl solution. 
Ethyl acetate (3 × 70 mL) was added and the organic layers were separated and combined. The 
organic layer was dried with MgSO4 and the solvent was removed in vacuo. The precipitate is 
then purified using column chromatography (ethyl acetate: petrol ether   (3:2)) to produce 112 
(62%, clear oil)  
δ = 1H-NMR (400 MHz, CDCl3): δ = 2.05 (3H, s, H-OCOCH3), 2.07 (3H, s, H-OCOCH3), 2.
10 (3H, s, H-OCOCH3), 2.21 (3H, s, H-OCOCH3), 4.21-4.27 (3H, m, H-5, H-6), 5.19 (1H, dd,
 J = 3.5 Hz, J = 10.5 Hz, H-3), 5.25 (1H, d,  J = 8.0 Hz, H-1), 5.52 (1H, d, J = 3.5 Hz, H-2), 5.
56 (1H, dd, J = 8.0 Hz, J = 10.5 Hz, H-4),  6.78 (1H, s, H-17), 7.07 (1H, dd, J = 2.5 Hz, J = 9.
0 Hz, H-21), 7.16 (1H, d, J = 2.0 Hz, H-8), 7.49-7.57 (3H, m, H-13, H-14, H-15), 7.87-7.92 (2
H, add, J = 2.0 Hz, J = 7.0 Hz, H-12, H-16), 8.17 (1H, d, J = 9.0 Hz, H-20) ppm. 13C-NMR (
100 MHz, CDCl3): δ = 20.5 (C-OCOCH3), 20.6 (C-OCOCH3), 20.7 (C-OCOCH3), 21.0 (C-O




07.6 (C-17), 115.3 (C-21), 119.6 (C-19), 126.2 (C-12, C-16), 127.4 (C-20), 129.0 (C-13, C-15
), 131.8 (C-11, C-14), 156.6 (C-9), 160.2 (C-7), 163.2 (C-10), 170.0 (C-OCOCH3), 170.2 (C-
OCOCH3), 170.3 (C-OCOCH3), 171.1 (C-OCOCH3), 177.6 (C-18) ppm. 
FTMS (ESI) m/z: 591.5192 [M + Na]+, found 591.1462 [M + Na]+.   FT-IR (ATR): 
1685 (C=O), 1035 (C-O) cm-1. 
 










Following the general method outlined in Section 6.4.1: To a mixture of DMF: acetone (100:60 
mL), K2CO3 (11.50 g, 84.00 mmol) was added. This was followed by the addition of 
7-hydroxyflavone (0.95 g, 4.00 mmol), TBAB (100 mg) and the acetobromogalactcose 
(10.00 g, 20.00 mmol). The reaction was stirred for 18 h at room temperature. Upon 
completion, the acetone was removed in vacuo and remaining solvent washed with a saturated 
LiCl solution. Ethyl acetate (3 × 70 mL) was added and the organic layers were separated and 
combined. The organic layer was dried with MgSO4 and the solvent was removed in vacuo. 
The precipitate is then purified using column chromatography (ethyl acetate: petrol ether   (3:2)) 




1H-NMR (400 MHz, CDCl3): δ = 2.05 (3H, s, H-OCOCH3), 2.08 (3H, s, H-OCOCH3), 2.11 (
3H, s, H-OCOCH3), 2.12 (3H, s, H-OCOCH3), 4.26-4.31 (3H, m, H-5, H-6), 5.24 (1H, dd, J =
 3.5 Hz, J = 10.5 Hz, H-3), 5.32 (1H, d,  J =8.0 Hz, H-1), 5.54 (1H, d, J   = 3.5 Hz, H-2), 5.57 
(1H, dd, J = 8.0 Hz, J = 11.0 Hz, H-4),  6.75 (1H, s, H-17), 7.08 (1H, dd, J = 2.5 Hz, J = 9.0 
Hz, H-21), 7.18 (1H, d, J = 2.5 Hz, H-8), 7.49-7.57 (3H, m, H-13, H-14, H-15), 7.87-7.92 (2H
, m, H-12, H-16), 8.16 (1H, d, J = 9.0 Hz, H-20) ppm. 13C-NMR (100 MHz, CDCl3): δ = 20.4
 (C-OCOCH3), 20.5 (C-OCOCH3), 20.6 (C-OCOCH3), 20.9 (C-OCOCH3),  61.6 (C-6), 67.0 (
C-2), 68.4 (C-4), 70.6 (C-3), 71.5 (C-5), 98.7 (C-1), 104.2 (C-8), 107.5 (C-17), 115.1 (C-21), 
115.4 (C-19),125.9 (C-12, C-16), 127.5 (C-20), 129.1 (C-13, C-15), 131.4 (C-11), 132.6 (C-1
4), 157.7 (C-9), 160.9 (C-7),163.6 (C-10), 169.9 (C-OCOCH3), 170.1 (C-OCOCH3), 170.3 (C
-OCOCH3), 171.1 (C-OCOCH3), 177.5 (C-18) ppm. FTMS (ESI) m/z: 591.5192 [M + Na]
+,  
found 591.0245 [M + Na]+.   FT-IR (ATR): 1741 (C=O), 998 (C-O) cm-1. 
 








Following the general method outlined in Section 6.4.1: To a mixture of DMF: acetone 
(100:60 mL), K2CO3 (11.50 g, 84.0 mmol) was added. This was followed by the addition of 
chrysin (1.02 g, 4 mmol), TBAB (100 mg) and the acetobromoglucose (10.00 g, 20.00 mmol). 




removed in vacuo and remaining solvent washed with a saturated LiCl solution. Ethyl acetate 
(3 × 70 mL) was added and the organic layers were separated and combined. The organic layer 
was dried with MgSO4 and the solvent was removed in vacuo. The precipitate is then purified 
using column chromatography (ethyl acetate: petrol ether   (3:2)) to produce 114 (68%, clear 
oil). 
1H-NMR (400 MHz, CDCl3): δ = 2.05 (3H, s, H-OCOCH3), 2.07 (3H, s, H-OCOCH3), 2.09 (
3H, s, H-OCOCH3), 2.11 (3H, s, H-OCOCH3), 3.96 (1H, dq, J   = 3.0 Hz, J   = 6.0 Hz, H-5), 4
.21 (1H, dd, Ha-6), 4.30 (1H, dd, Hb-6), 5.16 (1H,d, J   = 9.0 Hz, H-4), 5.20 (1H, d, J   = 7.5 
Hz, H-1), 5.32 (2H, aquin, J   = 7.5 Hz, J   = 9.0 Hz, H-2, H-3), 6.45 (1H, d, J   = 2.0 Hz, H-8)
, 6.60 (1H, d, J   = 2.0 Hz, H-21), 6.69 (1H, s, H-17), 7.50-7.60 (3H, m, H-13, H-14, H-15), 7.
50-7.88 (2H, m, H-12, H-16), 12.74 (1H, s, H-OH) ppm. 13C-NMR (100 MHz, CDCl3): δ = 2
0.6 (C-OCOCH3), 20.7 (C-OCOCH3), 61.9 (C-6), 68.2 (C-4), 70.8 (C-2), 72.5 (C-3), 72.6 (C-
5), 95.7 (C-21), 98.1 (C-1), 99.9 (C-8), 106.1 (C-17), 126.4 (C-12, C-16), 129.2 (C-13, C-15),
 132.2 (C-14), 157.1 (C-9), 159.2 (C-7), 162.2 (C-19),  162.4 (C-20), 164.4 (C-10, C-11), 169.
2 (C-OCOCH3), 169.4 (C-OCOCH3), 170.2 (C-OCOCH3), 170.6 (C-OCOCH3), 182.5 (C-18) 
ppm. FTMS (ESI) m/z: 607.5192 [M + Na]+, found 607.1397 [M + Na]+.   FT-IR (ATR):      




















Following the general method outlined in Section 6.4.1: To a mixture of DMF: acetone 
(100:60 mL), K2CO3 (11.50 g, 84.0 mmol) was added. This was followed by the addition of 
chrysin (1.02 g, 4 mmol), TBAB (100 mg) and the acetobromogalactose 
(10.00 g, 20.00 mmol). The reaction was stirred for 18 h at room temperature. Upon 
completion, the acetone was removed in vacuo and remaining solvent washed with a saturated 
LiCl solution. Ethyl acetate (3 × 70 mL) was added and the organic layers were separated and 
combined. The organic layer was dried with MgSO4 and the solvent was removed in vacuo. 
The precipitate is then purified using column chromatography (ethyl acetate: petrol ether   (3:2)) 
to produce 115 (69%, clear oil). 
1H-NMR (400 MHz, CDCl3): δ = 2.03 (3H, s, H-OCOCH3), 2.09 (3H, s, H-OCOCH3), 2.10 (
3H, s, H-OCOCH3), 2.20 (3H, s, H-OCOCH3), 4.07-4.30  (3H, m, H-5, H-6), 5.13-5.18 (2H, 
m, H-1, H-3), 5.47-5.56 (2H, m, H-2, H-4), 6.48 (1H,d, J   = 2.5 Hz, H-8), 6.63 (1H, d, J   = 2.
5 Hz, H-21),  6.69 (1H, s, H-17), 7.50-7.60 (3H, m, H-13, H-14, H-15), 7.86-7.91 (2H, m, H-1
2, H-16), 12.73(1H, s, H-20OH) ppm.13C-NMR (100 MHz, CDCl3): δ = 20.6 (C-OCOCH3), 2
0.7 (C-OCOCH3), 21.0 (C-OCOCH3), 62.0 (C-6), 66.7 (C-4), 69.1 (C-2), 71.0 (C-3), 72.4 (C-
5), 95.5 (C-21), 98.7 (C-1), 99.9 (C-8), 106.1 (C-17), 126.2 (C-12, C-16), 129.2 (C-13, C-15),




OCH3), 170.0 (C-OCOCH3), 170.2(C-OCOCH3), 170.5 (C-OCOCH3), 183.1 (C-18) ppm. FT















Following the general method outlined in Section 6.4.1: To a mixture of DMF: acetone 
(100:60 mL), K2CO3 (11.50 g, 84.0 mmol) was added. This was followed by the addition of 
7,8-dihydroxyflavone (1.02 g, 4 mmol), TBAB (100 mg) and the acetobromoglucose 
(10.00 g, 20.00 mmol). The reaction was stirred for 18 h at room temperature. Upon 
completion, the acetone was removed in vacuo and remaining solvent washed with a saturated 
LiCl solution. Ethyl acetate (3 × 70 mL) was added and the organic layers were separated and 
combined. The organic layer was dried with MgSO4 and the solvent was removed in vacuo. 
The precipitate is then purified using a column chromatography (9:1 to 2:8 petrol ether: ethyl 




1H-NMR (400 MHz, CDCl3): δ = 1.80 (3H, s, H-OCOCH3), 1.99 (3H, s, H-OCOCH3), 2.02-2
.05 (9H, m, H-OCOCH3), 2.06 (3H, s, H-OCOCH3), 2.07 (3H, s, H-OCOCH3), 2.10 (3H, s, H
-OCOCH3), 3.71-3.78 (1H, m, H-5), 3.85-3.91 (2H, m, H-26), 3.94 (1H, ad, J   = 12.5 Hz, Ha-
6), 4.14 (1H, ad, J   = 13.0 Hz, Ha-27), 4.20 (1H, dd, J   = 5.0 Hz, J   = 13.0 Hz, Hb-6), 4.31 (
1H, dd, J   = 5.5 Hz, J   = 13.0 Hz, Hb-27), 5.20 (2H, aq, J   = 10.0 Hz, H-4, H-25), 5.27-5.41 
(5H, m, H-1, H-2, H-3, H-23, H-24), 5.52 (1H,d, J   = 7.5 Hz, H-22), 6.80 (1H, s, H-17), 7.16 
(1H, d, J   = 9.0 Hz, H-21), 7.51-7.58 (3H, m, H-13, H-14, H-15), 7.94 (1H, d, J   = 9.0 Hz, H
-20), 7.98-8.03 (2H, m, H-12, H-16) ppm. 13C-NMR (100 MHz, CDCl3): δ = 20.4 (C-OCOC
H3), 20.6 (C-OCOCH3), 20.7 (C-OCOCH3), 20.8 (C-OCOCH3), 61.5 (C-6, C-27), 67.9 (C-4), 
68.3 (C-25), 71.3 (C-2, C-23), 72.5 (C-5), 72.5 (C-3, C-26), 72.8 (C-24),  99.4 (C-1), 99.9 (C-
22), 106.9 (C-17), 114.5 (C-19), 114.8 (C-21), 121.6 (C-20), 126.4 (C-12, C-16), 129.2 (C-13,
 C-15), 131.3 (C-11), 132.0 (C-14), 134.3 (C-8), 150.5 (C-9), 152.8 (C-7), 163.8 (C-10), 169.
4 (C-OCOCH3), 170.2 (C-OCOCH3), 170.4 (C-OCOCH3), 178.0 (C-18) ppm. FTMS (ESI) m
/z: 937.8092 [M + Na]+, found 936.9584 [M + Na]+.   FT-IR (ATR):  1784 (C=O) cm-1. 
 












Following the general method outlined in Section 6.4.1: To a mixture of DMF: acetone 
(100:60 mL), K2CO3 (11.50 g, 84.0 mmol) was added. This was followed by the addition of 
7,8-dihydroxyflavone (1.02 g, 4 mmol), TBAB (100 mg) and the acetobromogalactose 
(10.00 g, 20.00 mmol). The reaction was stirred for 18 h at room temperature. Upon 
completion, the acetone was removed in vacuo and remaining solvent washed with a saturated 
LiCl solution. Ethyl acetate (3 × 70 mL) was added and the organic layers were separated and 
combined. The organic layer was dried with MgSO4 and the solvent was removed in vacuo. 
The precipitate is then purified using a column chromatography (9:1 to 2:8 petrol ether: ethyl 
acetate) to produce 117 (41%, clear oil). 
1H-NMR (400 MHz, CDCl3): δ = 1.86 (3H, s, H-OCOCH3), 2.01 (9H, s, H-OCOCH3), 2.10(3
H, s, H-OCOCH3), 2.14 (3H, s, H-OCOCH3), 2.21 (3H, s, H-OCOCH3), 3.95-4.07 (4H, m, 
H-5, H-6, H-26), 4.14-4.22  (2H, m, H-27), 5.12-5.19  (2H, m, H-3, H-24), 5.27 (1H, d, J   = 8
.0 Hz, H-1), 5.40 (1H, d, J   = 4.0 Hz, H-4), 5.44-5.52  (3H, m, H-2, H-22, H-25),5.58 (1H, a.t
, J   =  9.0 Hz, H-23), 6.81 (1H, s, H-17), 7.18 (1H, d, J   = 9.0 Hz, H-21), 7.50-7.56 (3H, m, 
H-13, H-14, H-15), 7.93 (1H, d, J  = 9.0 Hz, H-20), 8.01-8.05 (2H, m, H-12, H-16) ppm. 
13C-NMR (100 MHz, CDCl3): δ = 20.5 (C-OCOCH3), 20.6 (C-OCOCH3), 20.8 (C-OCOCH3)
, 60.6 (C-6), 61.4 (C-27), 66.8 (C-4), 67.1 (C-25), 68.7 (C-2),  69.6 (C-23), 70.6 (C-3), 70.9 (
C-24), 71.2 (C-5), 71.6 (C-26),100.0 (C-1), 100.3 (C-22), 106.8 (C-17), 114.7 (C-21), 114.9 (
C-19), 121.4 (C-20), 126.6 (C-12, C-16), 129.1 (C-13, C-15), 131.8 (C-11), 131.9 (C-14), 133
.8 (C-8), 150.6 (C-9), 152.5 (C-7), 163.4 (C-10), 169.4 (C-OCOCH3), 169.5 (C-OCOCH3), 17
0.0 (C-OCOCH3), 170.1 (C-OCOCH3), 170.2 (C-OCOCH3), 170.3 (C-OCOCH3), 178.3 (C-1
8) ppm. FTMS (ESI) m/z: 937.8092 [M + Na]+, found 937.2543[M + Na]+.   FT-IR (ATR):  






6.4.2 General procedure for deprotection of the flavonoid glycosides 92-97 
 
The product was dissolved in anh. methanol (30 mL) and K2CO3 (90 mg) was added and stirred 
for 20 h. The reaction was neutralised to pH 7 using 1.0 M HCl. The filtrate was filtered through 
a sintered funnel and the solid was collected. The crude solid was purified using RP-column 
































Following the general method outlined in Section 6.4.2: The acetylated product 112 was 
dissolved in anh. methanol (30 mL) and K2CO3 (90 mg) was added . This reaction was left to 
stir for 20 h at room temperature. The reaction was neutralised to pH 7 using 1.0 M HCl. The 
filtrate was filtered and the solid was collected to produce 92 (65%, white solid, Purity: 97%). 
1H-NMR (400 MHz, (CD3)2SO): δ = 3.43-3.48 (1H, m, H-3), 3.49-3.60 (2H, m, H-6), 3.60-3.
67 (1H, m, H-2), 3.69-3.70 (2H, m, H-4, H-5), 4.57 (1H, d, J = 4.5 Hz, H-4OH), 4.72 (1H, t, J
 = 5.5 Hz, H-6OH), 4.94 (1H, d, J = 5.5 Hz, H-3OH), 5.09 (1H, d, J = 8.0 Hz, H-1), 5.29 (1H,
 d, J = 5.5 Hz, H-2OH), 6.98 (1H, s, H-17), 7.15 (1H, dd, J = 2.5 Hz, J = 9.0 Hz, H-21), 7.39 (
1H, d, J = 2.0 Hz, H-8), 7.56-7.62 (3H, m, H-13, H-14, H-15), 7.97 (1H, d, J = 9.0 Hz, H-20),
8.07-8.11 (2H, m, H-12, H-16) ppm. 13C-NMR (100 MHz, (CD3)2SO): δ = 61.3 (C-6), 68.0 (
C-4), 70.2 (C-2), 73.5 (C-3), 75.9 (C-5), 101.3 (C-1), 103.8 (C-8), 107.0 (C-17), 115.8 (C-21),
 118.4 (C-19), 126.8 (C-12, C-16, C-20), 129.2 (C-13, C-15), 131.5 (C-11), 132.0 (C-14), 157
.7 (C-9), 157.8 (C-7), 161.9 (C-10), 176.2 (C-18) ppm. FTMS (ESI) m/z : 417.1186 [M + OH















Following the general method outlined in Section 6.4.2: The acetylated product 113 was 
dissolved in anh. methanol (30 mL) and K2CO3 (90 mg) was added . This reaction was left to 
stir for 20 h at room temperature. The reaction was neutralised to pH 7 using 1.0 M HCl. The 
filtrate was filtered and the solid was collected to produce 93 (68%, white solid, Purity: 98%). 
1H-NMR (400 MHz, (CD3)2SO): δ = 3.43-3.48 (1H, m, H-3), 3.49-3.60 (2H, m, H-6), 3.60-3.
67 (1H, m, H-2), 3.69-3.70 (2H, m, H-4, H-5), 4.57 (1H, d, J = 4.5 Hz, H-4OH), 4.72 (1H, t, J
 = 5.5 Hz, H-6OH), 4.94 (1H, d, J = 5.5 Hz, H-3OH), 5.09 (1H, d, J = 8.0 Hz, H-1), 5.29 (1H,
 d, J = 5.5 Hz, H-2OH), 6.98 (1H, s, H-17), 7.15 (1H, dd, J = 2.5 Hz, J = 9.0 Hz, H-21), 7.39 (
1H, d, J = 2.0 Hz, H-8), 7.56-7.62 (3H, m, H-13, H-14, H-15), 7.97 (1H, d, J = 9.0 Hz, H-20),
8.07-8.11 (2H, m, H-12, H-16) ppm. 13C-NMR (100 MHz, (CD3)2SO): δ = 61.3 (C-6), 68.0 (
C-4), 70.2 (C-2), 73.5 (C-3), 75.9 (C-5), 101.3 (C-1), 103.8 (C-8), 107.0 (C-17), 115.8 (C-21),
 118.4 (C-19), 126.8 (C-12, C-16, C-20), 129.2 (C-13, C-15), 131.5 (C-11), 132.0 (C-14), 157
.7 (C-9), 157.8 (C-7), 161.9 (C-10), 176.2 (C-18) ppm 
FTMS (ESI) m/z : 417.1186 [M + OH]+,found 417.1176 [M + OH]+. Melting point: 264-268













Following the general method outlined in Section 6.4.2: The acetylated product 114 was 
dissolved in anh. methanol (30 mL) and K2CO3 (90 mg) was added . This reaction was left to 
stir for 20 h at room temperature. The reaction was neutralised to pH 7 using 1.0 M HCl. The 
filtrate was filtered and the solid was collected to produce 94 (51%, yellow solid, Purity: 99%). 
1H-NMR (400 MHz, (CD3)2SO): δ = 3.39-3.47 (1H, m, H-3), 3.49-3.57 (2H, m, H-6), 3.57-3.
64 (1H, m, H-2), 3.67-3.73 (2H, m, H-4, H-5), 4.57 (1H, d, J = 4.0 Hz, H-4OH), 4.71 (1H, t, J
 = 5.5 Hz, H-6OH), 4.93 (1H, d, J = 6.0 Hz, H-3OH), 5.03 (1H, d, J = 7.5 Hz, H-1), 5.27 (1H,
 d, J = 5.0 Hz, H-2OH), 6.48 (1H, as, H-21), 6.87 (1H, as, H-8), 7.05 (1H, s, H-17), 7.54-7.65 
(3H, m, H-13, H-14, H-15), 8.05-8.12 (2H, m, H-12, H-16) ppm. 13C-NMR (100 MHz, 
(CD3)2SO): δ = 60.3 (C-6), 68.1 (C-4), 69.7 (C-2), 73.2 (C-3), 75.7 (C-5), 94.1 (C-8), 100.2 (
C-21), 100.4 (C-1), 105.4 (C-17), 105.9 (C-19), 126.6 (C-12, C-16), 129.2 (C-13, C-15), 130.
3 (C-11), 132.2 (C-14), 156.5 (C-9), 163.7 (C-7, C-10), 182.1 (C-18) ppm. FTMS (ESI) m/z :
 417.3820 [M + H]+, found 417.1175 [M + H]+. 439.3718 [M + Na]+, found 439.0996 
[M + H]+. Melting point: 208-210 ̊C. FT-IR (ATR): 3312 (O-H), 1343 (O-H, phenolic), 















Following the general method outlined in Section 6.4.2: The acetylated product 115 was 
dissolved in anh. methanol (30 mL) and K2CO3 (90 mg) was added . This reaction was left to 
stir for 20 h at room temperature. The reaction was neutralised to pH 7 using 1.0 M HCl. The 
filtrate was filtered and the solid was collected to produce 95 (53%, yellow solid, Purity: 99%). 
1H-NMR (400 MHz, (CD3)2SO): δ = 3.41-3.46 (1H, m, H-3), 3.48-3.57 (2H, m, H-6), 3.58-3.
64 (1H, m, H-2), 3.67-3.74 (2H, m, H-4, H-5), 4.50 (1H, d, J = 4.5 Hz, H-4OH), 4.72 (1H, t, J
 = 5.0 Hz, H-6OH), 4.94 (1H, d, J = 6.0 Hz, H-3OH), 5.04 (1H, d, J = 8.0 Hz, H-1), 5.27 (1H,
 d, J = 5.0 Hz, H-2OH), 6.47 (1H, d, J = 2.0 Hz, H-21), 6.87 (1H, d, J = 2.0 Hz, H-8), 7.07 (1
H, s, H-17), 7.54-7.66 (3H, m, H-13, H-14, H-15), 8.10 (2H, d, J = 8.5 Hz, H-12, H-16) ppm. 
13C-NMR (100 MHz, (CD3)2SO): δ = 61.3 (C-6), 68.9 (C-4), 69.7 (C-2), 73.1 (C-3), 77.7 (C-
5), 92.6 (C-8), 101.0 (C-21), 101.5(C-1), 105.8 (C-17), 107.5 (C-19), 127.2 (C-12, C-16), 
130.6(C-13, C-15), 135.7 (C-11), 137.2 (C-14), 156.5 (C-9), 161.6 (C-7, C-10), 182.1 (C-18) 
ppm. FTMS (ESI) m/z : 417.3820 [M + H]+, found 417.1175 [M + H]+. 439.3718 [M + Na]+, 
found 439.0996 [M + H]+. Melting point: 208-210 ̊C. FT-IR (ATR): 3312 (O-H), 1343 
















Following the general method outlined in Section 6.4.2: The acetylated product 116 was 
dissolved in anh. methanol (30 mL) and K2CO3 (90 mg) was added . This reaction was left to 
stir for 20 h at room temperature. The reaction was neutralised to pH 7 using 1.0 M HCl. The 
filtrate was filtered and the solid was collected to produce 96 (64%, white solid, Purity: 97%). 
1H-NMR (400 MHz, (CD3)2SO): δ = 3.13-3.24 (3H, m, H-24, H-25, H-26), 3.25-3.33 (2H, m,
 H-5, H-23), 3.39-3.49 (4H, m, H-2, H-3, H-4, Ha-27), 3.46-3.54 (1H, m, Ha-6), 3.61 (1H, dd,
 J = 5.0 Hz, J = 11.0 Hz, Hb-27), 3.73 (1H, dd, J = 5.0 Hz, J = 11.0 Hz, Hb-6), 4.32 (1H, t, J 
= 6.0 Hz, H-27OH), 4.63 (1H, t, J = 5.5 Hz, H-6OH), 4.97-5.01 (2H, m, H-22, H-24OH), 5.04
 (1H, d, J = 7.5 Hz, H-1), 5.07-5.13 (1H, m, H-3OH, H-25OH), 5.16 (2H, d, J = 5.5 Hz, H-4O
H, H-23OH), 5.43 (1H, d, J = 4.0 Hz, H-2OH), 6.98 (1H, s, H-17),  7.39 (1H, d, J = 9.5 Hz,  
H-21), 7.77 (1H, d, J = 9.0 Hz,  H-20), 7.54-7.63 (3H, m, H-13, H-14, H-15), 8.22 (2H, d, J = 
8.0 Hz, H-12, H-16) ppm. 13C-NMR (100 MHz, (CD3)2SO): δ = 61.1 (C-6), 61.4 (C-27), 69.6
(C-4), 69.9 (C-25), 73.4 (C-2), 74.4 (C-23), 75.9 (C-3), 76.2 (C-24), 77.2 (C-5), 77.3 (C-26),  
101.2 (C-1), 104.3 (C-22), 107.0 (C-17), 114.1 (C-21), 119.8 (C-19), 120.5 (C-20), 126.9 (C-




-7), 163.3 (C-10), 177.7 (C-18) ppm. FTMS (ESI) m/z : 579.5230 [M + H]+, found 579.1701 
[M + H]+. 601.5128[M + Na]+, found 601.1520 [M + Na]+. Melting point: 245-246 ̊C. 
FT-IR (ATR): 3329 (O-H), 1341 (O-H, phenolic), 1032 (C-O) cm-1. 
 
 









Following the general method outlined in Section 6.4.2: The acetylated product 117 was 
dissolved in anh. methanol (30 mL) and K2CO3 (90 mg) was added . This reaction was left to 
stir for 20 h at room temperature. The reaction was neutralised to pH 7 using 1.0 M HCl. The 
filtrate was filtered and the solid was collected to produce 97 (62%, white solid Purity: 97%). 
1H-NMR (400 MHz, (CD3)2SO): δ = 3.26-3.32 (1H, m, Ha-6), 3.37-3.40 (1H, m, H-26), 3.42-
3.49 (2H, m, H-3, H-4, H-24), 3.51-3.61 (3H, m, Hb-6, H-27), 3.64-3.69 (1H, m, H-5), 3.69-3
.75 (3H, m, H-2, H-4, H-25), 3.77-3.85 (1H, m, H-23), 4.44 (1H, t, J = 6.0 Hz, H-27OH), 4.67
 (1H, d, J = 4.5 Hz, H-25OH), 4.70 (1H, d, J = 5.0 Hz, H-4OH), 4.76 (1H, t, J = 5.5 Hz, H-6O
H), 4.91 (1H, d, J = 8.5 Hz, H-22), 4.92-4.99 (4H, m, H-1, H-3OH, H-23OH, H-24OH), 5.29 
(1H, d, J = 4.0 Hz, H-2OH), 6.97 (1H, s, H-17),  7.38 (1H, d, J = 9.5 Hz,  H-21),7.54-7.62 (3




6) ppm. 13C-NMR (100 MHz, (CD3)2SO): δ = 59.9 (C-6), 60.3 (C-27), 67.8 (C-4), 68.0 (C-25
), 70.9 (C-2), 72.2 (C-23), 72.8 (C-3, C-24), 75.5 (C-5), 75.9 (C-26), 102.3 (C-1), 105.0 (C-22
), 106.2 (C-17), 114.2 (C-21), 119.1 (C-19), 120.7 (C-20), 127.1 (C-12, C-16), 127.6 (C-11), 
129.1 (C-13, C-15), 131.8 (C-14), 134.2 (C-8), 150.3 (C-9), 154.3 (C-7), 162.5 (C-10), 176.8 
(C-18) ppm. FTMS (ESI) m/z : 579.5230 [M + H]+, found 579.7021 [M + H]+. 601.5128 
[M + Na]+, found 601.1522 [M + Na]+. Melting point: 231-232 ̊C. 
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A(1): Nutrient broth 2 
Component description g/L 
‘Lab-Lemco’ powder 10 
Peptone 10 
Sodium chloride 5 
pH 7.5 ± 0.2  
 
 














Component description g/L 
Beef, dehydrated infusion 300 
Caesein hydrolysate 17.5 
Starch 1.5 
pH 7.3 ± 0.1 @ 25 ̊C  
Component description g/L 
Beef, dehydrated infusion 300 
Caesein hydrolysate 17.5 
Starch 1.5 
Agar 17 













Component Description g/l Component Description g/l 
Adenine 0.01 Nicotinamide 0.01 
Ammonium sulfate 1 4-aminobenzoic acid (PABA) 0.1 
ATP 0.07 Dibasic phosphate buffer 7 
Biotin 0.01 Dipotassium hydrogen phosphate 7 
Calcium chloride 0.1 Folic acid 0.01 
Calcium pantothenate 0.05 Glucose 2.5 
Choline chloride 0.01 Iso sensitest peptone 3 
Cytosine 0.01 Ketoglutaric acid 0.1 
Glycine 0.1 L-asparagine 0.1 
Guanine 0.01 L-glutamine 0.1 
L-arginine 0.1 L-ornithine monohydrochloride 0.1 
L-aspartic acid 0.1 Monobasic phosphate buffer 2 
L-cysteine 0.1 NAD 0.07 
L-cystine 0.1 Potassium dihydrogen phosphate 2 
L-glutamate 0.1 Pyridoxal hydrochloride 0.01 
L-histidine 0.1 Pyridoxamine 0.01 
L-isoleucine 0.1 Pyridoxine 0.01 
L-leucine 0.1 Riboflavin 0.01 
L-lysine HCL 0.1 Sodium citrate 0.5 
L-methionine 0.1 Sodium pyruvate 2.5 
L-phenylalanine 0.1 Taurine 0.1 
L-proline 0.1 Thiamine hydrochloride (aneurine) 0.01 
L-serine 0.1 Trans-4-hydroxy-L-proline 0.1 
L-threonine 0.3 Veal peptone 3 
L-tryptophan 0.1 Vitamin B12 0.01 
L-tyrosine 0.1 Yeast extract 0.1 
L-valine 0.1 Zinc sulphate 0 
Magnesium sulfate heptahydrate 0.1 α aminobutyric acid 0.1 























A(5): List of figures 
Figure 1: The sites of action for antimicrobial drugs. Adapted from a figure in ref. 34 
Figure 2: The structure of the cell walls for both Gram positive and Gram negative bacteria.  ...    
Adapted from ref. 36. 
Figure 3: The elongation stage of fatty acid synthesis. The antibiotics are shown in red,        
displaying where they are effective. Modified from ref. 45. 
Figure 4: Examples of antimicrobials that affect the protein/ RNA synthesis. Streptomycin 7 is 
an example of an aminoglycoside. Tetracycline 8, erythromyocin 9 is a macrolide       and 
dafopristin 10 is an example of a streptogramin. The MIC data displayed shows     their activities 




Figure 5: Systemic antibacterial new molecular entities approved by the US Food and Drug 
Administration from ref. 56. 
Figure 6: A timeline of when antibiotics were introduced and when resistance was identified.  .     
Adapted from ref. 60. 
Figure 7: A simplified diagram of the prodrug concept. Modified from ref. 92. 
Figure 8: Data analysis of the composition of carbohydrate drugs records from the       
aforementioned pharmacopoeias. Adapted from ref. 97. 
Figure 9: The structures of TTS-12 (22) and TTS-15 (23). 
Figure 10: Four of the key enzymatic glycosylations in nature. Glycosyltransferase (A),           
reverse glycosidase (B), glycan donor transferase (C) transglycosylation (D). Adapted from 33. 
Figure 11: The structure of ciprofloxacin 24 with its glucose 26 and galactose 25           
conjugates. The data shown is the diameter of the zone of inhibition in a disc diffuse assay. 
Data adapted from ref. 113. 
Figure 12: The structure of nadifloxacin 27 with its glucose 28 and galactose 29                 
conjugates. The data shown is the MIC determined by the bioscreen method. Work adapted 
from ref. 114. 
Figure 13: The previously synthesised compounds, 30-33,113 and the target structures, 24-25, 
for the bisphenol containing carbohydrate compounds. 
Figure 14: The structure of triclosan 26.  The MIC data is also shown; data collected using a      
micro-dilution assay.115 A table showing triclosan’s 26 mechanism of resistance and antibiotic 
cross-resistance in different bacteria. 
Figure 15:The structures of bromochlorophen (BCP) 28, dichlorophen (DP) 29 and         
hexachlorophene (hex) 27. Data was collected using a bioscreen method.113 
Figure 16 : The structures of the previously synthesised glycosides from Dr. Brieley’s work. 
Figure 17: The target compounds 24-25. The retrosynthetic route is also shown beneath the ....        
target compounds. 
Figure 18: The possible hydrogen bond present in the acetylated intermediates in for the          
synthesis of 24b and 25b. 
Figure 19: A table showing the different glycosylation methods used. NR = no reaction. 
Figure 20: 1H-NMR spectrum for 25a, the highlighted peak is the hydrogen present at the 
anomeric centre. The J value highlights that’s it’s the β-anomer has been synthesised. The table 
below  shows the J values (Hz) for the four compounds, 24-25, as determined from their         
respective 1H-NMRs spectra. 
Figure 21: The dipole interactions shown on the α- and β- anomers. 
Figure 22: The hyperconjugation model. This shows the lone pair orbital on the oxygen and       
the σ* orbital in C-1 position. 
Figure 23: A graph showing the growth of a bacterium, in relation to time. 
Figure 24: A diagram showing the SAR collected form the different bisphenol                moieties 
attached as glucosides and galactosides. 
Figure 25: The target structure 24-25, with their respective yields and purities shown. 
Figure 26: The basic structures for this series of compounds. In 35-42, the R groups are          




Figure 27: The structure of Azidothymidine 43 and thymidine 44. The hydroxyl on the 3’                          
position of the thymidine is replaced with an azido group in AZT 43.  The ID50 is   displayed 
for 43-50. 
Figure 28: The mechanism of action for azidothymidine. The use of enzymes allows for the       
active metabolite (AZT-Thymidine 53) to be synthesised and used as a DNA chain        
terminator. Adapted from ref. 201. 
Figure 29: Examples of ester prodrugs of AZT. 54-57are reported in ref. 205, 58-61 in ref. 206.  .      
The MIC data is presented below each compound. 54-57 MIC was assayed using  
Mueller-Hinton broth against Klebsiella pneumoniae ATCC 10031. 58-61 were assayed using 
Mueller-Hinton broth against Klebsiella pneumoniae. * compared to the parent compound, 
AZT 43, which had an MIC= 2 µg/mL. ** compared to commercial antibiotics: Norfloxacin 
MIC = 0.0381 µg/mL and Ciprofloxacin MIC = 0.0381 µg/mL. 
Figure 30: The structures 62-69 which were tested against various bacteria. These are from ref. 
212. The MIC data is also displayed for compounds 62-69. 
Figure 31: Compounds 70-75, which all contain a 1,2,3- triazole in the 3’ position.                The 
data is showing the phosphorylation by UpTK and hTK1, with 100 M ATP and the nucleosides, 
respectively. The data is presented as relative activity (%) when compared to dThd. Data from 
ref. 74. 
Figure 32: Cefatrizine 76 is a commercial drug that contains a 1,2,3,-triazole. The MIC data 
(µg/mL) is displayed, with good activity against the bacteria shown. Data from ref. 213. 
Figure 33: Annotated structures, 35-42, showing the justification for their drug design. 
Figure 34: Three different ‘click’ reactions. (A) is the Huisgen 1, 3-Dipolar Cycloaddition,          
stereocontrol is achieved. (B) uses CuAAC and (C) uses RuAAC. 
Figure 35: The general reaction schemes for the synthesis of the 1,4 and 1,5 isomers of the 
1,2,3- triazoles. The target compounds 35-42 are shown below the general reaction scheme. 
Figure 36: The copper catalytic cycle for the formation of a 1,4-isomer. Adapted from ref.       219. 
R1= AZT, This shows the formation of 35. 
Figure 37: The ruthenium catalytic cycle for the formation of the 1,5-isomer. Adapted         from 
ref. 220. R = AZT. This figure displays the formation of 39. 
Figure 38: The key resonance forms on the 1,2,3-triazole ring. The 1,4 and 1,5 isomers are       
shown. The hydrogen coloured is the hydrogen resonance peak on the 1H NMR spectra that is 
being shown. 
Figure 39: A diagram showing the SAR collected from the different triazole containing           
compounds. 
Figure 40: A computer model of AZT triphosphate chelating to the magnesium ion. AZT     43 
in incorporated into the DNA and causes the chain to end. 
Figure 41: The fitting of the compounds 35-42 with the active site of HIV reverse transcriptase. 
A =35, B = 36, C = 37, D = 38, E = 39, F = 40, G = 41, and H = 42. 
Figure 42: The overlapped view of 36 and 40 (36 =blue and 40 = green) in the active site of 
HIV-1 reverse transcriptase. 
Figure 43: The target structure 35-42, with their respective yields and purities shown. 
Figure 44: The target structures for the flavonoid series, 82-87. 
Figure 45: The general structures of the different flavonoids. The general flavonoid structure is 




Figure 46: Quercetagetin-7-arabinosyl-galactoside 88 equivalent concentrations against          
select bacteria. 
Figure 47: The structures of the flavonoids and their glycosidic counter parts found in                               
Scutellaria baicalensis. The MIC and MBC were determined using methods                        
described by Hansen et al.297S. aureus (ATCC 19115), and L. monocytogenes                (ATCC 
27217). Data adapted from ref. 248. 
Figure 48: Chrysin 93 MIC values against selective gram-positive and gram-negative          
bacteria. Four gram-negative (Agrobacterium tumefaciens (ATCC 11158), Escherichia coli 
(ATCC 29425), Pseudomonas lachrymans (ATCC 11921) and Xanthomonas vesicatoria 
(ATCC 11633)) and three gram-positive (Bacillus subtilis (ATCC 11562), Staphylococcus 
aureus (ATCC 6538) and Staphylococcus  haemolyticus (ATCC 29970)). The method used was 
a modified broth dilution- colorimetric assay. Adapted from ref. 261. 
Figure 49: Part of the elongation stage in the fatty acid synthesis in bacteria which involved        
FabH. 
Figure 50: The structures of C (7) derivatives. The MIC were determined using broth dilution         
methods. B. subtilis (MTCC 441), B. sphaericus (MTCC 11), S. aureus (MTCC 96),         
K.aerogenes (MTCC 39), C. violaceum (MTCC 2656), and P. aeruginosa (MTCC 741). The n 
refers to a=1, b= 2 and c=4.Data adapted from ref.257. 
Figure 51: The structures of C (7) derivatives. The MIC values were determined using the MTT 
method in MHB. Data adapted from ref.256. 
Figure 52: The mechanism by which chrysin 93 undergoes glucuronidation. Modified from ref. 
261. 
Figure 53: The glucosides 84 and 86 and galactosides 85 and 87 of their respective parent        
flavonoids. 
Figure 54: The glucosides 82 and galactosides 83 of 7-hydroxyflavone 100. 
Figure 55: The target compounds 82-87. The retrosynthetic route is also shown beneath the         
target compounds. 
Figure 56: The catalytic cycle for the formation of the glycosidic flavonoids. The transition        
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